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A B S T R A C T
Background
Gastric cancer is the fifth most common cancer worldwide. In “Western” countries, most people are either diagnosed at an advanced
stage, or develop a relapse after surgery with curative intent. In people with advanced disease, significant benefits from targeted therapies
are currently limited to HER-2 positive disease treated with trastuzumab, in combination with chemotherapy, in first-line. In second-
line, ramucirumab, alone or in combination with paclitaxel, demonstrated significant survival benefits. Thus, systemic chemotherapy
remains the mainstay of treatment for advanced gastric cancer. Uncertainty remains regarding the choice of the regimen.
Objectives
To assess the efficacy of chemotherapy versus best supportive care (BSC), combination versus single-agent chemotherapy and different
chemotherapy combinations in advanced gastric cancer.
Search methods
We searched the Cochrane Central Register of Controlled Trials, MEDLINE and Embase up to June 2016, reference lists of studies,
and contacted pharmaceutical companies and experts to identify randomised controlled trials (RCTs).
Selection criteria
We considered only RCTs on systemic, intravenous or oral chemotherapy versus BSC, combination versus single-agent chemotherapy
and different chemotherapy regimens in advanced gastric cancer.
Data collection and analysis
Two review authors independently identified studies and extracted data. A third investigator was consulted in case of disagreements.
We contacted study authors to obtain missing information.
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Main results
We included 64 RCTs, of which 60 RCTs (11,698 participants) provided data for the meta-analysis of overall survival. We found
chemotherapy extends overall survival (OS) by approximately 6.7 months more than BSC (hazard ratio (HR) 0.3, 95% confidence
intervals (CI) 0.24 to 0.55, 184 participants, three studies, moderate-quality evidence). Combination chemotherapy extends OS slightly
(by an additional month) versus single-agent chemotherapy (HR 0.84, 95% CI 0.79 to 0.89, 4447 participants, 23 studies, moderate-
quality evidence), which is partly counterbalanced by increased toxicity. The benefit of epirubicin in three-drug combinations, in which
cisplatin is replaced by oxaliplatin and 5-FU is replaced by capecitabine is unknown.
Irinotecan extends OS slightly (by an additional 1.6 months) versus non-irinotecan-containing regimens (HR 0.87, 95% CI 0.80 to
0.95, 2135 participants, 10 studies, high-quality evidence).
Docetaxel extends OS slightly (just over one month) compared to non-docetaxel-containing regimens (HR 0.86, 95% CI 0.78 to
0.95, 2001 participants, eight studies, high-quality evidence). However, due to subgroup analyses, we are uncertain whether docetaxel-
containing combinations (docetaxel added to a single-agent or two-drug combination) extends OS due to moderate-quality evidence
(HR 0.80, 95%CI 0.71 to 0.91, 1466 participants, four studies, moderate-quality evidence).When another chemotherapywas replaced
by docetaxel, there is probably little or no difference in OS (HR 1.05; 0.87 to 1.27, 479 participants, three studies, moderate-quality
evidence). We found there is probably little or no difference in OS when comparing capecitabine versus 5-FU-containing regimens
(HR 0.94, 95% CI 0.79 to 1.11, 732 participants, five studies, moderate-quality evidence) .
Oxaliplatin may extend (by less than one month) OS versus cisplatin-containing regimens (HR 0.81, 95% CI 0.67 to 0.98, 1105
participants, five studies, low-quality evidence). We are uncertain whether taxane-platinum combinations with (versus without) fluo-
ropyrimidines extend OS due to very low-quality evidence (HR 0.86, 95% CI 0.71 to 1.06, 482 participants, three studies, very low-
quality evidence). S-1 regimens improve OS slightly (by less than an additional month) versus 5-FU-containing regimens (HR 0.91,
95% CI 0.83 to 1.00, 1793 participants, four studies, high-quality evidence), however since S-1 is used in different doses and schedules
between Asian and non-Asian population, the applicability of this finding to individual populations is uncertain.
Authors’ conclusions
Chemotherapy improves survival (by an additional 6.7 months) in comparison to BSC, and combination chemotherapy improves
survival (by an additional month) compared to single-agent 5-FU. Testing all patients for HER-2 status may help to identify patients
with HER-2-positive tumours, for whom, in the absence of contraindications, trastuzumab in combination with capecitabine or 5-
FU in combination with cisplatin has been shown to be beneficial. For HER-2 negative people, all different two-and three-drug
combinations including irinotecan, docetaxel, oxaliplatin or oral 5-FU prodrugs are valid treatment options for advanced gastric cancer,
and consideration of the side effects of each regimen is essential in the treatment decision. Irinotecan-containing combinations and
docetaxel-containing combinations (in which docetaxel was added to a single-agent or two-drug (platinum/5-FUcombination) show
significant survival benefits in the comparisons studied above. Furthermore, docetaxel-containing three-drug regimens have increased
response rates, but the advantages of the docetaxel-containing three-drug combinations (DCF, FLO-T) are counterbalanced by increased
toxicity. Additionally, oxaliplatin-containing regimens demonstrated a benefit in OS as compared to the same regimen containing
cisplatin, and there is a modest survival improvement of S-1 compared to 5-FU-containing regimens.
Whether the survival benefit for three-drug combinations including cisplatin, 5-FU, and epirubicin as compared to the same regimen
without epirubicin is still valid when second-line therapy is routinely administered and when cisplatin is replaced by oxaliplatin and
5-FU by capecitabine is questionable. Furthermore, the magnitude of the observed survival benefits for the three-drug regimens is not
large enough to be clinically meaningful as defined recently by the American Society for Clinical Oncology (Ellis 2014). In contrast
to the comparisons in which a survival benefit was observed by adding a third drug to a two-drug regimen at the cost of increased
toxicity, the comparison of regimens in which another chemotherapy was replaced by irinotecan was associated with a survival benefit
(of borderline statistical significance), but without increased toxicity. For this reason irinotecan/5-FU-containing combinations are an
attractive option for first-line treatment. Although they need to be interpreted with caution, subgroup analyses of one study suggest that
elderly people have a greater benefit form oxaliplatin, as compared to cisplatin-based regimens, and that people with locally advanced
disease or younger than 65 years might benefit more from a three-drug regimen including 5-FU, docetaxel, and oxaliplatin as compared
to a two-drug combination of 5-FU and oxaliplatin, a hypothesis that needs further confirmation. For people with good performance
status, the benefit of second-line chemotherapy has been established in several RCTs.
P L A I N L A N G U A G E S U M M A R Y
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Chemotherapy for advanced gastric cancer
Background
Of all people with gastric cancer, in countries where screening is not routinely performed, 80% to 90% are either diagnosed at an
advanced stage when the tumour is inoperable, or develop a recurrence within five years after surgery. Before starting any systemic
chemotherapy in advanced disease, testing for over expression of the Human Epidermal growth factor Receptor-2 (abbreviated HER-2)
testing is mandatory, and people with HER-2 over expression need, in the absence of contraindications, to be treated by a combination
of a cisplatin/fluoropyrimidine-based chemotherapy and trastuzumab (i.e. amonoclonal antibody directed against the human epidermal
growth factor receptor II).
Study Characteristics
We searched biomedical databases (MEDLINE, Embase, Cochrane Central Register of Clinical Trials) until June 2016. We included
64 RCTs, of which 60 studies with 11,698 participants contained data on overall survival, in this review. We excluded 195 studies with
reasons.
Quality of the evidence
The quality of evidence ranged from very low to high, depending on the comparison and outcome being assessed. Reasons for down
grading the quality were due to risk of bias due to lack of blinded or independent radiological review, imprecision or heterogeneity.
Key results
Chemotherapy improves survival (by approximately 6.7 months) and quality of life in comparison to best supportive care alone, and
first-line combination chemotherapy improves survival (by one month) compared to single-agent 5-FU.
The addition of docetaxel to platinum-fluoropyrimidine-based chemotherapy regimens appears to extend survival (by just over one
additional month) at the cost of increased toxicity. Whether the benefit from adding a third drug (docetaxel or epirubicin) to a two-
drug platinum-fluoropyrimidine chemotherapy combination outweighs its toxicity is unclear.
Consideration of the profile of side effects and the impact of these side effects on the individual person’s quality of life, as well as the
tumour burden and necessity to obtain a response rapidly is therefore essential in the choice of the regimen. Additionally, irinotecan-
containing regimens prolonged overall survival (by an additional 1.6 months) compared to non-irinotecan-containing regimens.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Chemotherapy versus best supportive care for advanced gastric cancer
Patient or population: people with advanced gastric cancer
Settings: outpat ient clinics part icipat ing in internat ional mult icentre studies
Intervention: chemotherapy
Control: best support ive care alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Best supportive care Chemotherapy
Overall survival Study population HR 0.37
(0.24 to 0.55)
184
(3 studies)
⊕⊕⊕©
moderate1
Weighted average of me-
dian survival durat ions
f rom included studies4.3 months 11.0 months
Time to progression Study population HR 0.31
(0.22 to 0.43)
144
(2 studies)
⊕⊕⊕©
moderate1
Weighted average of me-
dian survival durat ions
f rom included studies2.5 months 7.4 months
* For t ime-to-event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculat ing the weighted average of the median survival durat ions
reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% conf idence interval) are based on proport ions of events in the
control and intervent ion groups respect ively.
CI: Conf idence interval; HR: Hazard rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Early term inat ion of Pyrhönen 1995; downgraded by one level for risk of bias.
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Outcomes shown include those which were measured in the studies, or reported in a consistent fashion across included
studies. Several crit ical outcomes (e.g. tumour response, treatment-related death, and discont inuat ion due to toxicity) were
not evaluated or reported in a consistent fashion in these studies, as they were mainly conducted before year 2000.
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B A C K G R O U N D
Description of the condition
Epidemiology and pathogenesis
With an estimated 1.3 million new cases in 2015, gastric can-
cer is currently the fifth most common malignancy and the third
leading cause of cancer-relatedmortality worldwide (GBDCancer
Collaboration 2017). Only approximately 25% of all people with
gastric cancer have resectable disease at presentation. Stomach can-
cer incidence rates show substantial variation internationally, with
endemic regions inAsia, EasternEurope and SouthAmerica (Ferro
2014).Helicobacter pylori, atrophic gastritis, intestinal metaplasia,
and dysplasia have been identified as important steps in the patho-
genesis of gastric cancer (Correa 1996). Due to improvements in
food conservation and diet, as well as eradication of Helicobacter
pylori, gastric cancer incidence and mortality has steadily fallen in
the last 50 years (Peleteiro 2012).
In contrast, a dramatic rise in cardial and gastroesophageal junc-
tion tumour incidence rates has been observed in middle-aged,
male, white Caucasians (Abrams 2013; Sharma 2003; Wu 2001).
A proportion of these cases seems to be associated with Barrett’s
epithelium (intestinal metaplasia of the distal oesophagus), devel-
oping from chronic oesophageal reflux disease (MacDonald 1992;
Wu-Williams 1990). Although it is difficult to determine whether
these cancers are gastroesophageal junction tumours or distal oe-
sophageal malignancies (Rusch 2004), in clinical studies for ad-
vanced disease they are usually treated in the same manner.
Gastric cancer is a heterogenous disease entity, with major differ-
ences in growth patterns, differentiation, and molecular patho-
genesis. More than 90% of stomach tumours are adenocarcino-
mas. While Lauren already in 1965 distinguished (Lauren 1965)
the well-differentiated or intestinal type and the undifferentiated
or diffuse-type, the current World Health Organization (WHO)
classification Bosman 2010 differentiates the following five major
histopathological subtypes: papillary, tubular, and mucinous ade-
nocarcinoma, as well as poorly cohesive (with or without signet
cells) and mixed carcinoma. While the first three types correspond
to the former “well differentiated or intestinal type”, the undiffer-
entiated or diffuse type according to Lauren corresponds to the
poorly cohesive type in the current classification.
While the intestinal type is more common in males, older age
groups, and in high-risk geographic areas, diffuse-type carcinomas
have a more equal male to female distribution, are more frequent
in younger individuals, and have a more uniform geographic dis-
tribution (Crew 2004; Kelley 2003; Lauren 1965; Munoz 1968).
Ninety per cent of gastric cancers are sporadic. Hereditary diffuse
gastric cancer is rare, with less than 3% of cases. According to
a recently published landmark paper (TCGA 2014), which de-
scribes the results of a comprehensive molecular evaluation of 295
primary gastric adenocarcinomas as part of The Cancer Genome
Atlas (TCGA), the following four molecular subtypes can be dis-
tinguished.
1. Tumours positive for Epstein-Barr virus, which display
recurrent PIK3CA mutations, extreme DNA hyper methylation,
and amplification of JAK2, CD274 (also known as PD-L1) and
PDCD1LG2 (also known as PD-L2).
2. Microsatellite unstable tumours, which show elevated
mutation rates.
3. Genomically stable tumours, which are enriched for the
diffuse histological variant and mutations of RHOA or fusions
involving RHO-family GTPase-activating proteins.
4. Tumours with chromosomal instability, which show marked
aneuploidy and focal amplification of receptor tyrosine kinases.
While this classification has no impact in the choice of systemic
treatment at present, it will provide a roadmap for patient strati-
fication and development of targeted therapies in the future.
In contrast, the over expression of the Human Epidermal growth
factor Receptor-2 (HER-2), which is observed in 10% to 20% of
the people, is clinically relevant today as it predicts a significant
benefit from treatment with trastuzumab (Bang 2010). Further
details of the pathogenesis of gastric cancer have been reviewed
recently by Wadhwa and colleagues (Wadhwa 2013).
Prognosis and management options
Apart from endoscopic treatment for a minority of very small tu-
mours, partial or complete gastrectomy with lymphadenectomy
is the only potentially curative therapy for gastric cancer. Stage I
to IVM0 tumours are principally resectable (MacDonald 2001a).
However, although surgery carries a high cure rate for stage IA
and IB cancers, the results for stage IIIA and IIIB cancers are
poor. Many people with advanced disease, especially stage IIIA/
B, are technically inoperable. Results for both resectable and lo-
cally advanced gastric cancer may be improved by either periop-
erative (e.g. Cunningham 2006; Ychou 2011) or adjuvant che-
motherapy (Bang 2012; Paoletti 2013; Sakuramoto 2007). Un-
fortunately, even after an apparently ’curative’ gastrectomy, re-
lapse rates in prospective studies remain in the range of 40% to
60% (Bonenkamp 1999; Cunningham 2006;MacDonald 2001b;
Songun 2010) in European studies. In the Western world, most
people are diagnosed at an advanced stage, when the tumour is
inoperable. People with inoperable, recurrent or metastatic tu-
mours have a poor prognosis with a median survival time of three
to five months without chemotherapy. Several small randomised
studies have provided evidence that first-line chemotherapy im-
proves survival in these people (Glimelius 1994; Pyrhönen 1995;
Scheithauer 1996), but benefit has to be weighed against treat-
ment-related toxicities. Furthermore, second-line chemotherapy
has shown to improve survival and quality of life in several re-
cent randomised studies (Ford 2014; Kang 2012; Thuss-Patience
2011).
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While a significant number of phase-III studies have studied the
value of targeted therapies in advanced gastric cancer (e.g. Lordick
2013; Ohtsu 2011; Ohtsu 2013; Satoh 2014), only three phase III
studies (Bang 2010; Fuchs 2014; Wilke 2014) have had positive
results and impact on clinical practice:
According to the randomised phase III “TOGA” study (Bang
2010), response rate, progression-free- and overall survival are
greatly improved by adding themonoclonal antibody trastuzumab
to the combination of cisplatin and capecitabine in HER-2 pos-
itive gastric cancer, and introduced trastuzumab as a standard of
care for HER-2 positive disease. This study changed the workup
of all people with advanced gastric cancer since all people with
advanced gastric cancer must now undergo HER-2 testing before
the initiation of any chemotherapy and, in the absence of con-
traindications, be treated with trastuzumab in combination with
cisplatin and 5-FU or capecitabine in case of HER-2 over expres-
sion on IHC (IHC 3+, or IHC 2+/FISH+). All other treatment
options discussed in this review (oxaliplatin, irinotecan, docetaxel,
as well as the anthracycline-containing regimen ECF) are there-
fore valid only for people with HER-2 negative disease. Studies
on combinations of other chemotherapies with trastuzumab are
currently limited to phase II and cannot be recommended for this
reason. Furthermore, the VEGF-receptor-targeting antibody ra-
mucirumab, with or without chemotherapy, has been evaluated in
two phase III studies as second-line treatment, and emerged as a
new treatment option in this indication. Thus, despite this recent
progress, chemotherapy remains the mainstay of treatment for the
majority of people with advanced gastric cancer.
Description of the intervention
Systemic chemotherapy
5-FU is not only the most important and extensively studied
single agent in this disease, but it is part of most combination
chemotherapy regimens as well. Its single-agent response rate is
about 20%. Differences in effect and toxicity profile are the rea-
sons for its application as continuous infusion. Oral capecitabine
(Cunningham 2008) or S-1 (Ajani 2010) may replace infusional
5-FU, thus avoiding the risk and inconvenience associated with
portable pumps.Other single agents with relevant activities are cis-
platin (Leichman 1991) and anthracyclines (Preusser 1988). Fur-
thermore, oxaliplatin, docetaxel, and irinotecan have been eval-
uated in recent phase III studies (Al Batran 2008; Cunningham
2008; Dank 2008; Van Cutsem 2006).
How the intervention might work
5-FU, an antimetabolite, pyrimidine-antagonist and inhibitor of
thymidilate-synthethase is the backbone of chemotherapy in gas-
tric cancer. Capecitabine is an oral fluoropyrimidine that is se-
lectively activated in tumour tissue by a three-step enzymatic
conversion, S-1 another oral fluoropyrimidine. Cisplatin is an
alkylan, which acts through induction of intra- and inter-strand
crosslinks. The diamino-cyclohexane platinum derivative oxali-
platin also leads to the formation of DNA crosslinks, but they are
not recognised by the intracellular mismatch repair system. Doc-
etaxel, as well as paclitaxel are agents which inhibit depolymeriza-
tion of micro tubuli. Irinotecan is an inhibitor of topoisomerase I,
thereby disrupting DNA replication and cell division. These drugs
have major differences in their toxicity profile.
Why it is important to do this review
Combination chemotherapy has become an accepted standard for
first-line treatment. Although a large number of different regimens
have been tested in randomised studies, uncertainty remains re-
garding the choice of the regimen.
O B J E C T I V E S
To evaluate the effect of chemotherapy in participants with ad-
vanced adenocarcinoma of the stomach and gastroesophageal
junction.
Comparisons were as follows.
1. First-line chemotherapy plus best supportive care (BSC)
versus BSC alone.
2. First-line combination versus single-agent chemotherapy.
3. First-line 5-FU/cisplatin/anthracycline-containing
combinations versus 5-FU/cisplatin combinations (without
anthracyclines).
4. First-line 5-FU/cisplatin/anthracycline-containing
combinations versus 5-FU/anthracycline combinations (without
cisplatin).
5. First-line chemotherapy with irinotecan versus non-
irinotecan-containing regimens.
6. First-line chemotherapy with docetaxel versus non-
docetaxel-containing regimens.
7. First-line chemotherapy with capecitabine versus 5-FU-
containing regimens.
8. First-line chemotherapy with oxaliplatin versus the same
regimen containing cisplatin.
9. First-line taxane-platinum-fluoropyrimidine combinations
versus taxane-platinum (without fluoropyrimidine).
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10. First-line S-1 versus 5-FU-containing regimens.
Due to limited information, we considered second-line therapy
only in selected sensitivity analyses of first-line therapy where data
were available. In addition to comparisons 1 and 2, which were
planned and described in the first version of the protocol, we per-
formed two more comparisons (3 and 4) in the original version
of the review (Wagner 2005). As there was a large number of cat-
egories of different combination chemotherapy regimens and the
number of relevant studies in each category was not known when
writing the protocol, it was impossible to plan in advance the best
way to compare directly the different categories of combination
chemotherapies. We chose to perform these additional compar-
isons based on their clinical relevance and the availability of a suf-
ficient number of relevant studies.
In the first update of this review (Other published versions of
this review, Wagner 2010), comparisons (5) to (8) (5: First-line
chemotherapy with irinotecan versus non-irinotecan-containing
regimens, 6: First-line chemotherapy with docetaxel versus non-
docetaxel-containing regimens, 7: First-line chemotherapy with
capecitabine versus 5-FU-containing regimens, 8: First-line che-
motherapy with oxaliplatin versus the same regimen contain-
ing cisplatin were added. In this second update,comparisons (9)
to (10) (9: First-line taxane-platinum-fluoropyrimidine combina-
tions versus taxane-platinum (without fluoropyrimidine) and 10:
First-line S-1 versus 5-FU-containing regimens) were added (see
- Differences between protocol and review).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled studies, with or without
blinding. We included abstracts or unpublished data if sufficient
information on study design, characteristics of participants, in-
terventions, and outcomes was available and if full information
and final results were confirmed by the first author. We excluded
cross-over studies in order to assess the overall treatment effect on
survival. We excluded quasi-randomised studies, e.g. treatment al-
location alternate or by date of birth, as we considered this study
design to be not of sufficiently high quality.
Types of participants
We included participants with histologically confirmed, unre-
sectable (as decided by a multidisciplinary team), recurrent or
metastatic adenocarcinoma of the stomach or gastroesophageal
junctionwithout any prior chemotherapy or radiotherapy for com-
parisons 1 to 10. We also included studies which included partic-
ipants with adenocarcinoma of the distal oesophagus. Most stud-
ies included participants with locally advanced, relapsed and/or
metastatic tumours, with the greater number of participants al-
ready having metastatic disease. However, in some studies only
participants with locally advanced cancer of the stomach were re-
ported in order to assess secondary resectability. We did not con-
sider these studies in this review. The proportion of participants
with locally advanced versus metastatic tumours is given for each
study.
Types of interventions
We included studies of systemic intravenous or oral, first-line che-
motherapy and/or best supportive care (BSC). Chemotherapy en-
compasses all cytotoxic or anti-neoplastic drug treatment, but ex-
cluding hormonal, biological, or targeted therapies, which are the
subject of a separate Cochrane review (Song 2016).However, stud-
ies on targeted therapies with clinical impact, as well as studies on
second-line chemotherapy are considered in the discussion.
We included single-agent as well as combination chemotherapy
studies in all doses and schedules, but did not consider combined
radio-chemotherapy.
Types of outcome measures
Primary outcomes
1. Overall survival on intention-to-treat analysis. Median,
one-, two- and three-year as well as five-year survival in
participants with locally advanced, secondary resectable tumours.
Secondary outcomes
1. Tumour response.
2. Time to progression.
3. Secondary resectability in participants with locally
advanced gastric cancer.
4. Toxicity, classified according to WHO or National Cancer
Institute Common Toxicity Criteria (NCI-CTC).
Quality of life is difficult to measure and was assessed with various
instruments. Quality of life results of recent phase-III studies are
described in the results section and considered in the discussion if
available.
Search methods for identification of studies
Electronic searches
We originally identified studies by searching theCochrane Central
Register of Controlled Trials (CENTRAL) (the Cochrane Library
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2004, Issue 1), MEDLINE, and Embase up to February 2004 and
reference lists of articles. We also contacted pharmaceutical com-
panies as well as national and international experts. We updated
searches in all databases in March 2009, January 2013, February
2014 and June 2016.
The Cochrane Highly Sensitive Search Strategy for identifying
randomised studies in MEDLINE, sensitivity-maximising ver-
sion, Ovid format (Higgins 2008) was combined with the search
terms in the Appendices to identify randomised controlled stud-
ies in MEDLINE. The MEDLINE search strategy was adapted
for use in the other databases searched. The search strategies are
documented in Appendix 1; Appendix 2 and Appendix 3. We did
not confine our search to English language publications.
In addition, we searched the following databases of ongoing stud-
ies: http://www.controlled-trials.com;
http://www.clinicaltrials.nci.nih.gov; http://www.eortc.be; http:/
/www.update-software.com/National/nrr-frame.html and http://
www.CenterWatch.com.
Searching other resources
We handsearched reference lists from studies selected by elec-
tronic searching to identify further relevant studies. We also hand-
searched published abstracts from conference proceedings from
the European Society forMedicalOncology from1978 (published
in the Annals of Oncology), the EuropeanCouncil of Clinical On-
cology from 1981 (published in the European Journal of Cancer),
as well as the American Society for Clinical Oncology from 1981.
All searches were updated in June 2016.
Data collection and analysis
Selection of studies
Two independent review authors initially scanned the title, ab-
stract section, and keywords of every record retrieved.We retrieved
full-text articles for further assessment if the information given
suggested that the study included participants with histologically
confirmed, inoperable adenocarcinoma of the stomach or gastroe-
sophageal junction, used random allocation to the comparison
groups and compared the following.
1. Best supportive care (BSC) versus chemotherapy plus BSC.
2. Combination versus single-agent chemotherapy.
3. 5-FU/cisplatin/anthracycline-containing combinations
versus 5-FU/cisplatin combinations (without anthracyclines).
4. 5-FU/cisplatin/anthracycline-containing combinations
versus 5-FU/anthracycline combinations (without cisplatin).
5. Irinotecan versus non-irinotecan-containing regimens.
6. Docetaxel versus non-docetaxel-containing regimens.
7. Capecitabine versus 5-FU-containing regimens.
8. Oxaliplatin versus the same regimen including cisplatin.
9. Taxane-platinum-fluoropyrimidin combinations versus
taxane-platinum (without fluoropyrimidine).
10. S-1 versus 5-FU-containing regimens.
If there was any doubt regarding these criteria from the informa-
tion given in the title and abstract, we retrieved the full-text ar-
ticle for clarification. If differences in opinion existed, they were
resolved by discussion.
Data extraction and management
Two review authors independently extracted details of study pop-
ulation, interventions, and outcomes. We resolved differences in
data extraction by consensus with a third review author, referring
back to the original article. If data were missing in a published
report, we contacted the primary author.
Data extraction included the following items.
1. General information: title, authors, source, contact address,
country, published/unpublished, language and year of
publication, sponsoring of study.
2. Study characteristics, including design, duration/follow up,
and quality assessment criteria as specified above.
3. Participants: inclusion and exclusion criteria, sample size,
baseline characteristics, similarity of groups at baseline,
withdrawals, and losses to follow-up.
4. Interventions: dose, route, timing of chemotherapy, and
comparison intervention.
5. Outcomes: hazard ratios and their 95% confidence intervals
or standard error, log rank Chi², log rank P values, number of
events, number of participants per group, median, one-, two-
and three-year survival rates and five-year survival rates in
participants with locally advanced, secondary resectable tumours.
Assessment of risk of bias in included studies
In this updated version of the review, we independently assessed
the risk of bias of the included studies using the ’Risk of bias’ as-
sessment tool described in Chapter 8 of theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2011). We compared
the evaluations, and discussed and resolved any inconsistencies
between the review authors’ decisions.
We rated the following domains separately for each of the included
studies as ’low risk of bias’, ’high risk of bias’, and ’unclear’ when
the risk of bias was uncertain or unknown:
1. generation of allocation sequence (’sequence generation’);
2. concealment of allocation (’allocation concealment’);
3. prevention of knowledge of the allocated interventions
during the study (’blinding’);
4. methods used to address incomplete outcome data;
5. selective outcome reporting;
6. other sources of bias that could put a study at high risk of
bias, including whether a calculation of sample size was carried
out including baseline comparability. We considered tumour
stage (advanced versus metastatic disease) and activity index
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(Eastern Cooperative Oncology Group status 0 to 1 versus 2 to
3), as well as the number of organs involved in metastatic disease
(one versus more than one) as the most important prognostic
factors. We considered a difference of more than 15% between
study arms as an important difference. For age, as a further
important factor, we considered baseline differences of five years
as important. We also assessed intention-to-treat (ITT) analysis.
We considered ITT analysis as randomised analysis, with the
analysis restricted to participants who received at least one cycle
of chemotherapy, and for which survival data were available.
Alternatively, we also considered studies including all participants
as randomised in the analysis as ITT. In addition, we analysed
the risk of bias and described this in the ’Risk of bias’ tables.
These assessments are reported in the ’Risk of bias’ table for each
individual study in the ’Characteristics of included studies’ section
of the review, and in the ’Risk of bias in included studies’ section
of this review.
Measures of treatment effect
Data analysis
We estimated hazard ratios (HR) and 95% confidence intervals
(CI) as relevant effectmeasures directly or indirectly from the given
data (Altman 2001). For each individual study, we extracted HRs
and their variances. If the figures were not given directly, methods
of indirect determination were used. HRs can be estimated (under
some assumptions) from log rank Chi², from log rank P values,
from observed to expected event ratios and from ratios of median
survival times or time point survival rates (Machin 1997; Parmar
1998; Tierney 2007). In several instances, medians and/or num-
ber of events had to be read from the graphs. If both medians and
survival rates at fixed time points were given, the medians were
preferred. If we had to pool several arms of a study, we approxi-
mated the common median by the weighted mean of the medians
given for the various arms.
For instance, statistical measures were taken to avoid double-
counting the irinotecan-treated population in Bouche 2004,
which was a three-arm study which compared 5-fluorouracil versus
5-fluorouracil plus cisplatin versus 5-fluorouracil plus irinotecan.
For Comparison 5, we estimated the hazard ratios for the irinote-
can-containing arm (N = 45) versus the non-irinotecan-contain-
ing arms (N = 89), which was not provided in the original report
by Bouche 2004.
Unit of analysis issues
Participants were individually randomised into two or more treat-
ment groups. The effect of the intervention was measured and
analysed on the basis of single measurements for each outcome
for each participant. For studies with more than one intervention
arm, we combined groups to create a single pair-wise comparison
as follows: the single-agent therapy arm with the pooled results of
both combination chemotherapy arms; the combination-therapy
arm was compared with the pooled results of both single agent
arms; or the pooled results of the sequential therapy arms were
compared with the pooled results of the concurrent therapy arms.
Dealing with missing data
We attempted to contact investigators to obtain missing data.
Assessment of heterogeneity
We assessed the heterogeneity in each pair-wise comparison by
assessing the Higgins I² (Higgins 2003), the Chi² test with signif-
icance set at a P value less than 0.1, and by visual inspection.
Data synthesis
We used the fixed-effect model for meta-analysis, with overall sur-
vival as the primary outcome measure. Where heterogeneity levels
were high (I² > 20% or P value < 0.1), we used a random-effects
model (see Differences between protocol and review).We used Re-
view Manager software for data synthesis (RevMan). . Previously
SAS was used for more sophisticated analysis. We recalculated (or
at least approximated) all outcomes concerning overall survival by
using hazard ratios.
Quality of Evidence (GRADE) and ’Summary of findings’
tables
We used the GRADEprofiler (GRADEpro) software to assist with
the preparation of the ’Summary of findings’ tables. The ’Sum-
mary of findings’ tables provide key information about the pooled
estimate of the magnitude of the effect in relative terms, assumed
and control risks, numbers of participants and studies addressing
each important outcome, and the quality of evidence for the com-
parisons for each outcome.
We included the following outcomes in the ’Summary of findings’
tables.
1. Overall survival
2. Tumour response
3. Progression-free survival; and/or time-to-progression; and/
or time-to-treatment failure
4. Treatment-related death
5. Treatment discontinuation due to toxicity
We assessed the quality of evidence as ’High’, ’Moderate’, ’Low’ or
’Very Low’ using theGrades ofRecommendation, Assessment,De-
velopment and Evaluation (GRADE) methodology, which eval-
uates the totality of included studies for their risk of bias (study
limitations), consistency, imprecision, indirectness, and publica-
tion bias.
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Subgroup analysis and investigation of heterogeneity
In seeking statistical heterogeneity between studies, we per-
formed Cochrane’s Q-test (with a significance threshold of alpha
= 0.1). Additionally, we calculated heterogeneity quantitatively
(Thompson 2002). We considered the following factors as possi-
ble sources of heterogeneity:
1. differences in prognostic factors;
2. quality of studies;
3. second-line therapy permitted versus no second-line
therapy;
4. Asian versus non-Asian studies;
5. substitutive, additive, and other comparisons in
comparisons 5 and 6.
Sensitivity analysis
We conducted a sensitivity analysis by repeating the primary anal-
ysis and investigated the influence of risk of bias, adequate alloca-
tion concealment, excluding those studies which were conducted
in Asia and studies with second-line therapies.
R E S U L T S
Description of studies
Results of the search
We identified a total of 2925 records through electronic searches of
CENTRAL, MEDLINE, Embase and databases of clinical trials.
After removing duplicates, 2597 records remained. We excluded
2495 references which were clearly irrelevant through screening
titles and reading abstracts. We retrieved 102 references for further
assessment. We excluded 195 studies and are listed in the table
Characteristics of excluded studies. Twenty-six new studies were
identified for inclusion. Please see Figure 1 for the flowchart of the
systematic search performed in June 2016.
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Figure 1. Study flow diagram: review update
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Included studies
Three eligible studies with 184 participants were identified for
analysis of comparison 1: chemotherapy versus best supportive
care (BSC).The study by Scheithauer 1996was published as an ab-
stract only, but all relevant informationwas provided by the author.
For more details of the included studies, please see Characteristics
of included studies.
Approximately 50% of the study investigators provided further
information. Data about survival and response rates were given
in most publications. Information about second-line therapy was
either reported in the text or provided by the authors only in a
limited number of studies.
Twenty-three studies, which included 4447 participants, were in-
cluded in the analysis of comparison 2, which is combination
versus single-agent chemotherapy. In studies that included more
than one single or combination chemotherapy arm, different arms
were combined in the analysis as specified below. Comparisons 3
and4 included 579 and 1147 participants in four and seven stud-
ies.Comparison 5 included 10 studies with a total of 2135 partic-
ipants and comparison 6 includes at present overall survival data
from eight studies including a total of 2001 participants. Com-
parisons 7 and 8 included 732 and 1105 participants from two
and five studies, respectively. Two new comparisons (9) and (10)
with 482 and 1793 participants from three and four randomised
studies, respectively were added in the current update.
It should be noted that some studies may appear in more than
one comparison if they meet relevant criteria for inclusion. For in-
stance, Hironaka 2016; Koizumi 2014; Komatsu 2011; Narahara
2011; Ochenduszko 2015 were included in two comparisons;
while Boku 2009 was included in three comparisons.
Participants
The median age of the participants in the population of studies
included in the analysis of comparisons 1 and 2 was in the range
of 56 to 67 years. The proportion of participants with metastatic
disease was between 62% (Cullinan 1985) and 100% (Bouche
2004; Koizumi 2008; Yamamura 1998).When comparing the dif-
ferent arms of one study, a difference in the proportion of partic-
ipants with advanced versus metastatic disease greater than 15%
between study armswas identified in only one study (Popov 2002),
with a larger number of metastatic participants in the combina-
tion chemotherapy arm (90% versus 73%). Performance status
was well-balanced in all studies with no differences greater than
15% between study arms. The percentage of participants with
ECOG 2+3 was in the range of 0% to 48%. Thirteen studies,
which included 3182 participants (Boku 2009; Hironaka 2016;
Koizumi 2008; Koizumi 2014; Komatsu 2011; Lu 2014;Narahara
2011; Nishikawa 2012; Ohtsu 2003; Shirao 2013; Wang 2013;
Wu 2015; Yamamura 1998), were conducted in Asia.
Regarding comparisons 3 and4, the median age of participants
included in these 11 studies was between 58 and 65 years. Be-
tween 46% (Kikuchi 1990) and 90% (Cascinu 2011; Kim 2001)
of participants had metastatic disease, the percentage of partici-
pants with ECOG 2+3 was between 6% (Cascinu 2011) and 88%
(Kikuchi 1990). The percentage of participants with advanced
versus metastatic disease was well-balanced in all studies included
in these two comparisons.
The participants in comparison 5 had a median age between 58
(Dank 2008) and 70 (Komatsu 2011) years in the different study
arms, with the majority of participants having metastatic disease.
The median age of the participants in comparison 6 was be-
tween 55 (Roth 2007; Van Cutsem 2006) and 70 years (Al-Batran
2013). The percentage of participants with metastatic disease was
between 69% (Al-Batran 2013; Ochenduszko 2015) and 98%
(Thuss-Patience 2005), with the largest study having 97% of par-
ticipants with metastatic disease and amedian age of 55 years (Van
Cutsem 2006). Most participants in these studies had a perfor-
mance status of 0 or 1.
Regarding comparisons 7 and8, the median age of participants
included in these studies was between 55 (Ocvirk 2012) and 65
years (Yamada 2015). Between 62% (Kim 2014) and 100% (Li
2016) had metastatic disease and most participants had a perfor-
mance status of 0 or 1. Only in Popov 2008 the percentage of
participants with ECOG 2-3 was 29%.
The median age of the participants included in comparisons 9
and 10 was between 54 (Ajani 2005; Huang 2013; Li 2015) and
76 years (Boku 2009), between 86% (Roth 2007) and 95% to
100% of participants (Ajani 2005; Ajani 2010; Chen 2015) had
metastatic disease. Most participants in these studies had a perfor-
mance status of 0 or 1.
Groups of participants were well-balanced regarding the most im-
portant prognostic factors as specified above in all studies included
into comparisons 3 to 8.
Interventions
Participants were individually randomised into two or more treat-
ment groups. The effect of the intervention was measured and
analysed on the basis of single measurements for each outcome
for each participant. In 11 studies, more than two groups with
different interventions were compared (Boku 2009; Bouche 2004;
Cullinan 1985; Cullinan 1994; Hironaka 2016; Loehrer 1994;
Lutz 2007; Nishikawa 2012; Ohtsu 2003; Roth 2007).
In the studies by Bouche 2004, Lutz 2007, Ohtsu 2003, and
Hironaka 2016 the single-agent therapy arm was compared with
the pooled results of both combination chemotherapy arms. In
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Loehrer 1994, Cullinan 1994, and Boku 2009 , the combination-
therapy arm was compared with the pooled results of both single-
agent arms. In Nishikawa 2012, the pooled results of the sequen-
tial therapy arms were compared with the pooled results of the
concurrent therapy arms. All these studies were included in the
comparison of single-agent versus combination chemotherapy.
Furthermore, the irinotecan-containing combination chemother-
apy was compared to the pooled results of the non-irinotecan-con-
taining combination chemotherapies and included in comparison
5 in 10 studies (Boku 2009; Bouche 2004; Dank 2008; Komatsu
2011; Li 2016; Moehler 2005; Moehler 2010; Narahara 2011;
Roy 2012; Sugimoto 2014), and the pooled results of the doc-
etaxel-containing chemotherapies were compared with the non-
docetaxel-containing combination chemotherapy and included in
comparison 6 in eight studies (Al-Batran 2013; Koizumi 2014;
Ochenduszko 2015; Ridwelski 2008; Roth 2007; Thuss-Patience
2005; Van Cutsem 2006; Wang 2016).
All three studies included in the analysis of comparison 1 used
combination therapy regimens in the chemotherapy arm (Murad
1993: FAMTX; Pyrhönen 1995: FEMTX; Scheithauer 1996: 5-
FU/LV/Epirubicin).
Regarding comparison 2, most studies used 5-FU in the sin-
gle-agent arm. In six of 17 studies (Barone 1998; Colucci 1995;
Cullinan 1985; Cullinan 1994; De Lisi 1986; Loehrer 1994), 5-
FU was given as a bolus in doses of approximately 500 mg/m²
days one to five every four weeks. A continuous infusion regimen
was used in two studies, with either 2600 mg/m² every two weeks
(Popov 2002), 800 mg/m² per day (Ohtsu 2003) on days one to
three every four weeks or a bolus of 400 mg/m² 5-FU, followed by
600 mg/m² as a two-hour continuous infusion on days one and
two every two weeks (Bouche 2004). One study (Levi 1986), ap-
plied doxorubicin 60 mg/m² every four weeks in the single-agent
arm. In the study by Loehrer 1994, the results from two single-
agent arms (5-FU bolus 500 mg/m² days one to five and epiru-
bicin 90 mg/m² day one every four weeks) were combined in the
analysis. In addition, in the studies by Bouche 2004, Lutz 2007,
Nishikawa 2012, andOhtsu 2003 , the results of two combination
therapy arms (LV5FU2/cisplatin and LV5FU2/irinotecan, D-FU/
FA and HD-FU/FA/cisplatin, 5-FU/paclitaxel and S-1/paclitaxel,
5-FU/cisplatin, and tegafur/mitomycin C) were combined in the
analysis. Nishikawa 2012 used 5-FU in doses of 800 mg/m² in
days one to five every four weeks in one group or daily S-1 in doses
of 80mg/m² for four weeks and a two-week rest in the single-agent
arm until progression. This therapy was followed by paclitaxel (80
mg/m² on days one, eight and 15 every four weeks). A similar reg-
imen of S-1 was used in Narahara 2011 and Komatsu 2011. Boku
2009 used the same 5-FU regimen in one arm or lower doses of
S-1 (40 mg/m² for four weeks and a two-week rest) in the single-
agent arm. Results of two arms were combined in the single-agent
arm in Boku 2009; Cullinan 1994 and Nishikawa 2012. Wang
2013 used S-1 according to body-surface area with 40 mg twice
daily for participants with a body surface area greater than 1.25
and lower than 1.5 for two out of four weeks. Koizumi 2008 and
Hironaka 2016 as well used the oral prodrug S-1.
In six of 23 studies, combination chemotherapy arms did con-
tain an anthracycline (epirubicin 60 mg/m² every three weeks or
90 mg/m² every four weeks or doxorubicin 40 mg/m² every four
to seven weeks) in addition to 5-FU. Non 5-FU-based combina-
tion chemotherapy regimens, which instead included etoposide,
irinotecan and cisplatin, S-1 and irinotecan, S-1 and paclitaxel or
an anthracycline and cisplatin were applied in six studies (Barone
1998; Boku 2009; Komatsu 2011; Narahara 2011; Popov 2002;
Wang 2013).
In comparisons 3 and4, regimens containing 5-FU, an anthra-
cycline and cisplatin were mainly FAP (5-FU bolus 300 mg/m²
either days one, eight, 15, 22 or days one to five, adriamycin 25 to
40 mg/m² and cisplatin 60 to 100 mg/m² once every three to five
weeks) (Cullinan 1994; GITSG 1988; Kikuchi 1990), and PELF
(cisplatin 40 mg/m² days one and five, epirubicin 30 mg/m² days
one and five, leucovorin 200 mg/m² and 5-FU bolus 300 mg/
m² days one to four every eight weeks) (Cocconi 1994) in stud-
ies published before 1995 (Kim 2001; Ross 2002; Webb 1997).
used mostly ECF (epirubicin 50 mg/m² and cisplatin 60 mg/m²
once every three weeks, with 5-FU as a continuous intravenous
infusion of 200 mg/m² for up to six months) or LdCF (pegylated
liposomal doxorubicin 20 mg/m² and cisplatin 50 mg/m² once
every two weeks, with 5-FU 400 mg/m² bolus followed by 600
mg/m² as 22-hour continuous infusion on days one and two every
two weeks) in Cascinu 2011.
In comparison 5, irinotecan was given in the following studies
to substitute either cisplatin (Bouche 2004; Dank 2008; Moehler
2010), etoposide (Moehler 2005) or 5-FU (Roy 2012) or paclitaxel
(Sugimoto 2014). In contrast, irinotecan was given in addition
to the treatment in the other arm in studies by Bouche 2004;
Komatsu 2011; and Narahara 2011; or as other comparisons (Li
2016). Irinotecan was given weekly at 80 mg/m² for six weeks
every 50 days in combination with infusional 5-FU 2000 mg/
m² and FA 500 mg/m² (Dank 2008; Moehler 2005). Moehler
2010 used irinotecan 250 mg/m² on day one in combination with
capecitabine 1000 mg/m² orally days one to 14 every 22 days and
Roy 2012 used irinotecan 250 mg/m² on day one in combination
with docetaxel 60 mg/m² as infusion on day one every 22 days.
Bouche 2004 used irinotecan at 180 mg/m² in combination with
infusional 5-FU every two weeks. Komatsu 2011 and Narahara
2011 used doses of 75 mg/m² and 80 mg/m² on days one and 15
every four weeks or six weeks in combination with oral S-1 (initial
doses of 40 mg/m² to 60 mg/m² twice daily on days one to 14
every four weeks or 80 mg/m²/day on days one to 21 every six
weeks). In subsequent cycles, doses were varied according to the
most severe adverse events during the preceding cycle.
In comparison 6, docetaxel was given to substitute either epiru-
bicin and cisplatin (Roth 2007; Thuss-Patience 2005) or 5-FU
and leucovorin (Ridwelski 2008). On the other hand, it was given
in addition to the treatment in the other study arm in the studies
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by Wang 2016, Koizumi 2014, Van Cutsem 2006 and Al-Batran
2013. The largest studies included in comparison 6’s meta-anal-
ysis of overall survival used the three-drug regimen DCF (doc-
etaxel 75 mg/m² intravenously day one, cisplatin 75 mg/m² in-
travenously day one, 5-FU 750 mg/m² as a 24-hour infusion) on
days one to five every three weeks (Van Cutsem 2006), and the
two-drug regimen of docetaxel 75 mg/m² intravenously day one,
in combination with cisplatin 75 mg/m² intravenously on day
one every three weeks (Ridwelski 2008). In Koizumi 2014, do-
cetaxel (40mg/m² intravenously on day one) was given with S-1
(tailored to body surface area; days one to 14) every 21 days. In
Roth 2007, the DCF regimen was used as described previously.
Sadighi 2006 and colleagues used a modification of DCF with
reduced doses of docetaxel and cisplatin (both at 60 mg/m²) ev-
ery three weeks. Thuss-Patience 2005 applied docetaxel 75 mg/
mg/m² intravenously on day one in combination with 5-FU 200
mg/m² /day over 24 hours on days one to 21 every three weeks.
Al-Batran 2013 used docetaxel 50 mg/m² intravenously on day
one in combination with oxaliplatin 85 mg/m² and leucovorin
200 mg/m² followed by 5-FU 2600 mg/m² as a 24-hour contin-
uous infusion.
Five studies (Kang 2009; Li 2016; Ocvirk 2012; Ochenduszko
2015; Van Cutsem 2015) are eligible for comparison 7. In Kang
2009 andOcvirk 2012, the oral 5-FU prodrug capecitabine (1000
mg/m² or 825 mg/m² twice daily on days one to 14 of a 21-day
regimen) was compared with 5-FU (both in combination with
cisplatin). In comparison 8, oxaliplatin was given once at 85 mg/
m² in two weeks and compared with cisplatin 50 mg/m² in Al
Batran 2008 and Popov 2008. Both agents were combined with
FU/ leucovorin in Al Batran 2008 and Popov 2008. In Kim 2014
a combination of weekly docetaxel (35mg/m²) on days one and
eight every three weeks, in combination with either cisplatin (60
mg/m²) or oxaliplatin (120 mg/m²) on day one was administered.
In Yamada 2015, S-1 (twice daily for the first three weeks of a five-
week cycle) plus (cisplatin 60 mg/m² on day eight) was compared
against S-1 (twice daily for first two weeks of a three-week cycle)
plus oxaliplatin (100mg/m² infused for twohours onday one). For
comparison 9, three studies (Ajani 2005; Roth 2007; Van Cutsem
2015) are available. Fluorouracil 200 mg/m²/day was given as a
24-hour continuous infusion in or in doses of 750 mg/m²/day on
days one to five every three weeks in Roth 2007. It was combined
with docetaxel and cisplatin in Ajani 2005 and Roth 2007, and
docetaxel and oxaliplatin in Van Cutsem 2015.
In comparison 10, S-1 50 mg/m² was given orally in two daily
doses on days one to 21 of a four-week cycle (Ajani 2010), or
in a lower dosage of 40 mg/m² orally in two daily doses on days
one to 28 of a six-week cycle (Boku 2009) and compared with
continuous infusions of 5-FU in doses of 1000 mg/m²/24 hours
as 120-hour infusion (Ajani 2010) or 800 mg/m²/day on days
one to five, respectively. Of note, S-1 was combined with 75 mg/
m² of cisplatin every three weeks, and 5-FU with 100 mg/m² of
cisplatin every three weeks in the study by Ajani 2010. Huang
2013 compared the combination of weekly paclitaxel (60 mg/m²)
on days one eight, and 15 every four-week cycle and S-1 (80 mg/
m² to 120 mg/m²), dependent on the body-surface area for two
out of four weeks, with the same regimen of paclitaxel, but with
5-FU (500 mg/m², in combination with leucovorin 20 mg/m² on
days one to five every four weeks).
Outcomes
Median survival and response rates were the outcomes most com-
monly described in the included studies. The newer studies re-
ported progression-free survival instead of time to progression.
Toxicity was not always classified according to WHO or NCI-
CTC and was reported in different ways (per number of partici-
pants, per number of cycles and only the worst toxicity per par-
ticipant). A comparison across studies was therefore not possible.
For this reason, the numbers of participants who discontinued
treatment due to toxicity as well as the numbers of treatment-re-
lated deaths were analysed. Information about second-line thera-
pies and secondary resectability was unavailable for most studies.
Details are listed in the Characteristics of included studies table.
Excluded studies
Please see Characteristics of excluded studies. Reasons for exclu-
sion of references in the updated search are specified in Figure
1 according to the recommendations of the PRISMA statement
(Moher 2009).
According to the protocol, we excluded studies in which cross-over
after failure was encouraged or planned. Information about sec-
ond-line therapy was generally unavailable in most first-line stud-
ies. However, in some large recent studies full information about
second-line therapy was provided after contacting the first author
and a limited number of participants did in fact cross over in the
second-line therapy. After discussion and balancing the loss of in-
formation when excluding these studies against the possible bias
caused by a limited number of participants crossing over, we de-
cided to include studies in which the number of participants who
crossed over between study arms was less than 10% of the whole
study population. Exclusion of these studies would have provoked
a bias in favour of studies where less informationwas available.Two
studies which have repeatedly been quoted in the literature are
especially mentioned: Glimelius 1994 was excluded because of
cross-over, as the research ethics committee had requested that
chemotherapy had to be provided to participants upon request in
the BSC group, and 12 of 30 participants in the BSC group finally
received chemotherapy. Kim 1993 was excluded since the alloca-
tion of participants was done by alternate allocation (information
provided by author YSP). Several studies currently published as
abstracts only were not included at this stage, because full informa-
tion and final results were currently unavailable or were not pro-
vided after contacting the author or sponsor. They are classified as
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’Studies awaiting classification’. We excluded studies using oral 5-
FU because of its varying bioavailability and unreliable effect. The
landmark ’REAL-2’ study (Cunningham 2008), which evaluated
the non-inferiority of oxaliplatin as compared to cisplatin and of
capecitabine as compared to 5-FU, was not included in this meta-
analysis after discussion because it included participants with squa-
mous cell cancer of the oesophagus (more than 10%), which were
not eligible according to the inclusion criteria for this meta-analy-
sis. We sought separate data on participants with adenocarcinoma
only, but they were not provided by the study investigator. The
study by Sadighi 2006 could not be included in the meta-analysis
of overall survival because published data for calculation of the
hazard ratio is not sufficient at present, but data on the other out-
comes were included. The study by Park 2006 was not included
in the comparison of docetaxel versus non-docetaxel-containing
regimens because both study arms included a taxane. Thus, the
analyses are essentially a comparison of docetaxel and paclitaxel.
If further studies relevant for this comparison are published in the
future, a separate comparison of paclitaxel versus docetaxel-con-
taining regimens will be included in the meta-analysis.The studies
Gubanski 2010 and Guimbaud 2014 were excluded because of
systematic cross-over between study arms.
Risk of bias in included studies
We summarised the overall risk of bias in Figure 2 and Figure 3.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
The risk of selection bias due to issues with random sequence gen-
eration was not stated in most instances (n = 35/64, 55%), while
the remaining studies which described the allocation sequence
generation approach used acceptable, unbiased methods (n = 29/
64, 45%).
Blinding
Potential bias arising from allocation concealment was low in 38
studies (59%), unclear in 25 studies (39%), and high in one study
(2%).
Incomplete outcome data
The risk of bias due to incomplete efficacy data was low in 49
studies (77%), unclear in nine9 studies (14%), and high in six
studies (9%). On the other hand, incomplete safety concern was
a low concern in 50 studies (78%), unclear in 11 studies (17%),
and high in three studies (5%).
Selective reporting
The potential for selective reporting was deemed to be low in 47
studies (73%), unclear in 11 studies (17%), and high in six studies
(9%).
Other potential sources of bias
The risk of bias due to lack of blinded or independent radiological
reviewwas a low concern in 16 studies (25%), unclear in 28 studies
(44%), and high in 20 studies (31%). The potential for bias due
to other causes was assessed to be low in 12 studies (19%), unclear
in 34 studies (53%), and high in 18 studies (28%).
Effects of interventions
See: Summary of findings for the main comparison
Chemotherapy versus best supportive care for advanced gastric
cancer; Summary of findings 2 Combination versus single-
agent chemotherapy for advanced gastric cancer; Summary
of findings 3 5-FU/cisplatin/anthracycline combinations
versus 5-FU/cisplatin combinations (without anthracyclines)
for advanced gastric cancer; Summary of findings 4 5-FU/
cisplatin/anthracycline combinations versus 5-FU/anthracycline
combinations (without cisplatin) for advanced gastric cancer;
Summary of findings 5 Irinotecan versus non-irinotecan-
containing regimens for advanced gastric cancer; Summary of
findings 6 Docetaxel versus non-docetaxel-containing regimens
for advanced gastric cancer; Summary of findings 7Capecitabine
versus 5-FU-containing regimens for advanced gastric cancer;
Summary of findings 8 Oxaliplatin versus the same regimen
including cisplatin for advanced gastric cancer; Summary of
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findings 9 Taxane-platinum-fluoropyrimidine combinations
versus taxane-platinum (without fluoropyrimidine) for advanced
gastric cancer; Summary of findings 10 S-1 versus 5-FU-
containing regimens for advanced gastric cancer
(1) Chemotherapy versus best supportive care
Overall survival
A total of three studies (N = 184) reported overall survival (Murad
1993; Pyrhönen1995; Scheithauer 1996). The overall hazard ratio
(HR) of 0.37 (95% confidence interval (CI) 0.24 to 0.55, mod-
erate-quality evidence) (Analysis 1.1) in favour of the chemother-
apy arms demonstrates a convincing benefit over best supportive
care (BSC) alone, which can be interpreted as an improvement
in median survival from 4.3 months (weighted average in BSC)
to 11 months (with chemotherapy). Cochrane’s Q test (P = 0.19)
as well as the index of homogeneity according to Thompson (I²
= 39.7) demonstrate a significant statistical heterogeneity among
the results of these studies, based on the differences in the che-
motherapy regimens studied. A sensitivity analysis including only
studies with adequate allocation concealment (Pyrhönen 1995;
Scheithauer 1996), does not change the overall HR of 0.37 (95%
CI 0.19 to 0.70).
Secondary outcomes
Tumour response
Data were available for 88 participants in the chemotherapy arms
of the three eligible studies. Response rates were between 33%
(Pyrhönen 1995) and 50% (Murad 1993).
Time to progression
In the chemotherapy and BSC arms time to progression was 7.8
versus 2.7 (P = 0.0001) and 6.5 versus 2.0 (P = 0.0001) months
in the studies by Murad 1993 and Scheithauer 1996 (N = 144).
The overall HR was 0.31 (95% CI 0.22 to 0.43, moderate-quality
evidence) (Analysis 1.2).
Secondary resectability
Information about secondary resectable participants was not given
in the text or provided by the authors in any of the three studies.
Toxicity
In the study by Murad 1993, WHO grade III/IV toxicities
occurred in 22 of 128 cycles in 30 participants treated with
chemotherapy, with one toxic death. Pyrhönen 1995 described
WHO gastrointestinal grade III/IV toxicities in 13 of 20 partici-
pants. Haematological toxicities occurred in the same frequency.
Scheithauer 1996 observed haematological grade III/IV toxicities
in 12%, gastrointestinal grade III/IV toxicities in 21%, and other
grade III/IV toxicities in 32.7% of 226 available cycles.
Quality of life
Quality of life was not analysed in any of the three included studies.
Pyrhönen 1995 assessed the palliative measures and observed an
increased use of analgesics in the control versus treated participants
after two months.
(2) Combination versus single-agent therapy
Overall survival
Twenty-three studies including 4447 participants were sum-
marised in this meta-analysis (Barone 1998; Boku 2009; Bouche
2004; Colucci 1995; Cullinan 1985; Cullinan 1994;De Lisi 1986;
Hironaka 2016; Koizumi 2008; Koizumi 2014; Komatsu 2011;
Levi 1986; Loehrer 1994; Lu 2014; Lutz 2007; Narahara 2011;
Nishikawa 2012; Ohtsu 2003; Popov 2002; Shirao 2013; Wang
2013; Wu 2015; Yamamura 1998). The overall HR in favour
of combination chemotherapy (HR 0.84, 95% CI 0.79 to 0.89,
moderate quality) provides evidence for a statistically significant,
but modest survival benefit of combination versus single-agent
chemotherapy in the studied regimens (Analysis 2.1). Cochrane’s
Q test for heterogeneity showed non-significant heterogeneity (I²
= 0%, P = 0.48), indicating that results of the different studies
were consistent in their findings. As the chemotherapy regimens
in studies published before 2000 might not have the same efficacy
as modern regimens, the median survival difference between sin-
gle and combination chemotherapy was calculated separately for
studies published before the year 2000 and thereafter. For stud-
ies published before 2000, the weighted median survival was ap-
proximately 7.3 with combination therapy and 6.4 months with
single-agent therapy. In studies published after 2000 (Boku 2009;
Bouche 2004; Hironaka 2016; Koizumi 2008; Koizumi 2014;
Komatsu 2011; Lu 2014; Lutz 2007; Narahara 2011; Nishikawa
2012; Ohtsu 2003; Popov 2002; Wang 2013, Wu 2015), median
survival was 11.6 months with combination therapy, as compared
to 10.5 months with single-agent therapy.
To evaluate the influence of second-line therapy, which was previ-
ously specified as a possible cause of heterogeneity, a second anal-
ysis was performed excluding the studies by Boku 2009, Koizumi
2008, Koizumi 2014, Narahara 2011, Ohtsu 2003, and Wang
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2013 in which more than 50% of participants received a second-
line therapy. Exclusion of theses studies had no influence on het-
erogeneity (I² = 0% and P = 0.56) and the overall HR of 0.82
(95% CI 0.75 to 0.90) in favour of combination chemotherapy.
Sensitivity analysis excluding those studies which were conducted
in Asia (Boku 2009; Hironaka 2016; Koizumi 2008; Koizumi
2014 ; Komatsu 2011; Lu 2014; Narahara 2011; Nishikawa 2012;
Ohtsu 2003; Shirao 2013; Wang 2013; Wu 2015; Yamamura
1998) resulted in a HR of 0.77 (95% CI 0.68 to 0.87) (I² =
0%, P = 0.57), with no appreciable change in heterogeneity as
compared to the original analysis. When only those studies with
adequate allocation concealment were included in the analysis
(Barone 1998; Boku 2009; Bouche 2004; De Lisi 1986; Koizumi
2008; Levi 1986; Loehrer 1994; Lu 2014; Lutz 2007; Narahara
2011; Nishikawa 2012; Ohtsu 2003; Shirao 2013; Wang 2013;
Wu 2015; Yamamura 1998), the resulting overall HR was 0.83
(95% CI 0.77 to 0.89) (I² = 24% and P = 0.19). For these rea-
sons, the results of this comparison can be considered to be highly
robust.
Secondary outcome measures
Tumour response
Data were available from 2833 participants in 18 eligible stud-
ies. The pooled objective response rate was 39% in the combi-
nation therapy arms versus 23% of the single-agent arms. The
corresponding odds ratio (OR 2.30, 95% CI 1.94 to 2.72, high-
quality evidence) confirms a statistically significant advantage in
tumour response in favour of combination therapy (Analysis 2.2).
Very low heterogeneity was observed across studies (I² = 0%, P =
0.60).
Time to progression
Data from four studies with 720 participants were available. The
overall HR for time to progression for combination versus single-
agent chemotherapy was 0.69 (95% CI 0.55 to 0.87, moderate-
quality evidence) (Analysis 2.3). Results across studies were con-
sistent, with moderate heterogeneity (I² = 23%, P = 0.27). Other
studies (Boku 2009; Bouche 2004; Hironaka 2016; Koizumi
2014; Lutz 2007; Lu 2014; Wu 2015) reported progression-free
survival instead of time to progression or time-to treatment failure
(Komatsu 2011; Narahara 2011; Nishikawa 2012).
Secondary resectability
Only one study (Colucci 1995) reported on a single participant
who became secondary resectable and was operated on with a
pathologic complete remission.
Toxicity
Because of the different ways of reporting (per number of partic-
ipants, per number of cycles or only the maximum toxicity per
participant), grade I to IV toxicities can be compared only within,
but not between studies. Overall, treatment-associated toxicities
were higher in the combination chemotherapy arms, but this was
usually not statistically significant. In contrast, the rate of treat-
ment-associated deaths may be summarised across studies. Eigh-
teen of 23 studies (N = 3876) in this comparison reported treat-
ment-related deaths (Analysis 2.4). The overall rate of toxic deaths
in these studies was 1.1% versus 0.5% for combination versus sin-
gle-agent therapy (OR 1.64, 95% CI 0.83 to 3.24). Six studies
observed no treatment-related deaths (Hironaka 2016; Koizumi
2008; Komatsu 2011; Lu 2014; Wang 2013; Wu 2015).
Quality of life
This was assessed in only one of these studies (Bouche 2004). All
participants in the single-agent and both combination chemother-
apy arms had a significant improvement in quality of life com-
pared with pretreatment scores.
(3) 5-FU/cisplatin/anthracycline combinations versus
5-FU/cisplatin combinations (without anthracyclines)
Overall survival
This meta-analysis was based on 579 participants in four ran-
domised studies (Cascinu 2011; Kim 2001; KRGGC 1992; Ross
2002). The data from the largest study in this comparison (pub-
lished by Ross 2002) which was included in this analysis were
provided by the authors and include people with gastric and GE-
junction adenocarcinoma only (the original publication included
people with squamous cell carcinoma of the oesophagus as well).
The resulting HR for overall survival of 0.74 (95% CI 0.61 to
0.89, moderate-quality evidence) demonstrates a statistically sig-
nificant benefit with very low heterogeneity (I² = 0%, P = 0.63)
in overall survival in favour of the three-drug combination, with
a weighted average survival of 9.9 and 8.6 months, respectively.
Allocation concealment was adequate in all three studies included
in this comparison and heterogeneity was non-significant (I² =
0%; P = 0.63) (Analysis 3.1).
(4) 5-FU/cisplatin/anthracycline combinations versus
5-FU/anthracycline combinations (without cisplatin)
Summarising the results for the comparison of FU/cisplatin/an-
thracycline combinations versus FU/anthracycline (without cis-
platin) results in a HR of 0.82 (95% CI 0.73 to 0.92, low-
quality evidence) in favour of the three-drug regimen (Analysis
4.1). Combination chemotherapy arms only from the study by
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Cullinan 1994 were included in this comparison. This meta-anal-
ysis, which included 1147 participants in seven studies (Cocconi
1994; Cocconi 2003; Cullinan 1994; GITSG 1988; Kikuchi
1990; Roth 1999; Webb 1997), once more confirms a overall sur-
vival benefit in favour of the three-drug combination, which cor-
responds to a difference in weighted mean average survival of ap-
proximately two months. A sensitivity analysis according to the
quality score has only little impact on the resulting HR (0.79,
95% CI 0.68 to 0.91). There was only moderate heterogeneity (I²
= 28%, P = 0.21).
The two regimens containing FU, an anthracycline and cisplatin,
which were evaluated in the largest number of participants are
cisplatin, epirubicin, leucovorin, and FU administered as bolus
(PELF; 184 participants) (Cocconi 1994; Cocconi 2003) and
epirubicin, cisplatin, and protracted venous-infusion FU (ECF;
327 participants) (Kim 2001; Ross 2002;Webb 1997). The rate of
treatment-related deaths was 3.3% for PELF versus 0.6% for ECF
(OR 5.36, 95% CI 1.1 to 27.4; Fisher’s exact test, P = .02834),
suggesting an increased toxicity of PELF. Quality of life was anal-
ysed in two studies evaluating ECF compared with FU, doxoru-
bicin, and methotrexate (Webb 1997), as well as ECF compared
with mitomycin, cisplatin, and FU (Ross 2002). Quality of life
was superior in participants treated with ECF.
(5) Chemotherapy with irinotecan versus non-
irinotecan-containing regimens
Overall survival
Ten studies (N = 2135) were summarised in this meta-analy-
sis (Boku 2009; Bouche 2004; Dank 2008; Komatsu 2011; Li
2016; Moehler 2005; Moehler 2010; Narahara 2011; Roy 2012;
Sugimoto 2014). To avoid double-counting the irinotecan-treated
population in the study by Bouche 2004, we approximated a
within-study hazard ratio of 0.72 (95% CI 0.30 to 1.72) for the
study’s irinotecan-treated population (N = 45) and non-irinote-
can-treated population (N = 89). Overall, the pooled hazard ra-
tio of irinotecan-containing regimens compared to non-irinote-
can containing regimens was 0.87 (95% CI 0.80 to 0.95, high-
quality evidence), with low heterogeneity (I² = 0%, P = 0.86)
(Analysis 5.1), and corresponds to pooled median survival times
of 11.3 and 9.7 months, with a small, but significant benefit for
the irinotecan-containing regimens.When only those studies with
information about adequate allocation concealment are included
in the analysis (Boku 2009; Bouche 2004;Moehler 2005;Moehler
2010; Narahara 2011; Roy 2012) the resulting overall HR was
0.84 (95% CI 0.76 to 0.93) (P = 0.84 and I² = 0%) when all stud-
ies were pooled. For these reasons, the results of this comparison
can be considered as robust. Further sensitivity analyses were not
performed due to the low number of studies.
Next, the HR for overall survival was separately investigated for
studies with substitutive (i.e. studies in which another chemo-
therapy was substituted by irinotecan), additive (i.e. studies in
which irinotecan was added to other chemotherapies), and other
comparisons of irinotecan and non-irinotecan-containing regi-
mens (Analysis 5.1). The summary of the six studies (826 partici-
pants) with substitutive comparisons (Bouche 2004; Dank 2008;
Moehler 2005; Moehler 2010; Roy 2012; Sugimoto 2014) results
in a HR of 0.87 (95% CI 0.75 to 1.00, high-quality evidence),
with low heterogeneity between study results (I² = 0%, P = 0.94).
The meta-analysis of the three studies (Bouche 2004; Komatsu
2011;Narahara 2011), including a total of 500 participants, where
irinotecan was given in addition to the treatment in the non-
irinotecan-containing arm shows a non-significant benefit for par-
ticipants treated with irinotecan (HR 0.88, 95% CI 0.76 to 1.03,
low-quality evidence) and small heterogeneity between treatment
effects of individual studies (I² = 6%, P = 0.34). This result corre-
sponds to a pooled median survival duration of 11.9 months with
compared to 10.9 months without irinotecan. Bouche 2004 and
Narahara 2011 stated a higher benefit of four and two months,
respectively. However, Komatsu 2011 showed a disadvantage of
threemonths for participants treatedwith irinotecan and S-1 com-
pared to participants with S-1 monotherapy.
The meta-analysis of two studies (Boku 2009; Li 2016), which
could neither be classified as substitutive nor additive, including a
total of 809 participants, revealed a slight benefit for participants
treated with irinotecan (HR 0.87, 95% CI 0.76 to 1.00, very low-
quality evidence). However, the pooled result needs to be inter-
preted with caution in light of the considerable clinical differences
between studies included under ’Other Comparisons’ as well as
their significant statistical heterogeneity (I² = 65%, P = 0.04). For
instance, Li 2016 allowed participants to switch to second-line
therapy after failure of first-line. The study by Boku 2009 alone,
which contributed the majority of participants (n = 704), showed
a HR of 0.84, 95% CI 0.73 to 0.95 and a corresponding benefit
in median survival of around one month in favour of participants
treated with irinotecan.
Secondary outcome measures
Tumour response
Data were available from 1266 participants in 10 eligible studies
(Analysis 5.2). In six studies (756 participants) with substitutive
comparisons (Bouche 2004; Dank 2008; Moehler 2005; Moehler
2010; Roy 2012; Sugimoto 2014) response rates were 38% and
30% (OR 1.53, 95% CI 0.93 to 2.50, low-quality evidence), with
substantial heterogeneity (I² = 56%, P = 0.04). In three stud-
ies (345 participants) with additive comparisons, pooled response
rates of 38% and 22% were observed (OR 2.18, 95% CI 1.25
to 3.80, low-quality evidence), with moderate heterogeneity (I² =
19%, P = 0.29). In two studies (165 participants) of other com-
parisons, response rates were 53% and 38% (OR 1.87, 95% CI
21Chemotherapy for advanced gastric cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
0.89 to 3.91, very low-quality evidence) with considerable hetero-
geneity (I² = 26%, P = 0.25).
Progression-free survival
Most studies reported progression-free survival instead of time to
progression. Again, a within-study hazard ratio was computed for
the irinotecan-treated population (N = 45) and non-irinotecan-
treated population (N = 89) in Bouche 2004 to avoid counting
the irinotecan-treated population twice (HR = 0.59, 95% CI 0.50
to 0.68). Overall, the pooled hazard ratio of irinotecan-containing
regimens compared to non-irinotecan-containing regimens was
0.76 (95% CI 0.69 to 0.84, high-quality evidence), with low het-
erogeneity (I² = 0%, P = 0.59) (Analysis 5.3).
Among five studies (N - 741) with substitutive comparisons
(Bouche 2004; Dank 2008; Moehler 2005; Moehler 2010;
Sugimoto 2014), the hazard ratio for progression-free survival was
0.85 (95% CI 0.72 to 1.00, moderate-quality evidence) in favour
of the participants treated with irinotecan (Analysis 5.3). The het-
erogeneity for this comparison was low (I² = 0%, P = 0.54).
The single study (N = 90) from the additive comparisons, from
which data for progression-free survival are available observed a
large benefit (HR of 0.51, 95% CI 0.33 to 0.77, moderate-qual-
ity evidence) with a median PFS of 6.9 and 3.2 months for par-
ticipants treated with and without irinotecan (Bouche 2004). A
smaller difference in TTP was reported by Komatsu 2011, with a
median TTP of 4.8 and 3.8 months for participants treated with
and without irinotecan. Two additional studies belonging to other
comparisons (Boku 2009; Li 2016) with a total of 809 participants
stated a pooled benefit for participants with irinotecan compared
to control (HR 0.74, 95% CI 0.66 to 0.84, high-quality evidence)
with low heterogeneity (I² = 0%, P = 0.39). The study by Boku
2009 alone demonstrated a HR of 0.73 (95% CI 0.64 to 0.83)
with median progression-free survival of 4.8 months in the group
treated with irinotecan and 4.2 and 2.9 months in the control
groups without irinotecan.
Secondary resectability
Information about secondary resectable participants was not pro-
vided.
Toxicity
Rates of treatment-related deaths and treatment discontinuation
due to toxicity showed substantial heterogeneity between studies
(P = 0.19, I² = 32%) and (P < 0.00001, I² = 87%), as well as a
low event rate for treatment-related deaths (0.8% versus 1.0%);
hence, the significance of pooled results are unclear and will not
be discussed in the text of this review (Analysis 5.4; Analysis
5.5). Three studies (Komatsu 2011; Roy 2012; Sugimoto 2014)
observed no treatment-related deaths.
Quality of life
Quality of life was assessed in the studies by Bouche 2004, Dank
2008, and Roy 2012. However, in the study by Bouche 2004,
which used the EORTC-QLQ C-30 as an assessment tool, the
absolute number of participants with follow-up data in the dif-
ferent study arms was very small (between 21 and 29 participants
at six months). As compared to treatment with 5-FU/cisplatin,
treatment with 5-FU/irinotecan in this study was associated with
higher global quality of life and functional scores, as well as lower
symptom scores. Dank 2008 compared the time to 5% deteri-
oration of the global health status, as measured by the EORTC
QLQ-C30 questionnaire in both treatment arms. In 288 assess-
able participants (86.5%), the median time to 5% deterioration
of the global health status was 4.9 months (95% CI 3.7 to 7.0)
in the irinotecan-containing arm and 5.9 months (95% CI 4.8 to
7.7) in the platinum-containing arm. In contrast, the results of the
EQ-5D instrument (data from 192 participants): time to definite
worsening of Karnofsky performance status, appetite, weight loss,
and pain-free survival all favoured the irinotecan-containing arm.
Detailed quality-of life results of this study have been published
by Curran 2009. Roy 2012 assessed the clinical benefit in terms of
times from baseline to definitive worsening of the Karnofsky per-
formance status (KPS) by at least one category, definitive weight
loss by at least 5% and worsening of appetite by at least one grade
on a scale of 1 to 5 and added pain-free survival. Median time
to definitive deterioration of KPS (4.9 months; 95% CI 1.9 to
11.2 versus 2.6 months; 95% CI not reached) and median time
to definitive 5% weight loss (not reached versus 7.6 months) were
better without irinotecan. Median time to definitive worsening of
appetite was 4.9 months (95% CI not reached) with no differ-
ence between groups. Median pain-free survival was not reached
in both groups.
(6) Chemotherapy with docetaxel versus non-
docetaxel-containing regimens
Overall survival
Eight studies (N = 2001) were summarised in this meta-analysis
(Al-Batran 2013; Koizumi 2014; Ochenduszko 2015; Ridwelski
2008; Roth 2007; Thuss-Patience 2005; Van Cutsem 2006;Wang
2016). The resulting HR for overall survival was estimated sepa-
rately for studies with substitutive (i.e. studies in which another
chemotherapy was substituted by docetaxel), additive (i.e. studies
in which docetaxel was added to other chemotherapies), and other
comparisons (Analysis 6.1).
The summary of the three studies (479 participants) with substi-
tutive comparisons (Ridwelski 2008; Roth 2007; Thuss-Patience
2005) slightly favours the non-docetaxel-containing regimens
(HR 1.05, 95% CI 0.87 to 1.27, moderate-quality evidence), but
does not reach statistical significance. The index of homogene-
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ity according to Thompson (I² = 0%) shows a low statistical het-
erogeneity among the results of these studies (Analysis 6.1). Be-
cause necessary data for calculation of the HR in the studies by
Sadighi 2006 weremissing, this study could not be included in the
meta-analysis of this comparison. Differences in pooled median
survival between the docetaxel-containing regimens (9.2 months)
and the non-docetaxel-containing regimens (9.4 months) are nei-
ther statistically significant nor clinically relevant. All publications
describe an adequate allocation concealment and all studies were
conducted in Europe.
Themeta-analysis of the four studies (N = 1466) (Al-Batran 2013;
Koizumi 2014; Van Cutsem 2006; Wang 2016), including a to-
tal of 1466 participants, where docetaxel was given in addition
to the treatment in the non-docetaxel-containing arm favours the
docetaxel-containing regimens (HR 0.80, 95% CI 0.71 to 0.91,
moderate-quality evidence)with little heterogeneity between treat-
ment effects of individual studies (I² = 0%, P = 0.82). This result
corresponds to pooled median survival times of 12.3 and 10.6
months, with a small benefit for the docetaxel-containing regi-
mens. Al-Batran 2013 was conducted in Germany, Koizumi 2014
in Japan and Korea, Wang 2016 in China, and the fourth study
(Van Cutsem 2006) was an international study that recruited par-
ticipants in America, Europe, and Asia. Due to the small number
of studies in the primary analysis, we did not perform sensitivity
analyses.
The single study belonging to other comparisons (Ochenduszko
2015) with 56 participants demonstrated a non-statistically sig-
nificant (P = 0.43) advantage of docetaxel-containing regimens
compared to control (HR 0.80, 95% CI 0.46 to 1.39, very low-
quality evidence). This study permitted second-line therapy with
irinotecan monotherapy.
Secondary outcome measures
Tumour response
Data were available from nine eligible studies of 1820 participants
(Al-Batran 2013; Dong 2014; Koizumi 2014; Ridwelski 2008;
Roth 2007; Sadighi 2006; Thuss-Patience 2005; Van Cutsem
2006;Wang 2016) (Analysis 6.2) (OR 1.37, 95%CI 1.03 to 1.83,
moderate-quality evidence).
In studies with substitutive comparisons (Ridwelski 2008; Roth
2007; Sadighi 2006; Thuss-Patience 2005) response rates of 525
participants were 31% in both arms (OR 1.03, 95% CI 0.71 to
1.50, moderate-quality evidence). However, in four studies with
additive comparisons and 1235 participants (Al-Batran 2013;
Koizumi 2014; Van Cutsem 2006; Wang 2016), pooled response
rates of 43% and 30% were observed (OR 1.83, 95% CI 1.45
to 2.32, high-quality evidence). Heterogeneity between results of
different studies was very low in both comparisons (I² = 0%, P =
0.98 and P = 0.69, respectively). Among other comparisons, the
study by Dong 2014 with 60 participants showed a substantial
survival advantage with docetaxel-containing regimens (OR 0.33,
95% CI 0.12 to 0.96, very low-quality evidence).
Time to progression and progression-free survival
Data on time to progression were available for two studies (N =
360) (Ridwelski 2008; Thuss-Patience 2005) (Analysis 6.3) and
data for progression-free survival were available for five studies (N
= 1498) (Koizumi 2014; Ochenduszko 2015; Roth 2007; Van
Cutsem 2006; Wang 2016) (Analysis 6.4).
In the case of time to progression, data based on 360 participants
from two studies revealed a non-significant difference between
docetaxel and non-docetaxel-containing regimens (HR 1.06, 95%
CI 0.85 to 1.32, very low-quality evidence) (Analysis 6.3).
In the case of progression-free survival, the pooled hazard ratio was
0.76 (95% CI 0.63 to 0.91, moderate-quality evidence) in favour
of docetaxel-containing regimens based on 1498 participants in
five studies, but a high level of heterogeneity was observed (I² =
52%, P = 0.08) (Analysis 6.4). When only additive comparisons
were considered (Koizumi 2014; Van Cutsem 2006; Wang 2016)
(N = 1323), the pooled hazard ratio was 0.70 (95% CI 0.61 to
0.81, high-quality evidence), and a lower level of heterogeneity
was observed (I² = 20%, P = 0.29).
Secondary resectability
This outcome was not reported in any of the studies.
Toxicity
Seven studies (N = 2113) reported rates of treatment-related
deaths, which were 1.4% in the docetaxel-containing arms ver-
sus 1.2% in the non-docetaxel-containing arms (OR 1.10, 95%
CI 0.55 to 2.20, moderate-quality evidence, I² = 0%, P = 0.44)
(Analysis 6.5). Treatment discontinuation due to toxicity was nu-
merically less frequent for the participants treated with docetaxel
(18.4% versus 21.1%, corresponding to an OR of 0.81 (95% CI
0.53 to 1.25, low-quality evidence), and different results between
the studies (I² = 35%, P = 0.19) (Analysis 6.6). In contrast, discon-
tinuation of treatment due to withdrawal of consent was observed
approximately twice as frequently in the participants treated with
DCF as compared to CF (22% versus 12%) in the study by Van
Cutsem 2006.
Quality of life
Quality of life was assessed by Sadighi 2006, Roth 2007, Van
Cutsem 2006, and Al-Batran 2013 with the EORTC-QLQ C30.
Furthermore, “clinical benefit”, defined as the time to definitive
decrease in performance status by > one category was analysed in
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the study by Van Cutsem 2006 and demonstrated a clinical benefit
for participants treated with DCF (Ajani 2007).
Sadighi 2006 used the Iranian version of the EORTC-QLQ C30.
The report by Ajani 2007a demonstrated a better preservation of
Quality of life in the participants treated with DCF. In Roth 2007,
global health status improved in participants treated with ECF,
but remained stable with both docetaxel regimens. Van Cutsem
2006 measured a longer time to 5% deterioration of the global
health status in the docetaxel-containing arm as compared to the
non-docetaxel-containing arm (HR 1.44, 95% CI 1.08 to 1.93).
Thuss-Patience 2005 measured subjective symptom improvement
rates. Al-Batran 2013 (Kripp 2014) administered both EORTC
QLQ-C30 and the gastric module STO22, and found that despite
the higher toxicity in elderly participants (aged 65 years or older)
receiving FLOT, the intensified chemotherapy regimen did not
affect quality of life parameters in the elderly.
(7) Chemotherapy with capecitabine versus 5-FU-
containing regimens
Overall survival
The results for this comparison are based on 732 randomised
participants in five studies (Kang 2009; Li 2016; Ocvirk 2012;
Ochenduszko 2015; Van Cutsem 2015). The HR for overall sur-
vival of 0.94 (95% CI 0.79 to 1.11, moderate-quality evidence)
favours the oral regimen, but does not reach statistical significance
(Analysis 7.1). The index of heterogeneity for this comparison was
small (I² = 12%, P = 0.34). The corresponding pooledmedian sur-
vival are 10.8 and 10.9 months, respectively for the capecitabine
and 5-FU-containing arms respectively. When the studies which
permitted second-line therapy were excluded as part of sensitivity
analysis (Li 2016; Ochenduszko 2015), the pooled HR for overall
survival remained stable at 0.93 (95% CI 0.77 to 1.14).
Secondary outcome measures
Tumour response
Datawere available in 636 participants in four studies (Kang 2009;
Li 2016; Ocvirk 2012; Van Cutsem 2015). The objective response
rate was 38% in both arms, corresponding to an OR of 0.85 (95%
CI 0.40 to 1.79, very low-quality evidence) with a non-significant
advantage for the capecitabine-containing regimen (Analysis 7.2).
Time to progression
Data from one study of 85 participants (Ocvirk 2012) showed a
small benefit for participants treated with capecitabine (HR 0.72,
95% CI 0.47 to 1.12, very low-quality evidence), with improved
median time to progression times of 6.8 versus 5.5 months for the
participants treated with and without capecitabine.
Kang 2009 provided the largest number of participants for the
evaluation of progression-free survival and showed a non-signif-
icant advantage for the capecitabine-containing arm (HR 0.80,
95% CI 0.62 to 1.03), corresponding to an improvement in me-
dian progression-free survival time of 5.6 versus 5.0months for the
participants treated with and without capecitabine. In total, four
studies (Kang 2009; Li 2016; Ochenduszko 2015; Van Cutsem
2015) were included in this comparison with a total of 647 partic-
ipants, demonstrating an overall HR of progression-free survival
of 0.98 (95% CI 0.77 to 1.23, very low quality) for participants
treated with vs without capecitabine (I²=23%, P=0.27) (Analysis
7.4). The exclusion of studies permitting second-line chemother-
apy (Li 2016; Ochenduszko 2015) did not alter the findings (HR
0.94, 95% CI 0.58 to 1.53).
Secondary resectability
This outcome was not reported in these studies.
Toxicity
Two studies (N = 481) reported deaths due to toxicity, where in
the capecitabine-containing arm was 5% in the capecitabine-con-
taining arm and 2% in the 5-FU arm (Kang 2009; Van Cutsem
2015) (Analysis 7.5). The pooled OR for treatment related death
is 1.88 (95% CI 0.23 to 15.15, very low-quality evidence), with
substantial heterogeneity (I² = 59%, P = 0.12). Treatment discon-
tinuation due to toxicity was similar in both arms (18%) (Kang
2009) (Analysis 7.6).
Quality of life
Was not reported in these studies.
(8) Chemotherapy with oxaliplatin versus the same
regimen including cisplatin
Overall survival
Data were available on 1105 participants in five studies (Al Batran
2008; Hironaka 2016; Kim 2014; Popov 2008; Yamada 2015).
The HR for overall survival of 0.81 (95% CI 0.67 to 0.98, low-
quality evidence) show a small, advantage for the regimen with
oxaliplatin (Analysis 8.1), with a moderate heterogeneity index
(I² = 38%, P = 0.17). This survival benefit is also reflected in the
pooled median overall survival time of 14.0 months versus 11.3
months, respectively.
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Secondary outcome measures
Tumour response
Data were available on 1081 participants of the five studies (Al
Batran 2008; Hironaka 2016; Kim 2014; Popov 2008; Yamada
2015). The response was 54% in the oxaliplatin-based arms and
47% in the cisplatin-based arms, with a statistically significant ad-
vantage for the oxaliplatin-containing regimen (OR1.38, 95%CI
1.08 to 1.76, moderate-quality evidence), and low heterogeneity
between studies (I² = 0%, P = 0.41) (Analysis 8.2).
Progression-free survival
Progression-free survival, rather than time to progression, was re-
ported in the studies by Al Batran 2008, Hironaka 2016, Kim
2014, and Yamada 2015 (N = 1034). The pooled hazard ratio of
oxaliplatin- versus cisplatin-based regimens, was 0.88 (95% CI:
0.66 to 1.19) with a high level of heterogeneity between studies
(I² = 59%, P = 0.06) (Analysis 8.3).
Secondary resectability
This outcome was not reported in these studies.
Toxicity
In Popov 2008, two participants (1.4%) experienced a toxic death
in the cisplatin-containing arms. These two participants suffered
from febrile neutropenia, developed sepsis, anddied of septic shock
despite antimicrobial therapy. No participant died of toxicity in
the oxaliplatin-containing arm (Popov 2008). One treatment-re-
lated death occurred in each arm in Kim 2014. Al Batran 2008
observed no treatment-related deaths. Overall, the pooled occur-
rence of treatment-related deaths (AlBatran 2008;Hironaka 2016;
Kim 2014; Popov 2008; Yamada 2015) (N = 1132) in both arms
were 0.9% and 2.0% in the oxaliplatin- and cisplatin-containing
arms, respectively (OR 0.47, 95% CI 0.17 to 1.30, low-quality
evidence), with a relatively stable effect across studies (I² = 0%,
P = 0.74) (Analysis 8.4). Data on treatment discontinuation due
to toxicity (Al Batran 2008; Hironaka 2016;Yamada 2015) (N =
970) were 8% and 10% in the oxaliplatin and cisplatin arms, re-
spectively (OR 0.97, 95% CI 0.44 to 2.13, very low-quality evi-
dence), with substantial between-study heterogeneity (I² = 60%,
P = 0.08) (Analysis 8.5).
Quality of life
This was not reported in these studies.
(9) Taxane-platinum-fluoropyrimidine combinations
versus taxane-platinum (without fluoropyrimidine)
Overall survival
The results for this comparison are based on 482 randomised par-
ticipants in three studies (Ajani 2005; Roth 2007; Van Cutsem
2015). The HR for overall survival of 0.86 (95% CI 0.71 to 1.06,
very low-quality evidence) favours the regimen with fluoropyrimi-
dine (I² = 0%, P = 0.47), but does not reach statistical significance
(Analysis 9.1). The corresponding pooled median survival times
are 11.7 versus 10.0 months with a small benefit for participants
treated with fluoropyrimidines. Allocation concealment was ade-
quate in the studies included in this comparison.
Secondary outcome measures
Tumour response
Data were available all participants in the above mentioned three
studies. The objective response rate was 38% in the 5-FU-contain-
ing regimen and 23% in the arm without 5-FU. This corresponds
to an OR of 2.08 (95% CI 1.37 to 3.15, low-quality evidence)
with an advantage for the 5-FU-containing regimen. Low hetero-
geneity (I² = 0%, P = 0.89) between studies was observed.
Time to progression
All three studies reported progression-free survival instead of time
to progression. Data from the included studies showed a benefit
(HR 0.74 95% CI 0.59 to 0.93, moderate-quality evidence) for
the participants treated with 5-FU (Analysis 9.3), and low hetero-
geneity between studies (I² = 0%, P = 0.83).
Secondary resectability
This outcome was not reported in these studies.
Toxicity numbers
In three studies (N = 482), treatment-related deaths were 6.2%
and 2.6% in the 5-FU-containing arms and non-FU-containing
arms respectively (OR 1.95, 95% CI 0.73 to 5.17, very low-qual-
ity evidence) (I² = 0%, P = 0.88) (Analysis 9.4). Treatment dis-
continuation due to toxicity was more frequent for the partici-
pants treated with 5-FU (16.7% versus 10.5%), corresponding to
an OR of 1.71 (95% CI 0.79 to 3.69, very low-quality evidence)
and results between studies were not different (I² = 0%, P = 0.93)
(Analysis 9.5).
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Quality of life
This was assessed in only one of these studies (Roth 2007). Treat-
ment burden increased over time in both treatment arms.
(10) S-1 versus 5-FU-containing regimens
Overall survival
This meta-analysis was based on 1793 participants in four ran-
domised studies (Ajani 2010; Boku 2009; Chen 2015; Li 2015).
The resulting HR for overall survival of 0.91 (95% CI 0.83 to
1.00, high-quality evidence) demonstrates a borderline statistically
significant benefit with low heterogeneity (I² = 0%, P = 0.50) with
overall survival in favour of S-1 (Analysis 10.1). The correspond-
ing pooled median survival times were 9.6 and 9.1 months with a
clinically negligible benefit for participants treated with S-1. Allo-
cation concealment was adequate in Ajani 2010 and Boku 2009.
Secondary outcome measures
Tumour response
Data were available in 1753 participants in seven studies (Ajani
2010; Boku 2009; Chen2015;Dong 2014;Huang 2013; Li 2015;
Li 2014). The objective response rate was 32% with S-1 and 26%
in the 5-FU arm. This corresponds to an OR of 1.73 (95% CI
1.01 to 2.94, very low-quality evidence) (Analysis 10.2). However,
considering the statistically significant heterogeneity (I² = 77%,
P = 0.0002), the results of this comparison have to be evaluated
cautiously.
Time to progression
Four studies (Ajani 2010; Boku 2009; Huang 2013; Li 2015)
(N = 1942) reported progression-free survival, with a small non-
significant benefit for participants treatedwith S-1 (HR0.85, 95%
CI 0.70 to 1.04, low-quality evidence) (Analysis 10.3) and with
substantial heterogeneity (I² = 70%, P = 0.02).
Three studies (Ajani 2010; Boku 2009; Huang 2013) reported
time to treatment failure (TTF) with a HR of 0.84 (95% CI 0.69
to 1.02) in favour of S-1. With the inclusion of Li 2014 and Chen
2015, who reported the time to progression, into themeta-analysis
of TTF (Analysis 10.4), (N = 1818), the pooled HR was 0.88
(95% CI 0.76 to 1.01. low-quality evidence), indicating a slight
but statistically non-significant benefit of S-1.
Secondary resectability
This outcome was not reported in these studies.
Toxicity
Rates of treatment-related deaths were less frequent in the S-1-
containing arm (1.5%) compared to 2.7% in the 5-FU-containing
arm (OR 0.56, 95% CI 0.30 to 1.06, moderate-quality evidence)
(I² = 0%, P = 0.52) (Analysis 10.5). Treatment discontinuation
due to toxicity was slightly less frequent for the participants treated
with S-1 (11.1% versus 12.8%, corresponding to an OR of 0.85
(95%CI 0.63 to 1.13, high-quality evidence) (I² = 11%, P = 0.32)
(Analysis 10.6).
Quality of life
Health-related quality of life was reported by Ajani 2010. There
was an advantage of CS compared to CF in terms of the Physical
Well-Being (PWB; 51.7%versus 45.1%, P = 0.044) component of
the FACT-Ga, longer time to worsening of PWB scores (median
duration; 4.5 versus 3.0 months, P = 0.014), and Chemotherapy
Convenience and Chemotherapy Concerns scores.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Combination versus single-agent chemotherapy for advanced gastric cancer
Patient or population: people with advanced gastric cancer
Settings: outpat ient clinics part icipat ing in internat ional mult icentre studies
Intervention: combinat ion
Control: single-agent chemotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Single-agent chemo-
therapy
Combination
Overall survival Study population HR 0.84
(0.79 to 0.89)
4447
(23)
⊕⊕⊕©
moderate1
Weighted average of
median survival dura-
t ions f rom included
studies
• 10.5 months in
studies published af ter
year 2000
• 6.4 months in
studies published
before year 2000
• 11.6 months in
studies published af ter
year 2000
• 7.3 months in
studies published
before year 2000
Tumour response Study population OR 2.30
(1.94 to 2.72)
2833
(18)
⊕⊕⊕⊕
high1
226 per 1000 402 per 1000
(361 to 442)
Moderate
231 per 1000 409 per 1000
(368 to 450)
2
7
C
h
e
m
o
th
e
ra
p
y
fo
r
a
d
v
a
n
c
e
d
g
a
stric
c
a
n
c
e
r
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Time to progression Study population HR 0.69
(0.55 to 0.87)
720
(4)
⊕⊕⊕©
moderate1
Weighted average of
median survival dura-
t ions f rom included
studies2.8 months 4.1 months
Treatment- related
death
Study population OR 1.64
(0.83 to 3.24)
3876
(18)
⊕⊕©©
moderate2
5 per 1000 9 per 1000
(4 to 17)
Moderate
0 per 1000 0 per 1000
(0 to 0)
* For t ime-to-event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculat ing the weighted average of the median survival durat ions
reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% conf idence interval) are based on proport ions of events in the
control and intervent ion groups respect ively.
CI: Conf idence interval; OR: Odds rat io; HR: Hazard rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded by one level for risk of bias.
2 Downgraded by two levels for serious imprecision.
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5-FU/cisplatin/ anthracycline combinations versus 5-FU/cisplatin combinations (without anthracyclines) for advanced gastric cancer
Patient or population: people with advanced gastric cancer
Settings: outpat ient clinics part icipat ing in internat ional mult icentre studies
Intervention: 5-FU/ cisplat in/ anthracycline combinat ions
Control: 5-FU/ cisplat in combinat ions (without anthracyclines)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
5-FU/cisplatin combi-
nations (without an-
thracyclines)
5-FU/cisplatin/ anthra-
cycline combinations
Overall survival Study population HR 0.74
(0.61 to 0.89)
579
(4)
⊕⊕⊕©
moderate1
Weighted average of
median survival dura-
t ions f rom included
studies8.6 months 9.9 months
Tumour response Study population OR 2.86
(1.14 to 7.16)
78
(1)
⊕⊕©©
low2
385 per 1000 641 per 1000
(416 to 817)
Moderate
385 per 1000 642 per 1000
(416 to 818)
Time to progression Study population HR 0.62
(0.38 to 0.98)
78
(1)
⊕⊕©©
low2
Median survival dura-
t ions f rom the only in-
cluded study7.9 months 12.1 months
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* For t ime-to-event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculat ing the weighted average of the median survival durat ions
reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% conf idence interval) are based on proport ions of events in the
control and intervent ion groups respect ively.
CI: Conf idence interval; OR: Odds rat io; HR: Hazard rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded by one level for risk of bias.
2 Downgraded by two levels for serious imprecision.
Outcomes shown include those which were measured in the studies, or reported in a consistent fashion across included
studies. Several crit ical outcomes (e.g. treatment-related death and discont inuat ion due to toxicity) were not evaluated or
reported in a consistent fashion in these studies, as they were mainly conducted before year 2000.
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5-FU/cisplatin/ anthracycline combinations versus 5-FU/anthracycline combinations (without cisplatin) for advanced gastric cancer
Patient or population: people with advanced gastric cancer
Settings: outpat ient clinics part icipat ing in internat ional mult icentre studies
Intervention: 5-FU/ cisplat in/ anthracycline combinat ions
Control: 5-FU/ cisplat in combinat ions (without anthracyclines)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
5-FU/anthracycline
combinations (without
cisplatin)
5-FU/cisplatin/ anthra-
cycline combinations
Overall survival Study population HR 0.82
(0.73 to 0.92)
1147
(7)
⊕⊕©©
low1,2
Weighted average of
median survival dura-
t ions f rom included
studies6.2 months 8.4 months
* For t ime-to-event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculat ing the weighted average of the median survival durat ions
reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% conf idence interval) are based on proport ions of events in the
control and intervent ion groups respect ively.
CI: Conf idence interval; HR: Hazard rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded by one level for risk of bias.
2 Downgraded by one level for stat ist ical heterogeneity.
Several crit ical outcomes (i.e. tumour response, progression-f ree survival, t reatment-related death and discont inuat ion due to
toxicity) were not evaluated or reported in a consistent fashion in these studies, most of which were conducted before year
2000.3
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Irinotecan versus non- irinotecan-containing regimens for advanced gastric cancer
Patient or population: people with advanced gastric cancer
Settings: outpat ient clinics part icipat ing in internat ional mult icentre studies
Intervention: irinotecan
Control: non-irinotecan-containing regimens
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Non- irinotecan-
containing regimens
Chemotherapy with
Irinotecan
Overall survival Study population HR 0.87
(0.80 to 0.95)
2135
(10 studies)
⊕⊕⊕©
moderate1
Weighted average of
median survival dura-
t ions f rom included
studies9.7 months 11.3 months
Overall survival - Sub-
stitutive comparisons
Study population HR 0.87
(0.75 to 1.00)
826
(6 studies)
⊕⊕⊕©
moderate1
Weighted average of
median survival dura-
t ions f rom included
studies9.1 months 9.9 months
Overall survival - Addi-
tive comparisons
Study population HR 0.88
(0.76 to 1.03)
500
(3 studies)
⊕⊕©©
low1,2
Weighted average of
median survival dura-
t ions f rom included
studies10.9 months 11.9 months
Overall survival - Other
comparisons
Study population HR 0.87
(0.76 to 1.00)
809
(2 studies)
⊕©©©
very low1,3
Weighted average of
median survival dura-
t ions f rom included
studies11.4 months 12.6 months
Tumour response Study population OR 1.72
(1.24 to 2.40)
1266
(10 studies)
⊕⊕©©
low3
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288 per 1000 410 per 1000
(334 to 493)
Moderate
275 per 1000 395 per 1000
(320 to 477)
Tumour response -
Substitutive compar-
isons
Study population OR 1.53
(0.93 to 2.50)
756
(6 studies)
⊕⊕©©
low3
297 per 1000 393 per 1000
(282 to 514)
Moderate
294 per 1000 389 per 1000
(279 to 510)
Tumour response - Ad-
ditive comparisons
Study population OR 2.18
(1.25 to 3.80)
345
(3 studies)
⊕⊕©©
low1,2
224 per 1000 386 per 1000
(265 to 522)
Moderate
219 per 1000 379 per 1000
(260 to 516)
Tumour response -
Other comparisons
Study population OR 1.87
(0.89 to 3.91)
165
(2 studies)
⊕©©©
very low1,2,4
376 per 1000 530 per 1000
(350 to 702)
Moderate
367 per 1000 520 per 1000
(340 to 694)
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Progression- free sur-
vival
Study population HR 0.76
(0.69 to 0.84)
1640
(7 studies)
⊕⊕⊕⊕
high
Weighted average of
median survival dura-
t ions f rom included
studies4.4 months 5.9 months
Progression- free sur-
vival - Substitutive
comparison
Study population HR 0.85
(0.72 to 1.00)
741
(5 studies)
⊕⊕⊕©
moderate1
Weighted average of
median survival dura-
t ions f rom included
studies4.2 months 5.3 months
Progression- free sur-
vival - Additive com-
parisons
Study population HR 0.51
(0.33 to 0.77)
90
(1)
⊕⊕⊕©
moderate2
Median survival dura-
t ions f rom the only in-
cluded study3.2 months 6.9 months
Progression- free sur-
vival - Other compar-
isons
Study population HR 0.74
(0.66 to 0.84)
809
(2 studies)
⊕⊕⊕⊕
high
Weighted average of
median survival dura-
t ions f rom included
studies5.4 months 6.6 months
Treatment- related
death
Study population OR 0.88
(0.23 to 3.32)
1979
(9 studies)
⊕⊕©©
low2,4
10 per 1000 9 per 1000
(2 to 32)
Moderate
2 per 1000 2 per 1000
(0 to 7)
Treatment discontinu-
ation due to toxicity
Study population OR 1.00
(0.46 to 2.20)
1979
(9 studies)
⊕©©©
very low2,3
137 per 1000 137 per 1000
(68 to 258)
Moderate
215 per 1000 215 per 1000
(112 to 376)3
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* For t ime-to-event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculat ing the weighted average of the median survival durat ions
reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% conf idence interval) are based on proport ions of events in the
control and intervent ion groups respect ively.
CI: Conf idence interval; OR: Odds rat io; HR: Hazard rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded by one level for risk of bias.
2 Downgraded by one level for imprecision.
3 Downgraded by two levels for severe stat ist ical heterogeneity.
4 Downgraded by one level for stat ist ical heterogeneity.
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Docetaxel versus non-docetaxel-containing regimens for advanced gastric cancer
Patient or population: people with advanced gastric cancer
Settings: outpat ient clinics part icipat ing in internat ional mult icentre studies
Intervention: docetaxel
Control: non-docetaxel-containing regimens
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Non-docetaxel-
containing regimens
Chemotherapy with do-
cetaxel
Overall survival Study population HR 0.86
(0.78 to 0.95)
2001
(8 studies)
⊕⊕⊕⊕
high
Weighted average of
median survival dura-
t ions f rom included
studies9.9 months 11.2 months
Overall survival - Sub-
stitutive comparisons
Study population HR 1.05
(0.87 to 1.27)
479
(3 studies)
⊕⊕⊕©
moderate1
Weighted average of
median survival dura-
t ions f rom included
studies9.4 months 9.2 months
Overall survival - Addi-
tive comparisons
Study population HR 0.80
(0.71 to 0.91)
1466
(4 studies)
⊕⊕⊕©
moderate2
Weighted average of
median survival dura-
t ions f rom included
studies10.6 months 12.3 months
Overall survival - Other
comparisons
Study population HR 0.80
(0.46 to 1.39)
56
(1 study)
⊕©©©
very low1,2,3
Median survival dura-
t ions f rom the only in-
cluded study9.5 months 11.9 months
Tumour response Study population OR 1.37
(1.03 to 1.83)
1820
(9 studies)
⊕⊕⊕©
moderate4
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311 per 1000 382 per 1000
(317 to 452)
Moderate
310 per 1000 381 per 1000
(316 to 451)
Tumour response -
Substitutive compari-
son
Study population OR 1.03
(0.71 to 1.50)
525
(4 studies)
⊕⊕⊕©
moderate1
314 per 1000 320 per 1000
(245 to 407)
Moderate
327 per 1000 334 per 1000
(256 to 422)
Tumour response - Ad-
ditive comparison
Study population OR 1.83
(1.45 to 2.32)
1235
(4 studies)
⊕⊕⊕⊕
high
295 per 1000 434 per 1000
(378 to 493)
Moderate
296 per 1000 435 per 1000
(379 to 494)
Tumour response -
Other comparison
Study population OR 0.33
(0.12 to 0.96)
60
(1 study)
⊕©©©
very low1,3
600 per 1000 331 per 1000
(153 to 590)
Moderate
600 per 1000 331 per 1000
(153 to 590)
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Time to progression Study population HR 1.06
(0.85 to 1.32)
360
(2 studies)
⊕©©©
very low1,2,3
Weighted average of
median survival dura-
t ions f rom included
studies6.0 months 5.9 months
Progression- free sur-
vival
Study population HR 0.76
(0.63 to 0.91)
1498
(5 studies)
⊕⊕⊕©
moderate4
Weighted average of
median survival dura-
t ions f rom included
studies4.8 months 6.0 months
Progression- free sur-
vival - Substitutive
comparisons
Study population HR 1.15
(0.77 to 1.72)
119
(1 study)
⊕©©©
very low1,2,3
Median survival dura-
t ions f rom the only in-
cluded study4.9 months 4.6 months
Progression- free sur-
vival - Additive com-
parison
Study population HR 0.70
(0.61 to 0.81)
1323
(3 studies)
⊕⊕⊕⊕
high
Weighted average of
median survival dura-
t ions f rom included
studies4.3 months 6.0 months
Progression- free sur-
vival - Other compari-
son
Study population HR 0.94
(0.55 to 1.60)
56
(1 study)
⊕©©©
very low1,3
Median survival dura-
t ions f rom the only in-
cluded study6.4 months 6.8 months
Treatment- related
death
Study population OR 1.10
(0.55 to 2.20)
2113
(7 studies)
⊕⊕⊕©
moderate1
12 per 1000 14 per 1000
(7 to 27)
Moderate
5 per 1000 5 per 1000
(3 to 11)
Treatment discontinu-
ation due to toxicity
Study population OR 0.81
(0.53 to 1.25)
1066
(5 studies)
⊕⊕©©
low1,4
211 per 1000 178 per 1000
(124 to 251)
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Moderate
197 per 1000 166 per 1000
(115 to 235)
* For t ime-to-event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculat ing the weighted average of the median survival durat ions
reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% conf idence interval) are based on proport ions of events in the
control and intervent ion groups respect ively.
CI: Conf idence interval; OR: Odds rat io; HR: Hazard rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded by one level for imprecision.
2 Downgraded by one level for risk of bias.
3 Downgraded by two levels for serious imprecision.
4 Downgraded by one level for stat ist ical heterogeneity.
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Capecitabine versus 5-FU-containing regimens for advanced gastric cancer
Patient or population: people with advanced gastric cancer
Settings: outpat ient clinics part icipat ing in internat ional mult icentre studies with approximately half of all part icipants enrolled f rom Asian countries
Intervention: capecitabine
Control: 5-FU-containing regimens
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
5-FU-containing regi-
mens
Capecitabine-
containing regimens
Overall Survival Study population HR 0.94
(0.79 to 1.11)
732
(5 studies)
⊕⊕⊕©
moderate1
Weighted average of
median survival dura-
t ions f rom included
studies10.9 months 10.8 months
Tumour response Study population OR 0.85
(0.40 to 1.79)
636
(4 studies)
⊕©©©
very low2,3
384 per 1000 347 per 1000
(200 to 528)
Moderate
394 per 1000 356 per 1000
(206 to 538)
Time to progression Study population HR 0.72
(0.47 to 1.12)
85
(1 study)
⊕©©©
very low1,3
Median survival dura-
t ions f rom the only in-
cluded study5.5 months 6.8 months
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Progression- free sur-
vival
Study population HR 0.98
(0.77 to 1.23)
647
(4 studies)
⊕©©©
very low1,3,4
Weighted average of
median survival dura-
t ions f rom included
studies6.7 months 6.5 months
Treatment- related
death
Study population OR 1.88
(0.23 to 15.15)
481
(2 studies)
⊕©©©
very low1,2,3
21 per 1000 38 per 1000
(5 to 241)
Moderate
24 per 1000 44 per 1000
(6 to 271)
Treatment discontinu-
ation due to toxicity
Study population OR 0.99
(0.56 to 1.77)
311
(1 study)
⊕⊕©©
low3
181 per 1000 179 per 1000
(110 to 281)
Moderate
181 per 1000 180 per 1000
(110 to 281)
* For t ime-to-event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculat ing the weighted average of the median survival durat ions
reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% conf idence interval) are based on proport ions of events in the
control and intervent ion groups respect ively.
CI: Conf idence interval; OR: Odds rat io; HR: Hazard rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded by one level for risk of bias.
2 Downgraded by two levels for severe stat ist ical heterogeneity.41
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3 Downgraded by two levels for serious imprecision.
4 Downgraded by one level for stat ist ical heterogeneity.
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Oxaliplatin versus the same regimen including cisplatin for advanced gastric cancer
Patient or population: people with advanced gastric cancer
Settings: outpat ient clinics part icipat ing in internat ional mult icentre studies with the majority of part icipants enrolled in Asia
Intervention: oxaliplat in-containing regimen
Control: the same regimen including cisplat in
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Cisplatin-containing
regimen
Oxaliplatin-containing
regimen
Overall Survival Study population HR 0.81
(0.67 to 0.98)
1105
(5 studies)
⊕⊕©©
low1,2
Weighted average of
median survival dura-
t ions f rom included
studies11.3 months 14.0 months
Tumour response Study population OR 1.38
(1.08 to 1.76)
1081
(5 studies)
⊕⊕⊕©
moderate1
468 per 1000 548 per 1000
(487 to 607)
Moderate
458 per 1000 538 per 1000
(477 to 598)
Progression- free sur-
vival
Study population HR 0.88
(0.66 to 1.19)
1034
(4 studies)
⊕⊕©©
low1,3
Weighted average of
median survival dura-
t ions f rom included
studies4.9 months 6.0 months
Treatment- related
death
Study population OR 0.47
(0.17 to 1.30)
1132
(5 studies)
⊕⊕©©
low1,34
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20 per 1000 9 per 1000
(3 to 25)
Moderate
24 per 1000 11 per 1000
(4 to 31)
Treatment discontinu-
ation due to toxicity
Study population OR 0.97
(0.44 to 2.13)
970
(3 studies)
⊕©©©
very low1,2,3
95 per 1000 93 per 1000
(44 to 183)
Moderate
102 per 1000 99 per 1000
(48 to 195)
* For t ime-to-event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculat ing the weighted average of the median survival durat ions
reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% conf idence interval) are based on proport ions of events in the
control and intervent ion groups respect ively.
CI: Conf idence interval; OR: Odds rat io; HR: Hazard rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded by one level for risk of bias.
2 Downgraded by one level for stat ist ical heterogeneity.
3 Downgraded by one level for imprecision.
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Taxane-platinum- fluoropyrimidine combinations versus taxane-platinum (without fluoropyrimidine) for advanced gastric cancer
Patient or population: people with advanced gastric cancer
Settings: outpat ient clinics part icipat ing in internat ional mult icentre studies, without Asian representat ion
Intervention: taxane-plat inum-f luoropyrim idine combinat ions
Control: taxane-plat inum (without f luoropyrim idine)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Taxane-
platinum (without fluo-
ropyrimidine)
Taxane-platinum- fluo-
ropyrimidine combina-
tion
Overall survival Study population OR 0.86
(0.71 to 1.06)
482
(3 studies)
⊕©©©
very low1,2
Weighted average of
median survival dura-
t ions f rom included
studies10.0 months 11.7 months
Tumour response Study population OR 2.08
(1.37 to 3.15)
482
(3 studies)
⊕⊕©©
low1,3
234 per 1000 389 per 1000
(295 to 491)
Moderate
231 per 1000 385 per 1000
(292 to 486)
Progression- free sur-
vival
Study population OR 0.74
(0.59 to 0.93)
482
(3 studies)
⊕⊕⊕©
moderate1
Weighted average of
median survival dura-
t ions f rom included
studies4.4 months 5.7 months
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Treatment- related
death
Study population OR 1.95
(0.73 to 5.17)
482
(3 studies)
⊕©©©
very low1,4
26 per 1000 50 per 1000
(19 to 121)
Moderate
13 per 1000 25 per 1000
(10 to 64)
Treatment discontinu-
ation due to toxicity
Study population OR 1.71
(0.79 to 3.69)
234
(2 studies)
⊕©©©
very low1,4
105 per 1000 167 per 1000
(85 to 303)
Moderate
99 per 1000 158 per 1000
(80 to 288)
* For t ime-to-event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculat ing the weighted average of the median survival durat ions
reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% conf idence interval) are based on proport ions of events in the
control and intervent ion groups respect ively.
CI: Conf idence interval; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded by one level for risk of bias.
2 Downgraded by two levels for severe stat ist ical heterogeneity.
3 Downgraded by one level for imprecision.
4 Downgraded by two levels for serious imprecision.
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S-1 versus 5-FU-containing regimens for advanced gastric cancer
Patient or population: people with advanced gastric cancer
Settings: outpat ient clinics part icipat ing in internat ional mult icentre studies, most ly performed in Asia
Intervention: S-1-containing regimens
Control: 5-FU-containing regimens
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
5-FU-containing regi-
mens
S-1 containing regi-
mens
Overall Survival Study population HR 0.91
(0.83 to 1.00)
1793
(4 studies)
⊕⊕⊕⊕
high
Weighted average of
median survival dura-
t ions f rom included
studies9.1 months 9.6 months
Tumour response Study population OR 1.73
(1.01 to 2.94)
1753
(7 studies)
⊕©©©
very low1,2
256 per 1000 374 per 1000
(258 to 503)
Moderate
320 per 1000 449 per 1000
(322 to 580)
Progression- free sur-
vival
Study population HR 0.85
(0.70 to 1.04)
1942
(4 studies)
⊕⊕©©
low1
Weighted average of
median survival dura-
t ions f rom included
studies4.3 months 5.0 months
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Time- to treatment fail-
ure
Study population HR 0.88
(0.76 to 1.01)
1818
(5 studies)
⊕⊕©©
low1
Weighted average of
median survival dura-
t ions f rom included
studies3.1 months 3.9 months
Treatment- related
deaths
Study population OR 0.56
(0.30 to 1.06)
1962
(4 studies)
⊕⊕⊕©
moderate2
27 per 1000 15 per 1000
(8 to 28)
Moderate
5 per 1000 3 per 1000
(2 to 5)
Treatment discontinu-
ation due to toxicity
Study population OR 0.85
(0.63 to 1.13)
1726
(3 studies)
⊕⊕⊕⊕
high
128 per 1000 111 per 1000
(85 to 142)
Moderate
144 per 1000 125 per 1000
(96 to 160)
* For t ime-to-event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculat ing the weighted average of the median survival durat ions
reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% conf idence interval) are based on proport ions of events in the
control and intervent ion groups respect ively.
CI: Conf idence interval; OR: Odds rat io; HR: Hazard rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded by two levels for severe stat ist ical heterogeneity.
2 Downgraded by one level for imprecision.48
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D I S C U S S I O N
Summary of main results
Only randomised controlled studies were included in this meta-
analysis. An exhaustive search for unpublished or ongoingmaterial
was performed to minimise publication bias. Sixty studies, with a
total of 11,698 participants, have been included in the meta-anal-
ysis of overall survival. Themeta-analyses of comparisons 1 (three
studies, 184 participants) and 2 (23 studies involving 4447 partic-
ipants) provide evidence for significant benefits in overall survival
for first-line chemotherapy versus best supportive care (BSC), as
well as a smaller benefit for combination versus single-agent che-
motherapy.Overall, regimens containing irinotecan demonstrated
improved results for overall survival in the substitutive comparison
(i.e. where another chemotherapy was substituted by irinotecan)
of irinotecan versus non-irinotecan-containing regimens (six stud-
ies with 826 participants, HR 0.87, 95% CI 0.75 to 1.00, high-
quality evidence), but not in the additive comparison (i.e. where
irinotecan was added to another chemotherapy; HR 0.88, 95%
CI 0.76 to 1.03, three studies with 500 participants, low-qual-
ity evidence). In contrast, the meta-analysis of all irinotecan-con-
taining versus non-irinotecan-containing regimens demonstrates
a small, but significant survival benefit in favour of the people
treated with irinotecan. Of note, both treatment-related deaths
and treatment-discontinuation due to toxicity were not increased
for people treated with irinotecan.
Furthermore, regimens in which docetaxel was added to a two-
drug platinum-fluoropyrimidine combination showed a signifi-
cant survival benefit (four studies with 1466 participants (HR
0.80, 95% CI 0.71 to 0.91, moderate-quality evidence). In con-
trast, substituting another chemotherapy (e.g. 5-FU (Ridwelski
2008), epirubicin (Roth 2007), or both epirubicin and 5-FU
(Thuss-Patience 2005)) by docetaxel provides no advantage - ei-
ther in survival, or in secondary outcomes (three studies involving
479 participants, HR 1.05; 0.87 to 1.27, moderate-quality evi-
dence). However, the addition of docetaxel to a two-drug chemo-
therapy regimen in first-line therapy slightly increases both the risk
of treatment-related deaths and treatment discontinuation due to
toxicity. The comparison of regimens including capecitabine ver-
sus 5-FU showed non-significant advantages in terms of overall
survival for the oral 5-FU prodrug capecitabine (732 participants
in five studies, 0.94, 95% CI 0.79 to 1.11, moderate-quality evi-
dence).
The comparison of regimens including oxaliplatin versus cisplatin
(comparison 8), and S-1 versus 5-FU (comparison 10), however
demonstrated the superior efficacy of oxaliplatin (1105 partici-
pants from five studies, HR 0.81, 95% CI 0.67 to 0.98, low-qual-
ity evidence) and S-1 (1793 participants in four studies, HR 0.91,
95% CI 0.83 to 1.00, high-quality evidence), respectively, the lat-
ter being statistically non significant. However the magnitude of
the benefit in individual populations is unclear due to differences
in dosing and treatment schedules, and drug metabolism of S-1
between Asian and Caucasian populations. Of note, the landmark
REAL-2 study could not be included in this analysis as it included
up to 13% of people with oesophageal squamous cell carcinoma
in the different study arms.
(1) First-line chemotherapy versus best supportive
care
Results for the comparison of first-line chemotherapy versus best
supportive care (BSC) convincingly demonstrate a benefit in me-
dian survival in favour of chemotherapy (HR0.37, 95%CI 0.24 to
0.55, three studies, 184 participants, moderate-quality evidence),
corresponding to 11 versus 4.3 months weighted average survival.
The validity of this result was limited by the small number of
participants included in this analysis. In two of four studies ad-
dressing this question, either the randomisation (Murad 1993)
or the study (Pyrhönen 1995) were terminated early. In another
one (Glimelius 1997) the conduct of the study was not possible
as planned because the research ethics committee requested the
provision of chemotherapy upon request in the BSC group. Fur-
ther studies addressing this comparison cannot be carried out as
BSC cannot be considered to be an appropriate control arm for
further studies. Exclusion of the studies by Murad and Pyrhönen,
both of which have severe methodological limitations as described
above, restricts the studies eligible for this analysis to the study
by Scheithauer (Scheithauer 1996). This study, which included
103 participants, was the largest of all studies performed for this
comparison and demonstrated a survival benefit of 10.2 versus
5.0 months in the chemotherapy versus BSC group (P = 0.0001),
which is statistically significant and in line with the results of the
other two studies, although not as large. Another study (Glimelius
1997), which was excluded from the analysis (see above) because
of cross-over, provided important insights about the quality of life
of participants in the chemotherapy and BSC arms. The average
quality-adjusted survival was longer in the group of participants
randomised to chemotherapy than in the BSC group (median six
versus two months). In addition to the benefits in median survival
and quality of life, between 10% and 24% of all participants in
the chemotherapy groups in these three studies were alive after
two years. In contrast, only one of 81 participants included in the
BSC arms of these studies survived longer than 24 months. Two-
year survival rates in chemotherapy-treated participants between
5% and 14% were confirmed by other authors (Ohkuwa 2000;
Waters 1999), confirming the observation that a limited number
of people do have a considerably greater survival benefit from che-
motherapy. The reason for the difference in pooled median sur-
vival between chemotherapy arms in the studies that compared
chemotherapy versus BSC (11.0 months) and the combination
therapy arms in studies comparing single-agent versus combina-
tion chemotherapy (7.0 months) remains unclear and cannot be
explained by differences in prognostic factors. Considering the
small number of participants included in the studies comparing
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chemotherapy versus BSC, as well as the methodological limita-
tions in two of these three studies, an over-estimation of the effect
of chemotherapy in these studies is likely.
(2) Single agent versus combination chemotherapy
Regarding comparison 2, 16 of 23 relevant individual studies (N
= 4447) did not demonstrate a benefit in terms of overall sur-
vival for the combination chemotherapy arms. In this context, the
results of this meta-analysis demonstrate a statistically significant
and consistent benefit for combination versus single-agent ther-
apy in terms of overall survival (HR 0.84, 95% CI 0.79 to 0.89,
moderate-quality evidence). Furthermore, response rate and time
to progression show advantages for the participants treated with
combination chemotherapy. The pooled results of these studies
represent a generalised estimate of the effectiveness of the combi-
nation chemotherapy regimens used in the last 25 years. Therefore,
the benefit of a modern two-drug combination, such as 5-FU/
irinotecan or 5-FU/oxaliplatin over a single-agent, usually fluo-
ropyrimidine-based chemotherapy regimen is likely to exceed this
global result.
Although any potential survival benefit associated with combina-
tion chemotherapy is achieved at the price of increased toxicity,
the toxicity of the above mentioned combinations of 5-FU and
irinotecan, and 5-FU and oxaliplatin is well managed by oncolo-
gists today. Furthermore, given the known correlation between tu-
mour response and quality of life (Sadighi 2006), and considering
that the ability of a chemotherapy tomaintain a person’s health-re-
lated quality of life is correlated to its efficacy (Al-Batran 2010), in
the absence of contraindications, modern two-drug combination
chemotherapy regimens as discussed above should clearly be the
preferred option for first-line treatment of people with advanced
gastric cancer.
(3) 5-FU/cisplatin/anthracycline combinations versus
5-FU/cisplatin (without anthracyclines)
This comparison was based on 579 participants in four ran-
domised studies and results in a HR of 0.74 (95%CI 0.61 to 0.89,
moderate-quality evidence) in favour of the three-drug combina-
tion. This comparison is limited by a small number of studies and
participants. The results of this comparison are predominantly at-
tributable to the study by Ross 2002, which compared ECF versus
MCF. The difference between the data included in this review and
the final publication is due to the fact that the original publica-
tion included people with squamous cell cancer of the oesophagus,
which do not correspond to the inclusion criteria of this review.
Therefore, data from people with gastric adenocarcinoma only as
provided by the authors were included in this review.
Whether these results are still relevant today is questionable for
two reasons.
1) Since the publication of the REAL-2 study (Cunningham
2008), which demonstrated a significant survival benefit for the
combination of EOX (epirubicin, oxaliplatin, and capecitabine)
as compared to ECF (epirubicin, cisplatin, and fluorouracil),
cisplatin is frequently replaced by oxaliplatin and 5-FU by
capecitabine in clinical practice. The relative contributionof epiru-
bicin to the efficacy of the three-drug regimen of capecitabine,
oxaliplatin, and epirubicin must be considered as unclear.
2) All studies included in this comparison were conducted at a
time when active drugs for second-line chemotherapy were not
available. Thus, the validity of these results in 2017, after the pub-
lication of 3 randomised studies comparing second-line therapy
versus BSC (Ford 2014; Kang 2012; Thuss-Patience 2011), which
all three demonstrated as clinically meaningful, statistically signif-
icant, and consistent benefit in survival of about 1.5 months, as
well as improvements in clinical symptoms Thuss-Patience 2011
and quality of life Ford 2014, needs to be questioned.
In addition, a recently published, french randomised multicentre
phase III study Guimbaud 2014, in which a total of 416 partic-
ipants were included, is of special interest in this context. This
study compared the combination of FOLFIRI, followed by ECX
(epirubicin, cisplatin, and capecitabine) with the reverse sequence
of the same regimens. It has not been included in this meta-anal-
ysis as all participants eligible for second-line chemotherapy were
systematically crossed over. The results of this study showed sim-
ilar results for PFS (5.3 versus 5.8 months) and OS (9.5 ver-
sus 9.7 months) for both treatment strategies, but a longer time-
to treatment-failure for FOLFIRI. Furthermore, the tolerance of
FOLFIRI (overall grade III+IV toxicities and haematological ad-
verse events) was better. For these reasons it must be considered as
questionable whether the benefit from adding epirubicin to a two-
drug regimen including capecitabine and oxaliplatin outweighs its
additional toxicity, especially in sequential treatment strategies.
(4) 5-FU/cisplatin/anthracycline-combinations versus
5-FU/anthracycline combinations (without cisplatin)
Comparison 4 was based on 1147 participants randomised in
seven studies and resulted in a HR of 0.82 (95% CI 0.73 to 0.92;
low-quality evidence, Analysis 4.1) in favour of the three-drug
combination. A sensitivity analysis according to the quality score
with inclusion of only those studies in which allocation conceal-
ment was adequate (Cocconi 1994; Cocconi 2003; Kikuchi 1990;
Webb 1997) does not cause a relevant change of the resulting HR
(0.82, 95%CI 0.73 to 0.92, low-quality evidence). Heterogeneity
was non-significant in comparison 3 and 4 (P = 0.71 and 0.21;
I² was 0% (95% CI 0% to 26.5%) and 28.5% (95% CI 0% to
69.2%).
This comparison, which included a greater number of participants
and studies compared to comparison 3, and is thus much more
robust, confirms a statistically significant advantage in overall sur-
vival for the addition of cisplatin to the combination of epirubicin
and fluorouracil, achieved at the price of increased toxicity. Again,
all studies included in this comparison were published more than
20 years ago, when second-line therapy was unavailable. There-
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fore, as discussed above, the benefit of anthracyclines in this three-
drug combination today is unclear. In view of the evidence dis-
cussed above, combinations of 5-FU/cisplatin and an anthracy-
cline are no longer considered as a preferred option for the first-
line treatment of advanced gastric cancer today.
(5) Irinotecan versus non-irinotecan-containing
regimens
Comparison 5 was based on 2135 participants randomised in
10 studies including six studies in substitutive comparisons, three
studies in additive comparison, and two other comparisons. Two
treatment arms without irinotecan (5-FU as single-agent and 5-
FU/cisplatin) were compared to FOLFIRI in Bouche 2004. Tak-
ing all studies into account, the pooled hazard ratio was 0.87 (95%
CI 0.80 to 0.95, high-quality evidence) in favour of irinotecan-
containing regimens. In subgroup analyses of overall survival, the
pooled HR were 0.87 (95% CI 0.75 to 1.00, high-quality evi-
dence) for the substitutive comparison, HR 0.88 (95% CI 0.76
to 1.03, low-quality evidence) for the additive comparison, and
HR 0.87 (95% CI 0.76 to 1.00, very low-quality evidence) for the
other comparisons, Analysis 5.1.
Objective response rates of 38% versus 30% were observed in sub-
stitutive (OR 1.53, 95% CI 0.93 to 2.50, low-quality evidence)
and 38% versus 22% in additive comparisons (OR 2.18, 95% CI
1.25 to 3.80, low-quality evidence). The pooled HR for progres-
sion-free survival was 0.76 (95% CI 0.69 to 0.84, high-quality
evidence); and 0.85 (95% CI 0.72 to 1.00, moderate-quality ev-
idence) and 0.74 (95% CI 0.66 to 0.84, high-quality evidence)
for subgroup analysis of substitutive and other comparisons, re-
spectively. Results for rates of treatment-related deaths and treat-
ment discontinuation due to toxicity showed high heterogeneity
between studies.
In view of these results, 5-FU/irinotecan-based two-drug combi-
nations should be considered as a true and at least equally effec-
tive alternative to platinum-based combinations in first-line ther-
apy. A further advantage of the irinotecan-based combination is
the different toxicity profile with no neurotoxicity (as compared
to the platinum derivatives) and no significant renal toxicity. In
addition, irinotecan-based regimens can easily be administered in
the outpatient setting and avoid the hyperhydration necessary for
the treatment with cisplatin. Again, the above mentioned study
Guimbaud 2014 clearly demonstrates not only the comparable
results of treatment with FOLFIRI in first- versus second-line, but
as well the feasibility of second-line chemotherapy in 40% to 50%
of people and third-line in about 20% of people in Europe.
(6) Docetaxel versus non-docetaxel-containing
regimens
Comparison 6 was based on 2001 participants randomised in
eight studies including three studies in substitutive comparisons,
four studies in additive comparison, and one study in other com-
parisons. Results from one study (Sadighi 2006) are not included
in this meta-analysis at present because data for the calculation of
the HR were not available. Overall, heterogeneity was not signifi-
cant in the former two comparisons (I² = 0%, P = 0.99 and 0.82).
Of special interest is the fact that studies, in which docetaxel was
added to a two-drug regimen of a platinum and a fluoropyrimidine
(Al-Batran 2013; Wang 2016; Van Cutsem 2006) or S-1 as single-
agent (Koizumi 2014) demonstrate a significant benefit not only
in terms of survival (HR 0.80; 0.71 to 0.91, moderate-quality evi-
dence), but also in terms of response rates where the OR was 1.83
(95% CI 1.45 to 2.32, high-quality evidence) for the regimens
with docetaxel. In contrast, when docetaxel is substituting another
chemotherapy, such as 5-FU, no OS benefit of the docetaxel-con-
taining chemotherapy regimen was observed (HR 1.05, 95% CI
0.87 to 1.27, moderate-quality evidence). Thus, docetaxel-con-
taining two-drug regimens are less efficient than docetaxel-con-
taining three-drug regimens. This observation is confirmed by the
recently published, randomised phase II study by Van Cutsem
2015, where overall survival was 14.59 months (95% CI:11.7 to
21.78) for participants treated with docetaxel, oxaliplatin, and 5-
FU, as compared to 11.3 (95% CI 8.08 to 14.03) months. How-
ever, survival was only a secondary endpoint of this study, and
the study was not powered to detect survival differences. Of note,
in the study by Van Cutsem 2006 32% and 41% of participants
in both study arms were treated with further chemotherapy lines,
while this figure was not given for the study by Al-Batran 2013.
The positive effect of the addition of docetaxel to the cisplatin/
fluorouracil combination on survival as well as the time to 5%
deterioration of global health status in the study by Van Cutsem
2006 was unfortunately achieved at the price of significant toxic-
ity, especially haematological toxicity. For this reason, the clinical
value of this regimen is regarded as controversial (Ilsen 2007). Of
note, grade III to IV infection (related to treatment) was more
frequent in elderly people (20% versus 9%), and infection was the
main cause of treatment-related deaths in both study arms.
Finally, the median age of 55 in the participants included in this
study, which was well below the median age of the participants
included in other studies (e.g. Al Batran 2008 or Cunningham
2008: 64 and 65 years), needs to be considered when applying
these findings to people outside a clinical study. In contrast, the
FLOT regimen (5-FU, leucovorin, oxaliplatin, and docetaxel) was
developed in an elderly population (median age 69 and 70 years
in both treatment groups) (Al-Batran 2013). The primary end-
point of this randomised phase II study, which compared FLOT
with FLO (5-FU, leucovorin and oxaliplatin) was the tolerability
and feasibility, defined as per group differences in toxic effects.
While the results of this study show - as expected - higher rates of
neutropenia, leukopenia, alopecia, and diarrhoea for the partici-
pants treated with FLOT, there were similar rates of complicated
neutropenia and serious adverse events in the two treatment arms.
However, progression-free and overall survival in people over 70
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years was similar for treatment with FLOT and FLO. Thus, al-
though FLOT has shown to be feasible in a population over 65
years old, according to a subgroup analysis of younger participants
(n = 68) versus equal to or older than 70 years (n = 75) in this study,
only in participants younger than 70 an improved survival was ob-
served for the three-drug combination (median survival 7.1 versus
10.6 months). However, these data are not more than hypothe-
sis generating based on a subgroup analysis from a randomised
phase II study. Nevertheless, although the same limitation is valid,
another subgroup analysis from this study, which compared the
benefit of FLOT to FLO in people with locally advanced versus
metastatic disease raised another interesting hypothesis. Accord-
ing to this subgroup analysis, median survival of people with lo-
cally advanced disease (n = 44) treated with FLOT versus FLO is
24.2 versus 10.3 months, as compared to 7.3 versus 6.0 months in
people with metastatic disease (n = 99). Thus, people with locally
advanced disease might have a greater benefit from FLOT than
people with metastatic disease.
(7) Regimens including capecitabine versus
intravenous 5-FU-containing regimens
Comparison 7 was based on 732 randomised participants in five
studies and resulted in a HR of 0.94 (95% CI 0.79 to 1.11; mod-
erate-quality evidence, Analysis 7.1). The finding of these studies
are in line with the study by Cunningham 2008, which confirms
the non-inferiority of capecitabine as compared to 5-FU although
it was not included in this comparison because of differences in
the participant population (inclusion of people with squamous
cell cancer of the oesophagus). For this reason, people with gas-
tric cancer without dysphagia, with adequate renal function and
compliance may be treated with capecitabine (or S-1 - see Analysis
10.1) instead of 5-FU.
(8) Regimens including oxaliplatin versus the same
regimen including cisplatin
Overall survival results for comparison 8 are based on 1105 ran-
domised participants in five studies. The HR for overall survival
was 0.81 (95% CI 0.67 to 0.98, low-quality evidence) show-
ing a statistically significant survival advantage in favour of oxali-
platin-containing regimens (Analysis 8.1). A higher rate of tumour
response was also observed in oxaliplatin-containing regimens
(54%) compared to cisplatin-containing regimens (47%) (OR
1.38, 95% CI 1.08 to 1.76, moderate-quality evidence). Again,
although data from the landmark REAL-2 study (Cunningham
2008) were not included in this comparison for reasons specified
above, they confirm the non-inferiority of oxaliplatin as compared
to cisplatin. It is worth noting that three of these included stud-
ies were conducted in Asia (Hironaka 2016; Kim 2014; Yamada
2015), potentially highlighting the applicability of these results to
an Asian cohort.
Of special interest in this context is a subgroup analysis of the study
by Al Batran 2008, which reports better results for elderly partici-
pants treated with oxaliplatin as compared to cisplatin. Therefore,
especially when taking into account the higher response rates and
lower risk of treatment-related death, oxaliplatin should be pre-
ferred to cisplatin in the treatment of gastric cancer.
9) Taxane-platinum-fluoropyrimidine combinations
versus taxane-platinum (without fluoropyrimidine)
This comparison was based on 482 randomised participants in
three studies and resulted in aHR for overall survival of 0.86 (95%
CI 0.71 to 1.06; very low-quality evidence, Analysis 9.1) in favour
of the taxane regimen plus fluoropyrimidine, without reaching
statistical significance. The potential drawback was the higher rate
of treatment-related deaths (6.2% versus 2.6%, OR 1.95; 95%
CI 0.73 to 5.17) and treatment discontinuation due to toxicity
(17% versus 11%, OR 1.71, 95% CI 0.79 to 3.69) in the regi-
menswith fluoropyrimidines.Of note; these results are partially at-
tributable to the docetaxel/oxaliplatin/capecitabine-combination,
which due to its clearly inferior therapeutic index as compared
to the same combination with 5-FU instead of capecitabine (Van
Cutsem 2015) is not recommended. However, objective response
rates (38% versus 23%, 2.08 (95% CI CI 1.37 to 3.15) and pro-
gression-free survival (HR 0.74, 95% CI 0.59 to 0.93, moderate-
quality evidence) were improved in regimens with fluoropyrim-
idine. Treatment burden increased over time in both treatment
arms. Thus, in conclusion, when a docetaxel-containing three-
drug combination chemotherapy regimen is chosen as first-line
treatment, oxaliplatin should be preferred to cisplatin, and 5-FU
should be preferred to capecitabine.
(10) S-1 versus 5-FU-containing regimens
This comparison was based on 1793 randomised participants in
four studies and resulted in a HR for overall survival of 0.91 (95%
CI 0.83 to 1.00; Analysis 10.1). In addition, a statistically signif-
icant advantage in tumour response (OR 1.73, 95% CI 1.01 to
2.94, very low-quality evidence), a numerical benefit in progres-
sion- free-survival (HR 0.85, 95% CI 0.70 to 1.04) and time-to-
treatment failure (HR 0.88, 95% CI 0.76 to 1.01, both low-qual-
ity evidence), less frequent treatment-related deaths (1.5% versus
2.7%, OR 0.56, 95% CI 0.30 to 1.06), and treatment discontin-
uations due to toxicity (11.1% versus 12.8%, OR 0.85, 95% CI
0.63 to 1.13) were observed in the S-1-containing compared to
the 5-FU-containing arms.
Overall completeness and applicability of
evidence
In most of these studies, the participants were only in part repre-
sentative of all people with gastric cancer because they were gen-
erally younger than the overall population of people with gastric
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cancer (Pye 2001). People with co-morbidities, such as renal or
cardiac disease, were excluded. For this reason, these findings are
only applicable to people who fulfil the inclusion criteria of these
studies and cannot be generalised to all people with gastric cancer.
The number of studies representing Asian people with gastric can-
cer in this 2017 updated review has increased considerably, with
now a total of 26 studies conducted at least in part in Asia (Boku
2009; Chen 2015; Dong 2014; Hironaka 2016; Huang 2013;
Kang 2009; Kikuchi 1990; Kim 2001; Kim 2014; Koizumi 2008;
Koizumi 2014; Komatsu 2011; KRGGC 1992; Li 2014; Li 2015;
Li 2016; Lu 2014; Narahara 2011; Nishikawa 2012; Ohtsu 2003;
Shirao 2013; Sugimoto 2014; Wang 2013; Wu 2015; Yamada
2015; Yamamura 1998). The largest number of Asian people was
included in comparison 2. Asian people were clearly underrepre-
sented in comparisons 3, 4, and 6. The example of S-1, which is
used in different doses in Caucasian (25 mg/m² twice daily) and
Asian people (40 mg/m² twice daily) (Satoh 2014) confirms that
chemotherapy regimens need to be tested in Asian and Caucasian
populations separately, and that the balance between efficacy and
toxicity of a given regimen might be different in different popula-
tions due in part to genetic differences (Syn 2015). Results from
clinical studies are thus applicable only to those populations where
they have been tested. Except for these limitations, the evidence
cited above should be regarded as complete and applicable.
Quality of the evidence
This review included a total of 60 studies and 11,698 participants
in the meta-analysis for the primary outcome of overall survival.
Seven of the 10 main comparisons for overall survival had low het-
erogeneity (I² < 20%), and even among comparisons with higher
levels of inconsistency (I² > 20%), the amount of heterogene-
ity present was not statistically significant (P > 0.05). Hence, the
pooled results can be considered to be relatively stable. The ma-
jority of studies had low risk of bias in terms of random sequence
generation, blinding, incomplete efficacy or safety outcome data,
and selective reporting. However, the risk of bias due to lack of
independent or blinded radiological review and other sources of
bias (see Risk of bias in included studies) are unclear or high in
more than 50% of included studies; hence, these can be consid-
ered areas for improvement in future studies. The main reasons
for downgrading of evidence in the ’Summary of findings’ tables
are due to lack of precision in pooled effect sizes, risk of bias (par-
ticularly, allocation bias), and statistical heterogeneity.
Potential biases in the review process
For this review, all reasonable effort has been made to reduce and
address potential sources of bias, such as inclusion of studies not
published in English, searches for unpublished and not fully pub-
lished studies. Therefore, the likelihood that relevant studies have
not been identified is considered as small. One factor with known
impact on overall survival after first-line chemotherapy is second-
line therapy, which is administered in up to 70% of some recent
studies. However, as second-line therapy is now a standard of care,
it should not be considered as a source of bias.
Agreements and disagreements with other
studies or reviews
Another meta-analysis (Okines 2008), which summarised the re-
sults from two studies that used capecitabine instead of 5-FU,
confirmed a significant survival benefit for the people treated
with capecitabine, thus lending further support to the use of
capecitabine in people with gastric cancer.
We agree with the following key issues in the review by Garrido
2014: DCF is - in terms of efficacy - one of the most promising
regimens in younger people with adequate general health. How-
ever, it is counterbalanced by significant toxicity, and other three-
drug regimens including docetaxel, 5-FU, and oxaliplatin, such
as FLOT or TEF (Van Cutsem 2015) are appropriate alternatives
with better tolerability, and that either FOLFIRI or the combina-
tion of irinotecan and 5-FU as described byDank 2008 should also
be considered among the most promising regimens on the basis
of their significant impact on overall survival, the overall reduced
toxicity and time to treatment failure as compared to three-drug
regimens (Guimbaud 2014), as well as the absence of cumulative
toxicity. However, we would strongly advise not to use IFL (a com-
bination of bolus 5-FU and irinotecan) in view of the higher rate
of treatment-related deaths of this regimen in colorectal cancer
(Hurwitz 2004). The conclusions of the review by Lordick 2014b
“both doublet and triplet drug-regimens can be used.....but careful
consideration of the potential toxic complications, impairment of
the person’s quality of life, and the relative benefit should be under-
taken”. Lordick 2014a gives an excellent, more general overview
of the current status and challenges in gastric cancer treatment.
It addresses not only medical treatment (both chemotherapy and
targeted therapies), but also the pathology and surgery. We agree
with the main conclusions of the meta-analysis published by the
GASTRIC Group 2013 that the addition of experimental chemo-
therapeutic agents to pre-existing control- or standard regimens
have produced a modest improvement in overall survival and pro-
gression-free survival, and that none of the regimens emerged as a
clear standard. The meta-analysis by Petrelli 2013 compared any
two-and three-drug regimens that included CDDP with any reg-
imen containing the same number of agents in which CDDP was
replaced by oxaliplatin, CPT-11 or a taxane, We agree with the
observation that substitution of cisplatin by modern agents, such
as oxaliplatin or irinotecan generally improves outcomes. We also
agree with the analysis by (Chen 2013) that DCF has a better
response-rate than non-taxane-containing regimens, but disagree
with their statement that chemotherapy-related toxicity of DCF
regimen is acceptable to some extent.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our review found that people with advanced gastric cancer would
benefit from being tested for HER-2 over expression, and in the
absence of contraindications receive trastuzumab in combination
with cisplatin and 5-FU or capecitabine in case of HER-2 positive
disease. For all other people, the use of combination chemother-
apy could be considered as standard of care for first-line treatment.
The results of this meta-analysis suggest a significant and conclu-
sive survival benefit for chemotherapy versus best supportive care
(BSC), as well as a modest survival benefit for combination ver-
sus single-agent chemotherapy. As many studies included in this
comparison have used combination chemotherapy regimens with
suboptimal efficacy, such as 5-FU/epirubicin or 5-FU/ cisplatin,
the benefit of combination chemotherapy is likely to be under-
estimated. In the absence of contraindications, the upfront use
of a two-drug combination is efficacious. Among the combina-
tion chemotherapy regimens, two-drug combinations including
a fluoropyrimidine and oxaliplatin is more efficacious than cis-
platin-based combinations in view of their survival benefit and
reduced risk of treatment-related deaths. 5-FU/irinotecan-based
two-drug combinations are an alternative to platinum-based regi-
mens for first-line treatment, which demonstrated superior results
for survival, as well as progression-free survival and tumour re-
sponse, without any negative impact on toxicity as compared to
the non-irinotecan-containing combination chemotherapy regi-
mens. Thus, based on both their efficacy and the balance between
efficacy and toxicity, two-drug combinations of a fluoropyrimi-
dine and oxaliplatin or 5-FU and irinotecan are superior treatment
regimens for first-line treatment of HER-2 negative gastric cancer.
Consideration of the side-effect profile of each regimen is essential
in the treatment decision for an individual person.
Three-drug combinations are not widely-used in clinical practice,
but might be beneficial for individual people: Two major groups
of three-drug-combinations need to be discussed:
1. Docetaxel-based three drug combinations (DCF, FLO-T or
TEF).
In which docetaxel is added to a single-agent or two-drug (plat-
inum/5-FU- combination) show significant advantages in terms
of overall survival, progression-free-survival, and response rates.
However, these advantages are counterbalanced by increased toxi-
city, especially hematological and neurotoxicity. Of note, while the
DCF regimen has been evaluated in a population with a median
age of 55 years (Van Cutsem 2006) with greater toxicity in the
elderly people included in this study, it cannot be recommended
for elderly people and for this reason FLOT has been shown to be
feasible in people over 65 (Al-Batran 2013). However, in this ran-
domised phase II study conducted in Germany, no benefit from
treatment with the three-drug combination of docetaxel, 5-FU,
and oxaliplatin (FLOT) as compared to the two-drug regimen
FLO (5-FU, leucovorin, and oxaliplatin) was observed in people
aged 70 years or older. In the age of personalised medicine, we
should not only ask which regimen is better, but which regimen
is better for which people. In the above mentioned study by Al-
Batran, the benefit from the three-drug combination was limited
to people under 70 years old and a small group of people with
locally advanced (versus metastatic) disease. Although data from
a subgroup analysis need to be interpreted with caution and the
validity of these findings needs to be confirmed in future studies,
this is an intriguing hypothesis. Of note, in the perioperative set-
ting an increased pathological response rate was demonstrated for
the use of FLOT - as compared to ECF- in a recent publication
(Al-Batran 2016), although survival results are still pending.
2. Three-drug regimens which include epirubicin.
Whether the survival benefit for three-drug combinations includ-
ing cisplatin, 5-FU, and epirubicin - as compared to the same reg-
imen without epirubicin - is still valid when second-line therapy
is routinely administered and when cisplatin is replaced by oxali-
platin and 5-FU by capecitabine is questionable.
Furthermore, the magnitude of the observed survival benefits for
both groups of three-drug combinations in the palliative setting is
not large enough to be clinically meaningful as defined recently by
the American Society for Clinical Oncology (ASCO) (Ellis 2014).
In contrast to comparisons, in which a survival benefit was ob-
served by adding a third drug to a two-drug regimen at the cost of
increased toxicity, the comparison of regimens in which another
chemotherapy was replaced by irinotecan was associated with a
survival benefit (of borderline statistical significance) without in-
creased toxicity.
Nevertheless, individual people in good performance status and
with a large tumour burden might have a greater advantage from
three-drug regimens (especially docetaxel-containing three-drug
combinations) due to their higher response rate.
The benefit of second-line chemotherapy in terms of symptom
relief and survival over BSC has been demonstrated in several well-
conducted and randomised studies in both European and Asian
populations, in people with good performance status. Routine ad-
ministration of second-line therapy to all people with good per-
formance status might further limit the benefit of a three-drug
combination upfront, as compared to the sequential administra-
tion of doublets followed by a single-agent, as recently shown in
the study by Guimbaud 2014. According to recent phase III stud-
ies, the vascular-endothelial-growth-factor-receptor-targeting an-
tibody ramucirumab (Fuchs 2014; Wilke 2014) as single-agent
treatment or in combination with paclitaxel chemotherapy might
be considered as an alternative to chemotherapy alone as second
line.
According to a randomised study among patients with metastatic,
non-small cell lung cancer, early palliative care led to significant
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improvements in both quality of life and mood. As compared to
patients receiving standard care, patients receiving early palliative
care had less aggressive care at the end of life, but longer sur-
vival (Temel 2010). According to their most recent update, ASCO
guidelines on “Integration of palliative care into standard oncol-
ogy care” (Ferrell 2017) recommend that - for newly diagnosed
people with advanced cancer - the specialised palliative care team
should be involved within eight weeks of diagnosis. Among people
with high symptom burdens, outpatient care programs should de-
liver palliative care services to complement existing program tools.
For elderly people, the use of a minimum dataset including the
Charlson Comorbidity Index (Charlson 1987), the G8 geriatric
assessment screening tool, and the instrumental activities of daily
living should be considered for the assessment of global health
status and functional status (Pallis 2011).
Finally, it should be noted that despite all progress in the last
decades, advanced gastric cancer remains a disease with a dismal
prognosis, and median survival exceeding 12 months only in a
small number of randomised studies. Thus, appropriate treatment
measure should follow the guidelines of palliative care, defined
by WHO (Sepulveda 2002) as “an approach that improves the
quality-of-life of people and their families facing the problems
associated with life-threatening illness”.
Implications for research
Further research is necessary to develop specific treatment strate-
gies for the different subtypes of gastric cancer (TCGA 2014).
This concerns not only the molecular subtypes described above,
but also clinically defined subgroups of people, for example peo-
ple with locally advanced or limited metastatic disease, as well
as a radiological response to chemotherapy. Considering systemic
treatment alone in all people with locally advanced and metastatic
gastric cancer is unlikely to achieve the best results for these sub-
groups with favourable prognostic factors: People with a radio-
logical response in the REAL-2 study (Cunningham 2008) had
one- and two-year survival rates of 70.9% (95% CI 61.8 to 78.3)
and 27.9% (95% CI 20.0 to 36.2). The value of surgery and/or
local ablative therapies in people with good performance status,
limited metastatic disease, and respond to chemotherapy is con-
troversial (Kataoka 2017). A randomised clinical study (FLOT-5,
NCT02578368) addressing the question if surgery further im-
proves survival and quality of life in people with limited metastatic
disease after pretreatment with FLOT is currently ongoing.
The question if strategies to reduce treatment burden, such as
maintenance therapy, may be integrated in the continuum of care
without compromising efficacy needs to be evaluated in further
studies (Digklia 2016).
According to preliminary data from the neoadjuvant setting, peo-
ple with well differentiated tumours have a greater chance to ben-
efit from chemotherapy than others (Al-Batran 2016). Further-
more, not only targeted therapies, but also chemotherapies might
not have the same efficacy in different molecular subtypes of gas-
tric caner (Tan 2011; Syn 2016)
Further integration of targeted therapies and development of new
treatment approaches, such as immunotherapy, for which promis-
ing preliminary results have just been presented (Kang 2017;Muro
2016) is highlywarranted. Furthermore, treatment strategies com-
bining different immunotherapeutic agents, or chemotherapy and
immunotherapy, or immunotherapy and anti-angiogenic thera-
pies need further development. Valid biomarkers, which permit
the selection of people with a high chance to respond to the dif-
ferent types of treatments are urgently required.
The role of intraperitoneal chemotherapy, in which cytotoxic
agents are infused into the peritoneum, particularly for peoplewith
advanced gastric cancer with peritoneal dissemination are being
actively investigated (Chan 2017). Randomised studies, including
phase III studies, are currently ongoing, and in a future update to
this review, it may be worth adding a comparison or subgroup to
evaluate the benefits of this mode of chemotherapy administra-
tion.
ForHer-2 positive breast cancer, great progress has beenmadewith
the introduction of agents like pertuzumab and T-DM1 (Swain
2015; Verma 2012), which showed major benefits in recent phase
III studies, andmany othermolecules targeting this pathway are in
clinical development. While a benefit for T-DM1 as second-line
treatment could not be demonstrated for HER-2 positive gastric
cancer (Kang 2016), phase III-results for pertuzumab in gastric
cancer are still pending.
For any new treatment, apart from the assessment of outcomes like
overall- and progression-free survival, the balance between relief
of tumour-associated symptoms and treatment-associated toxicity
needs to be evaluated from the person’s perspective to determine
the palliative value of new therapy regimens in advanced gastric
cancer.
Quality of life assessment deserves adequate methodology. Val-
idated measurement instruments are available: a disease-specific
module to supplement the EORTC core quality of life question-
naire has been published (Vickery 2001), a FACT-questionnaire
for people with stomach cancer has been developed concurrently
in North America and Asia (Eremenco 2004), and a clinical mean-
ingful benefit may be defined in advance (Norman 2003). Never-
theless, quality of life assessment remains challenging. Therefore,
according to a recent statement from the American Society for
Clinical Oncology (Ellis 2014), the interest has shifted to person’s
self reported specific symptom burden.
An ECOG performance status of 0 to 1 versus 2, and the presence
of liver metastases and peritoneal metastases have been identified
as poor prognostic factors by multivariate analysis (Chau 2004). A
prognostic index was constructed dividing people into a good (no
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risk factor), moderate (one or two risk factors), and poor (three
or more risk factors) risk group. This model has been validated
in a second data set from the REAL-2 study. This study did also
confirm the major prognostic impact of obtaining a radiological
response: One- and two-year survival rates for responders were
70.9% (95% CI 61.8 to 78.3) and 27.9% (95% CI 20.0 to 36.2).
Future studies should explicitly address the value of novel thera-
peutic strategies in different clinical risk groups.
Importantly, not all questions can be answered in randomised clin-
ical studies. Further research on the risks and benefits of chemo-
therapy in both the elderly people population, as well as people
who do not fulfil the inclusion criteria for clinical studies is re-
quired. Therefore, large observational cohort studies or registries
of people treated with standard treatment outside clinical studies
are important, such as the analysis published by Dixon 2016. Of
note, both EORTC and ASCO (Pallis 2011; Wildiers 2013) have
published recommendations for designing and reporting clinical
studies in Geriatric Oncology in the future, which include oblig-
atory reporting of age-related subgroup analysis, obligatory post-
marketing studies in vulnerable and frail older people, and oblig-
atory inclusion of a minimum dataset for senior adults in registra-
tion studies and post-marketing studies.
In view of the fact that second-line therapy has become a standard
of care in the treatment of this disease, endpoints for clinical studies
need reconsideration. Thus, in a disease where the sequential use
of different treatments is established, overall survival might not be
sufficiently sensitive as an endpoint for clinical studies. However,
the correlation of progression-free survival with overall survival in
advanced/recurrent gastric cancer was not confirmed in a recent
meta-analysis (Paoletti 2013).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ajani 2005
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 158 (68% with tumour location in the stomach; and 32 % with tumour location at
the GE-junction)
Median age: 57 years
ECOG 2-3: 0% (Karnofsky performance status KPS was ≥70% for all patients)
Metastatic disease: 95%
Interventions DCF: docetaxel (75 mg/m2d1) + cisplatin (75 mg/m2 d1) + FU (750 mg/m2/d d1-5),
repeated at d 21
versus
DC: docetaxel (85 mg/m2) + cisplatin (75 mg/m2) d 1, repeated at d 21
Outcomes Response rates
Time to progression
Overall survival
Toxicities
Notes This is the phase II to chose the investigational arm in Van Cutsem 2006. A similar
proportion of patients received second-line chemotherapy (DCF 39%; DC 45%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was centralised (Aventis,
Antony, France) and was stratified for cen-
tre, liver and/or peritonealmetastases, prior
gastrectomy, and measurable versus assess-
able disease
Allocation concealment (selection bias) Low risk Randomisation was centralised (Aventis,
Antony, France)
Incomplete outcome data (attrition bias)
efficacy
Low risk Modified ITT (randomised and treated pa-
tients)
Incomplete outcome data (attrition bias)
safety
Low risk Modified ITT
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Ajani 2005 (Continued)
Selective reporting (reporting bias) Unclear risk All treated patients were included in the
safety analyses.
The primary efficacy end point was initially
theCR rate in the per-protocol population.
However, because CRs were infrequent in
this study, the IDMC based its decision
regarding treatment selection on the best
ORR
Other bias Unclear risk Number of diffuse adenocarcinoma is
lower in the DC arm (22% vs. 38%)
The protocol required that the IDMC re-
view data on at least 70 patients (minimum
of 60 assessable patients) to make their de-
cision; however, by the time mature data
on 70 patients were verified, the study had
accrued 158 patients
Blinded review of CT/MRI-scans? Low risk All pertinent imaging studies (except for
those of four patients) were reviewed by
an External Response Review Committee
(ERRC)
Ajani 2010
Methods Multicentre RCT
2 arms
Quality score: A
Participants n = 1053
Median age: 59 years
ECOG 2-3: 0%
Metastatic disease: 96%
Interventions S-1+Cisplatin: S-1 (50 mg/m2) in two daily doses d1-21orally + cisplatin (75 mg/m2)
repeated at d 28
versus
FU+Cisplatin: fluorouracil (1000 mg/m2/24 hrs as 120-hour infusion) + cisplatin (100
mg/m2), repeated at d 28
Cisplatin was discontinued after 6 cycles; provision to continue S-1 or FU until progres-
sion of disease or unacceptable toxicities
Outcomes Overall survival
Progression-free survival
Time to treatment failure
Tumour response
Toxicity
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Ajani 2010 (Continued)
Notes Second-line therapy in 31.4% of patients, most frequently with fluoropyrimidine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated dynamic randomisa-
tion
Allocation concealment (selection bias) Low risk Centralised randomisation
Incomplete outcome data (attrition bias)
efficacy
Low risk Full analysis set of all treated patients (98.
8% inS-1+cisplatin armand94.6% inFU+
cisplatin arm)
Incomplete outcome data (attrition bias)
safety
Low risk Full analysis set of all treated patients
Selective reporting (reporting bias) Low risk PEP: OS
SEP: ORR, PFS, TTF, safety
Other bias Low risk None
Blinded review of CT/MRI-scans? Low risk Radiographic evidence of response to treat-
ment was also independently reviewed. An
independent data monitoring committee
oversaw the safety and efficacy data along
with other aspects of the conduct of the
study
Al Batran 2008
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 220
Median age: 64 years
ECOG 2-3: 9%
Metastatic disease: 94%
Interventions FLO: oxaliplatin 85 mg/m²; leucovorin 200 mg/m² and FU 2.600 mg/m² as 24-hour
continuous infusion every 14 days
FLP: cisplatin 50 mg/m²; leucovorin 200 mg/m²; FU 2.000 mg/m² weekly for 6 weeks
followed by a 2-week rest
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Al Batran 2008 (Continued)
Outcomes Median overall survival
Tumour response
Toxicity
Notes A pre-planned interim analysis of toxicity and response was conducted after 80 patients
were included in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk ITT analysis of all randomised patients (n
= 220)
Incomplete outcome data (attrition bias)
safety
Low risk Analysis of all treated patients (n = 214)
Selective reporting (reporting bias) Unclear risk Report includes all expected outcomes
(OS, RR and toxicity)
Other bias High risk Differences in baseline distribution of sex
(42.9% versus 25% female) and metastatic
disease (97.3% versus 90.7%). Preplanned
interim analysis
Blinded review of CT/MRI-scans? Unclear risk Not stated
Al-Batran 2013
Methods Multicentre RCT
2 arms
Quality score: B
Participants n = 143
Median age: 70 years
ECOG: 7.7 %
Metastatic disease: 69%
Interventions FLOT: oxaliplatin 85 mg/m2 + leucovorin 200 mg/m2 + docetaxel 50 mg/m2, followed
by 5-FU 2600 mg/m2 as a 24-hour continuous infusion d 1, repeated at 2 weeks
FLO: oxaliplatin 85 mg/m2 + leucovorin 200 mg/m2, each as infusion followed by 5-
FU 2600 mg/m2 as a 24-hour continuous infusion d 1, repeated at 2 weeks until disease
progression, or for a total of 8, maximum 12 cycles
81Chemotherapy for advanced gastric cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Al-Batran 2013 (Continued)
Outcomes Tolerabiliby and feasibility, defined as per group differences in toxicity, serious adverse
events, treatment duration, treatment withdrawal, discontinuation for toxicity or pa-
tient’s request, proportion of patients with a > 10 point change of QoL global health
status (EORTC QLQ C-30 questionnaires) at eight weeks, compared to baseline
Response rates
Overall survival
Progression-free survival
Notes Study included older adult patients (age ≥ 65 years). Second line therapy was permitted
(FLOT: 61% vs. FLO: 42.7%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer random generator
Allocation concealment (selection bias) Low risk Centralised randomisation
Incomplete outcome data (attrition bias)
efficacy
Low risk All 143 patients (FLOT, 72; FLO, 71) were
eligible for the efficacy analysis on an ITT
basis
Incomplete outcome data (attrition bias)
safety
Low risk Only 1 patient was excluded from the sa-
fety analysis because of consent withdrawal
before study treatment
Selective reporting (reporting bias) Low risk ITT analysis
Expected endpoints (ORR,OS, PFS, safety
byNCI-CTC etc) were included. QoL also
assessed
Other bias Low risk The treatment arms were well balanced for
pretreatment characteristics
Blinded review of CT/MRI-scans? High risk No blinded external radiologist
Barone 1998
Methods Multicentre RCT
2 arms
Quality score: B
Participants n = 72
Median age: 58 years
ECOG 2-3: 22%
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Barone 1998 (Continued)
Interventions 5-FU/Lv: Lv 100 mg/m²; 5-FU 370 mg/m² d 1-5, repeated at d 29
versus
EEP-L: epirubicine 30 mg/m² d,1,5; etoposide 100 mg/m² d 1, 3, 5; cisplatin
30 mg/m² d 2,4 and lonidamide 150 mg/d, repeated at d 29
Outcomes Median survival
1and 2-year survival rates
Response rates
Symptom control
Toxicity
Notes No standard error can be assessed for TTP
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised by a sealed en-
velope method, using random permutated
blocks unknown to the clinicians, to receive
either the 5-FU/6S-LV (Study A) or EEP-L
combination (Study B). Patients also were
stratified into four groups based on a re-
sected or nonresected primary tumor and
an ECOG PS ≤ 1 or > 1
Allocation concealment (selection bias) Low risk Sealed envelope method, using random
permutated blocks unknown to the clini-
cians
Incomplete outcome data (attrition bias)
efficacy
Low risk One patient refused further treatment af-
ter the first cycle and was excluded from
the response analysis, but not from the tol-
erance and survival analysis. Two patients
refused chemotherapy after randomisation
and were excluded completely from the
analysis
Incomplete outcome data (attrition bias)
safety
Low risk One patient refused further treatment af-
ter the first cycle and was excluded from
the response analysis, but not from the tol-
erance and survival analysis. Two patients
refused chemotherapy after randomisation
and were excluded completely from the
analysis
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
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Barone 1998 (Continued)
Other bias High risk 1 participant who died after the second cy-
cle of therapy has not been included in the
survival analysis = no ITT
Blinded review of CT/MRI-scans? High risk High risk. Likely unblinded
Boku 2009
Methods Multicentre RCT
3 arms
Quality score: A
Participants n = 704
Median age: 63.5 years
ECOG 2-3: 1.4%
The study was conducted in Japan.
Interventions 5-FU: 800 mg/m²/d, ci, d 1-5, repeated at 4 w
versus
IP: irinotecan 70 mg/m² d 1 +15 + cisplatin 80 mg/m² d 1, repeated at 4 w
versus
S-1: 40 mg/m² twice a day, d 1-28, repeated at 6 w
Outcomes Overall survival
Response rates
Time to treatment failure
Progression-free survival
Non-hospitalised survival
Toxicity
Notes This study was conducted in Japan. Aim of this study was to investigate superiority of
CP and non-inferiority of S-1 to 5-FU. Second-line therapy in 78% of patients, cross-
over of 39% (from 5-FU to IP), 57% (from IP to S-1) and 30% (from S-1 to IP)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimisation method
Allocation concealment (selection bias) Low risk Central allocation
Incomplete outcome data (attrition bias)
efficacy
Low risk Extremely low rate of withdrawals
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Boku 2009 (Continued)
Incomplete outcome data (attrition bias)
safety
Low risk Extremely low rate of withdrawals
Selective reporting (reporting bias) Low risk All expected endpoints reported
Other bias Low risk None
Blinded review of CT/MRI-scans? Low risk Reviewed centrally at a trial groupmeeting;
reviewers were unaware of treatment allo-
cations at this time
Bouche 2004
Methods Multicentre RCT
3 arms
Quality score: D
Participants n = 134
Median age: 65 years
Metastatic disease: 100%
Interventions LV5FU2: LV 200 mg/m² ; FU 400 mg/m² bolus; FU 600 mg/m² d 1 + 2 ,repeated at
15 d
LV5FU2-cisplatin: cisplatin 50 mg/m² d 1+ 2 + LV5FU2, repeated at d 15
LV5FU2-irinotecan: irinotecan 180 mg/m² d 1 + LV5FU2 ,repeated at d 15
Outcomes Tumour response
Median overall survival
1 year survival rates
Quality of life
Toxicity
Notes Adjuvant chemotherapy without cisplatin or irinotecan was allowed if completed at least
6 months before randomisation. Prior radiotherapy was allowed if completed more than
4 weeks before randomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Central allocation
Incomplete outcome data (attrition bias)
efficacy
Low risk One hundred thirty-six patients were en-
rolled between January 1999 and October
2001 in 41 centres in France. Two patients
85Chemotherapy for advanced gastric cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bouche 2004 (Continued)
were considered ineligible; one had a lym-
phoma and the other had nometastatic dis-
ease. No arm was closed after the two in-
terim analyses. Thus, the analyses were car-
ried out on an ITT basis with the remain-
ing 134 enrolled patients
Incomplete outcome data (attrition bias)
safety
Low risk One hundred thirty-six patients were en-
rolled between January 1999 and October
2001 in 41 centres in France. Two patients
were considered ineligible; one had a lym-
phoma and the other had nometastatic dis-
ease. No arm was closed after the two in-
terim analyses. Thus, the analyses were car-
ried out on an ITT basis with the remain-
ing 134 enrolled patients
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk LowQoL response (41% (n = 22) and 48%
(n = 29) at the third evaluation in arms A
and C can bias longitudinal QoL analysis.
Prior chemotherapy and radiotherapy were
allowed under certain circumstances
Blinded review of CT/MRI-scans? Unclear risk All objective tumor responses and cases of
disease stabilisation were reviewed retro-
spectively
Cascinu 2011
Methods Multicentre RCT
2 arms
Quality score: A
Participants n = 78
Median age: 63 years
ECOG 2-3: 6.3%
Metastatic disease: 89.7%
Interventions Arm A (LdCF): 5-FU (400 mg/m2 bolus +600 mg/m2 22 h continuous infusion d 1-2)
+ cisplatin (50 mg/m2 d 1) + pegylated liposomal doxorubicin (20 mg/m2 d1), repeated
at d 14
versus
Arm B (MCF) : 5-FU (400 mg/m2 bolus +600 mg/m2 22 h continuous infusion d 1-
2) + cisplatin (50 mg/m2 d 1, repeated at d 15) + mitomycin-C (7 mg/m2, repeated at
d 42)
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Cascinu 2011 (Continued)
Outcomes Response rates
Time to progression
Overall survival
Toxicity
Notes second-line treatment in 38.5% and 25.6 % of patients
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generated by a computer
programme
Allocation concealment (selection bias) Low risk Central allocation
Incomplete outcome data (attrition bias)
efficacy
Low risk Seventy-seven of 78 patients were assess-
able for response; one patient in arm B was
not assessable but was included in the ITT
analysis and kept in the denominator of the
response rate
Incomplete outcome data (attrition bias)
safety
Low risk Seventy-seven of 78 patients were assess-
able for response; one patient in arm B was
not assessable but was included in the ITT
analysis and kept in the denominator of the
response rate
Selective reporting (reporting bias) Low risk Expected endpoints reported
Other bias Low risk Patients characteristics resulted well bal-
anced between the treatment groups
Blinded review of CT/MRI-scans? Low risk Tumour response was assessed by an inde-
pendent radiologist as central reviewer
Chen 2015
Methods 60 AGC participants randomly divided into 2 groups by “random number table” - 30
vs 30
Participants Age range 18-75 years
Males:Females ratio was 18:12 in the DSOX group and 14:16 in the DCF group
Interventions Docetaxel plus S1 plus oxaliplatin (DSOX) vs Docetaxel plus fluorouracil plus cisplatin
(DCF)
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Chen 2015 (Continued)
Outcomes OS
TTP
Tumour response
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random number table”
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Unclear risk 2 patients lost to follow-up, reasons not
stated
Incomplete outcome data (attrition bias)
safety
Unclear risk 2 patients lost to follow-up, reasons not
stated
Selective reporting (reporting bias) Unclear risk Not clear how many were screened for eli-
gibility and randomised. Only the number
of evaluable patients are provided
Other bias Unclear risk Nothing to comment on
Blinded review of CT/MRI-scans? Unclear risk Not stated
Cocconi 1994
Methods Multicentre RCT
2 arms
Quality score: A
Participants n = 130
Metastatic disease: 88%
ECOG 2-3: 7%
Interventions FAM: 5-FU 600 mg/m² d 1, 8, 29, 36; adriamycin 30 mg/m² d 1, 29 and mitomycin
10 mg/m² d 1, repeated at d 57
versus
PELF: cisplatin 40 mg/m² d 1, 5; etoposide 30 mg/m² d 1, 5; Lv 200 mg/m² d 1-4 + 5-
FU 300 mg/m² d 1-4, repeated at d 22
Outcomes Median survival
Response rates
Time to progression
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Cocconi 1994 (Continued)
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Centralised
Incomplete outcome data (attrition bias)
efficacy
Low risk All eligible pts include din survival evalua-
tion
Incomplete outcome data (attrition bias)
safety
Low risk All eligible pts included
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Low risk Baseline characteristics well-balanced
Blinded review of CT/MRI-scans? Low risk Extramural review
Cocconi 2003
Methods Multicentre RCT
2 arms
Quality score: A
Participants n = 200
Metastatic disease: 85%
Interventions FAMTX: MTX 1500 mg/m² d1; 5-FU 1500 mg/m²; Lv 7.5 mg/m² p.o. every 6 hrs d
1-3, adriamycin 30 mg/m² d 15, repeated at d 29
versus
PELF: cisplatin 40 mg/m² d1, 5, etoposide 30 mg/m² d 1, 5; Lv 100 mg/m² d 1-4, 5-
FU 300 mg/m² d 1-4, repeated at d 22
Outcomes Median survival
Response rates
Time to progression
Toxicity
Notes -
Risk of bias
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Cocconi 2003 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Eligible patients were centrally randomised
by the operational office of GOIRC
(Parma, Italy)
Incomplete outcome data (attrition bias)
efficacy
Unclear risk Thirteen of the 200 randomised patients
(six in the PELF and seven in the FAMTX
group) did not begin the assigned chemo-
therapy and were not evaluated for toxicity.
Reasons were not provided, and it is possi-
ble that this proportion could have an im-
pact on analysis
The response of 15 patients in the PELF
group and 14 in the FAMTX group were
unevaluable or not evaluated for the follow-
ing reasons: the treatment was never started
(five versus five), protocol violations (zero
versus one), insufficient treatment due to
early death (five versus three), refusal (four
versus two), early discontinuation due to
toxicity (zero versus three) or severe medi-
cal events (one versus zero)
Incomplete outcome data (attrition bias)
safety
Unclear risk Thirteen of the 200 randomised patients
(six in the PELF and seven in the FAMTX
group) did not begin the assigned chemo-
therapy and were not evaluated for toxicity.
Reasons were not provided, and it is possi-
ble that this proportion could have an im-
pact on analysis
Selective reporting (reporting bias) Unclear risk Toxicity was evaluated in all of the patients
receiving at least one dose of chemotherapy
whether they were eligible or not
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Unclear risk Response was assessed by the clinical in-
vestigators at each participating unit, and
centrally reviewed in the case of CR, PR,
no change for more than 6 months, or in
the case of patients who underwent gastric
resection at the end of the chemotherapy
programme
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Colucci 1995
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 71
Median age: 60 years
Interventions 5-FU/Lv: Lv 200 mg/m²; 5-FU 375 mg/m² d 1-5, repeated at d 22
versus
5-FU/Lv+E: Lv 200 mg/m²; 5-FU 375 mg/m² d 1-5, repeated at d 22; epirubicin 60
mg/m² d 1, repeated at d 22
Outcomes Median survival
Response rates
Secondary resectability
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk Reasons for exclusion clearly documented
and valid
Incomplete outcome data (attrition bias)
safety
Low risk Reasons for exclusion clearly documented
and valid
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk No ITT, missing information about type
and schedule of follow-up between groups
Blinded review of CT/MRI-scans? High risk Not stated, likely unblinded/by investiga-
tors
Cullinan 1985
Methods Multicentre RCT
3 arms
Quality score: D
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Cullinan 1985 (Continued)
Participants n = 151
Metastatic disease: 62%
Interventions 5-FU included 5-FU 500 mg/m² on dayS 1-5, repeated at 4 weeks, 8 weeks and every
5 weeks thereafter
FAM included 5-FU at 600 mg/m² on days 1, 8, 29 and 36; doxorubicin 30 mg/m² on
days 1 and 29, and mitomycin 10 mg/m² on day 1
FA included 5-FU 400 mg/m² with 40 mg of doxorubicin on day 1 every 4 weeks
Outcomes Overall survival, response rates, toxicity (not classified according to WHO or CTC)
Notes Study included participants with pancreatic and gastric cancer. Patients were stratified
within institution according to the primary tumour. Separate results were given for
participants with gastric cancer. Results only for participants with gastric cancer are
included in this analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk ITT analysis with 3.3% exclusion from
analysis
Incomplete outcome data (attrition bias)
safety
Low risk ITT analysis
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias High risk 5-FU/doxorubicin(FA) and FAM arm will
be combined in the analysis
Blinded review of CT/MRI-scans? High risk High risk - likely unblinded
Cullinan 1994
Methods Multicentre RCT
4 arms
Quality score: D
Participants n = 252
Median age: 62 years
ECOG 2-3: 30%
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Cullinan 1994 (Continued)
Interventions FAMe: 5-FU 325 mg/m² d1-5; adriamycin 40 mg/m² d 1, repeated at d 36; methyl-
CCNU 110 mg/m² p.o. d 1, repeated at d 71
versus
FAMe+Tzt: 5-FU 325 mg/m², d 1-5; adriamycin 40 mg/m² d 1, repeated at d 36;
triazinate 250 mg/m² d 36-38, repeated at d 57; methyl-CCNU 110 mg/m² p.o. d 1,
repeated at d 71
versus
FAP: 5-FU 300 mg/m² d 1-5; adriamycin 40 mg/m² d 1; cisplatin 60 mg/m² d 1,
repeated at d 36
versus
FU: 5-FU 500 mg/m² d 1-5 repeated at d 36
Outcomes Median survival
Toxicity
Effects on performance status and weight gain
Notes Three combination chemotherapy arms combined in the analysis. The single-agent 5-
FU arm was opened after 56 participants were randomised. FAMe and FAP were closed
after a planned interim analysis because of slightly higher death rate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk Low attrition rate with long follow-up
(only 7 of 252 patients remain alive at the
time of analysis)
Incomplete outcome data (attrition bias)
safety
Low risk n = 69 + 51 + 53 + 79
Selective reporting (reporting bias) Unclear risk Missing response rates
only a small minority of patients had mea-
surable disease so regression rate was not
used as a study endpoint
Other bias High risk Missing information to type and follow-up
in the treatment groups, combination of 3
combination treatment arms in the analy-
sis, 2 arms were closed after a planned in-
terim analysis
Blinded review of CT/MRI-scans? Unclear risk Not stated
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Dank 2008
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 337
Median age: 59 years
Metastatic disease: 95.5%
Interventions IF: irinotecan 80 mg/m² i.v.; FA 500 mg/m² i.v.; 5-FU 2000 mg/m² as a 22-hour
continuous infusion on d 1 weekly for 6 weeks, followed by 1 week rest
versus
CF: cisplatin 100 mg/m² i.v. d 1; 5-FU 1000 mg/m²/day as 24-hour continuous infusion
d 1-5, repeated at 4 weeks
Outcomes Hazard ratios and median survival for overall survival and time to progression, tumour
response, toxicity, QoL
Notes The trial was planned to establish superiority or non-inferiority of IF over CF. Patients
have finished prior radiotherapy and surgery 6 and 3 weeks, respectively, before ran-
domisation. Previous adjuvant or neo-adjuvant chemotherapy was allowed if completed
12 months before first relapse
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Biased coin method
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk Analysis of the full-analysis population of
treated patients
Incomplete outcome data (attrition bias)
safety
Low risk Analysis of the full-analysis population of
treated patients
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias High risk Rate of non-evaluable response was imbal-
anced between arms (IF 9.4% versus CF
16.8%), largely due to the higher rate of
early discontinuations for toxicity in the
CF arm. This difference may result from
closer follow-up in IF. Prior radiotherapy
and chemotherapy were allowed under cer-
tain circumstances
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Dank 2008 (Continued)
Blinded review of CT/MRI-scans? Low risk An External Radiological Review Commit-
tee (ERRC), blinded to treatment arm, re-
viewed all disease assessments and deter-
mined evaluability for response and date of
progression
De Lisi 1986
Methods Multicentre RCT
2 arms
Quality score: B
Participants n = 85
Median age: 64 years
Interventions Arm A: 5-FU 13.5 mg/kg/day for 5 days, every 5 weeks
Arm B: carmustine 50 mg/m² on days 1 and 29; doxorubicine 25 mg/m² on days 1, 8,
15, 29 and 36 and mitomycin C 10 mg/m² on day 15
Outcomes Overall survival, response rate, haematological toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Centralised
Incomplete outcome data (attrition bias)
efficacy
Low risk ITT
Incomplete outcome data (attrition bias)
safety
Low risk n = 82
Selective reporting (reporting bias) Low risk Only haematological toxicity given (in ta-
ble format - but nonhaematologic side ef-
fects were also mentioned)
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? High risk High risk
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Dong 2014
Methods Single-centre, randomised
Participants Total of 60 patients: 30 each received TIROX or DCF
“Included patients: (i) gastric cancer diagnosed by pathology; (ii) patients not currently
receiving chemotherapy (i.e. chemotherapy-naïve) or those who had stopped chemo-
therapy ≥1 month prior to enrolment”
Enrolled “consecutive patients with recurrent or metastatic gastric cancer”
21 and 20 pts in the TIROX and DCR group are 60 years or older
Interventions “In the TIROX group, patients received 40 mg/m2 S-1 orally twice daily after a meal
on days 1-14; 150 mg/m2 irinotecan intravenously (i.v.) infused over 90 min on the
first day; 85 mg/m2 oxaliplatin i.v. infused over 2 h on the first day. This treatment
regimen was repeated every 21 days and a 21-day treatment period was defined as one
chemotherapy cycle. In the DCF group, patients received 75 mg/m2 docetaxel i.v. and
75 mg/m2 cisplatin i.v. on the first day; 750 mg/m2 5-FU via continuous i.v. infusion
once a day from the first day to the fifth day.”
Outcomes Response rates
Safety
Notes No registration number found but “All of the studymethods were approved by the Ethics
Committee of the First Affiliated Hospital of Zhengzhou University (no. 2010-003854)
”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Low
“computer-generated randomization schedule”
Allocation concealment (selection bias) Unclear risk None stated
Incomplete outcome data (attrition bias)
efficacy
Unclear risk Number screened for eligibility and excluded not provided.
Only number of evaluable patients stated
Incomplete outcome data (attrition bias)
safety
Unclear risk Number screened for eligibility and excluded not provided.
Only number of evaluable patients stated
Selective reporting (reporting bias) High risk Only response rates and certain safety data were presented.
“The rates of long-term progression-free survival and over-
all survival were not measured”. Not clear if any of these
endpoints were prespecified
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Unclear risk Not stated
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GITSG 1988
Methods Multicentre RCT
3 arms
Quality score: D
Participants n = 249
Median age: 61
ECOG 2-3: 34%
Interventions FAP: 5-FU 300 mg/m² d 1,8,15,22; adriamycin 30 mg/m² d 1; cisplatin 100 mg/m² d
1, repeated at d 29
versus
FAT: 5-FU 300 mg/m² d1-5; adriamycin 30 mg/m² d 1; triazinate 250 mg/m² d 22-24,
repeated at d 36
versus
FAMe: 5-FU 325 mg/m² d1-5, adriamycin 40 mg/m² d 1, Semustine 110 mg/m² p.os
d 1, repeated at d 71
Outcomes Median survival
Response rates
Toxicity not classified according to WHO or NCI
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Unclear risk Not clear howmany screened for eligibility
and excluded
Incomplete outcome data (attrition bias)
safety
Unclear risk Not clear howmany screened for eligibility
and excluded
Selective reporting (reporting bias) Unclear risk Toxicity not classified according to WHO
or NCI
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Unclear risk Not stated
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Hironaka 2016
Methods Multicentre, randomised, open-label, 3-armed, phase 2 trial
Participants Median (IQR) age in the 3 arms was 65 (60-70), 65 (58-71), 65 (59-69) years
Interventions S-1 plus leucovorin (S-1 40-60 mg orally plus oral leucovorin 25 mg twice a day for
1 week, every 2 weeks), S-1 plus leucovorin and oxaliplatin (S-1 plus leucovorin and
intravenous oxaliplatin 85 mg/m2 on day 1, every 2 weeks), or S-1 plus cisplatin (S-1
40-60 mg orally twice a day for 3 weeks, plus intravenous cisplatin 60 mg/m2 on day 8,
every 5 weeks)
49 patients were randomly assigned to the S-1 plus leucovorin group, 47 to the S-1 plus
leucovorin and oxaliplatin group, and 49 to the S-1 plus cisplatin group
Outcomes Primary endpoint was overall response as assessed by an independent review committee,
defined as a confirmed complete response or partial response. Secondary endpoints
were overall survival, progression-free survival, time to treatment failure, disease control,
duration of response, and toxic effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationwas done centrally with the
minimisation method using performance
status (0 vs 1) and tumour stage (stage IV
vs recurrent) as stratification factors
Allocation concealment (selection bias) Low risk Randomisation sequence was generated by
EPS Corporation (Tokyo, Japan) indepen-
dently from the study sponsor
Incomplete outcome data (attrition bias)
efficacy
Low risk After randomisation, one patient did not
receive treatment because of aspiration
pneumonia. †Two patients who were
judged to have nomeasurable lesions by the
independent review committee after enrol-
ment were excluded from the efficacy anal-
yses
Incomplete outcome data (attrition bias)
safety
Low risk After randomisation, one patient did not
receive treatment because of aspiration
pneumonia. †Two patients who were
judged to have nomeasurable lesions by the
independent review committee after enrol-
ment were excluded from the efficacy anal-
yses
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
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Hironaka 2016 (Continued)
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Low risk independent data monitoring committee
(but not stated review committee was
blinded)
Huang 2013
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 240
Median age: 55 years
Metastatic disease: 93%
Interventions Paclitaxel+S-1: Paclitaxel 60 mg/m2 d 1,8,15, S-1 depending on body surface area (BSA
< 1.25 m2: 80 mg/d; BSA 1.25 to <1.5 m2: 100 mg/d; BSA > 1.5 m2, 120 mg/d twice
daily) twice daily d 1-14, repeated at d 29
versus
Paclitaxel+5-FU: Paclitaxel 60 mg/m2 d 1,8,15, 5-FU 500mg/m2 d 1-5, leucovorin 20
mg/m2 d 1-5 repeated at d 29
Outcomes Response rates
Progression-free survival
Time to treatment failure
Toxicity
Notes 6% of patients had no adenocarconoma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned
Allocation concealment (selection bias) Low risk Central randomisation
Incomplete outcome data (attrition bias)
efficacy
Low risk 229/240 included in full analysis set: One
patient was not eligible for the current anal-
ysis due to a lack of measurable lesions, 11
patients withdrew informed consent
Incomplete outcome data (attrition bias)
safety
Low risk 229/240 included in full analysis set: One
patient was not eligible for the current anal-
ysis due to a lack of measurable lesions, 11
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Huang 2013 (Continued)
patients withdrew informed consent
Selective reporting (reporting bias) Low risk All expected outcomes except OS analysed
Other bias Unclear risk OS not analysed
Blinded review of CT/MRI-scans? Unclear risk Not stated
Kang 2009
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 316
Median age: 56 years
Interventions XP: capecitabine 1000 mg/m² twice daily d 1-14; cisplatin 80 mg/m² d 1 every 3 weeks
versus
FP: 5-FU 800 mg/m²/d as continuous infusion d 1-5 every 3 weeks; cisplatin 80 mg/
m² d 1 every 3 weeks
Outcomes Progression-free-survival, overall survival
Tumour response
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random permuted block design
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk Analysis of ITT population (n = 316)
Incomplete outcome data (attrition bias)
safety
Low risk Analysis of all treated patients (n = 311)
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Low risk Patients followedup forOS till end of study
regardless of withdrawal + ITT vs PP, and
unadjusted vs adjusted analyses performed
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Kang 2009 (Continued)
Blinded review of CT/MRI-scans? Low risk An independent review committee (IRC)
reviewed patients’ radiological images and
assessed tumour responses without knowl-
edge of treatment assignment
Kikuchi 1990
Methods Multicentre RCT
2 arms
Quality score: B
Participants n = 77
Metastatic disease: 46%
ECOG 2-3: 88%
Interventions FA: 5-FU 270 to 300 mg/m² CI d 1- 5; adriamycin 25 mg/m² d 5, repeated at d 22
versus
FAP: 5-FU 270 to 300 mg/m² CI d 1- 5; adriamycin 25 mg/m² d 5; cisplatin 70 mg/
m² d 1, repeated at d 22
Outcomes Median survival
Response rates
Notes Translated from Japanese
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Sequential opaque envelopes
Incomplete outcome data (attrition bias)
efficacy
Low risk All evaluable pts analysed
Incomplete outcome data (attrition bias)
safety
Low risk All evaluable pts analysed
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? High risk Evaluated during group meetings
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Kim 2001
Methods Single-centre RCT
2 arms
Quality score: B
Participants n = 121
Metastatic disease: 90%
ECOG 2-3: 12%
Interventions FP: 5-FU 1000 mg/m² over 6 hours d 1-5; cisplatin 60 mg/m² d 1, repeated at d 29
versus
ECF: epirubicine 50 mg/m² d 1; cisplatin 60 mg/m² d 1, 5-FU: 1000 mg/m² d 1-5,
repeated at d 29
Outcomes Median survival
1- and 2-year survival rates
Response rates
Toxicity
Notes Study currently published as abstract only. Final results were provided by the first author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Abstract / supplement only
Allocation concealment (selection bias) Unclear risk Abstract / supplement only
Incomplete outcome data (attrition bias)
efficacy
Unclear risk Abstract / supplement only
Incomplete outcome data (attrition bias)
safety
Unclear risk Abstract / supplement only
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk Abstract / supplement only
Blinded review of CT/MRI-scans? High risk Per first author
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Kim 2014
Methods Single-centre RCT
2 arms
Quality score: D
Participants n = 77
Median age: 57 years
Metastatic disease: 62%
ECOG 2-3: 13%
Interventions wDP: docetaxel (35 mg/m2) d 1, 8, cisplatin
(60 mg/m2) d 1 repeated at d 22
versus
wDO: docetaxel (35 mg/m2) d 1, 8, oxaliplatin
(120 mg/m2) d 1 repeated at d 22
Outcomes Response rates
Overall survival
Progression-free survival
Toxicity
Notes Second-line treatment in 63 % (wDP) and 77% (wDO): irinotecan monotherapy or
irinotecan plus 5-fluorouracil/ leucovorin in 67% and 70 % of the wDP and wDO arms
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk ITT analysis
Incomplete outcome data (attrition bias)
safety
Low risk ITT analysis
Selective reporting (reporting bias) Low risk All expected endpoints included
Other bias Low risk Patients in the wDP arm received 85% and
82 % of the planned dose intensities of
docetaxel and cisplatin, respectively. In the
wDO arm, the mean relative dose intensity
was 83 % for docetaxel and 80 % for ox-
aliplatin
Blinded review of CT/MRI-scans? Unclear risk Not stated
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Koizumi 2008
Methods Multicentre RCT
2 arms
Quality score: A
The study was conducted in Japan.
Participants n = 305
Median age: 62 years
Metastatic disease: 100%
ECOG 2-3: 3%
Interventions S-1 + cisplatin: S-1 twice daily d 1-20 repeated at d 36, dose of S-1 according to the
patient’s body surface area (< 1.25 m²: 40 mg; 1.25-1.5 m²: 50 mg; > 1.5 m²: 60 mg) +
cisplatin 60 mg/m² d 8, repeated at d 36
versus
S-1 : S-1 twice daily d 1-27 repeated at d 41, dose of S-1 according to the patient’s body
surface area (< 1.25 m²: 40 mg; 1.25-1.5 m²: 50 mg; > 1.5 m²: 60 mg)
Outcomes Hazard ratio for overall survival
Tumour response
Toxicity
Notes This study was conducted in Japan. Due to polymorphic differences in the CYP2A6
gene in Asians and whites, the tolerability of S-1 is different in whites (Ajani 2006). The
dose of S-1, which was used in this trial may not be used in non-Asian populations for
this reason
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimisation by use of biased coinmethod
Allocation concealment (selection bias) Low risk Central allocation
Incomplete outcome data (attrition bias)
efficacy
Low risk 298/305 patients included in analysis.
Incomplete outcome data (attrition bias)
safety
Low risk 298/305 patients included in analysis.
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Low risk If second-line treatment was started with-
out progressive disease (i.e. due to adverse
events), patients were censored
Blinded review of CT/MRI-scans? Low risk Images were assessed by an extramural re-
view committee
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Koizumi 2014
Methods Multicentre RCT
2 arms
Quality score: D
The study was conducted in Japan and Korea.
Participants n = 639, 635 eligible (ITT)
Median age: 65 years
Advanced disease: 83%, relapse: 17%
ECOG 2-3: 0%
Interventions S-1+docetaxel: docetaxel (40mg/m2 d1) + S-1 (40-60mg/m2 -according to BSA- twice
daily d 1-14), repeated at d 21
versus
S-1: S-1 (40-60mg/m2 -according to BSA- twice daily d 1-28), repeated at d 42
Outcomes Overall survival, progression-free survival, response rate, safety
Notes The study was conducted in Japan and Korea. The dose of S-1 which was used in this
trial may not be valid for non-Asian populations for this reason
This study was registered (NCT00287768).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk 4 (0.6%) patients were ineligible (no mea-
surable or non-measurable lesions)
Incomplete outcome data (attrition bias)
safety
Low risk All treated patients were included (98%)
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias High risk Second-line treatment was given to 69.7%
of patients in the S-1+docetaxel group and
76% in the S-1 group, planned interim
analysis
Blinded review of CT/MRI-scans? Unclear risk Images were reviewed by a central review
board.
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Komatsu 2011
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 95
Median age: 66 years
ECOG 2-3: 0%
Interventions irinotecan/S-1: irinotecan 75 mg/m2 as iv infusion d 1, 15 repeated at d 29 + S-1 initial
40-60 mg/m2 orally twice daily d 1-14, repeated at 4 weeks
versus
S-1: S-1 initial 40-60 mg/m2 orally twice daily d 1-28, repeated at 6 weeks
In subsequent cycles doses were varied according to themost severe adverse events during
the preceding cycle
Outcomes Response rates
Time to treatment failure
Time to progression
Overall survival
Toxicity
Notes This study was conducted in Japan.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimization
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Unclear risk 16.7 versus 9.4% were not evaluable for
tumour response (RECIST)
Incomplete outcome data (attrition bias)
safety
Low risk Two untreated patients who were excluded
from safety evaluation
Selective reporting (reporting bias) Low risk Response rates
Time to treatment failure
Time to progression
Overall survival
Toxicity
Other bias High risk Patients aged over 70 years were more fre-
quent in the group treated with irinotecan
and S-1: 45.8% (irinotecan/S-1) vs. 14.9%
(S-1). Median age was 70 years for patients
treatedwith irinotecan/S-1 and 63 years for
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Komatsu 2011 (Continued)
patients treated with S-1 alone
Blinded review of CT/MRI-scans? High risk High risk
KRGGC 1992
Methods Multicentre RCT
2 arms
Participants n = 60
Inoperable or metastatic gastric adenocarcinoma
Interventions FP: cisplatin 50 mg/m²; 5-FU 250 mg/m² on day 1; 5-FU 250 mg/m² days 2-5
FPEPIR: cisplatin 50 mg/m²; 5-FU 250 mg/m² days 2-5; epirubicin 30 mg/m² day 2
Outcomes Response rates
Overall survival
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Sealed envelopes
Incomplete outcome data (attrition bias)
efficacy
High risk 5 patients not evaluated: 3 death from PD with 4 weeks of
treatment, 1 due to relocation, 1 due to absence of follow-
up exam
Incomplete outcome data (attrition bias)
safety
Unclear risk Toxic reactions classified by “standardization of reporting of
results of cancer treatment” grading
Selective reporting (reporting bias) Low risk RR, OS, toxicity (but not CTCAE/WHO)
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Unclear risk Not stated
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Levi 1986
Methods Multicentre RCT
2 arms
Quality score: B
Participants n = 203
Median age: 60 years
ECOG 2-3: 22%
Interventions A: adriamycin 60 mg/m² d 1, repeated at d 22
versus
FAB: 5-FU 600 mg/m², d1,8; adriamycin 40 mg/m² d 1, repeated at d 28
BCNU 100 mg/m² d 1, repeated at d 56
Outcomes Median survival
1- and 2-year survival rates
Response rates
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Central
Incomplete outcome data (attrition bias)
efficacy
High risk 16 patients not included because of ?inad-
equate follow-up, 3 = treatment cancella-
tion, 2 = protocol violation
Incomplete outcome data (attrition bias)
safety
High risk Not ITT
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk No information about type and schedule
of follow-up in the treatment groups
Blinded review of CT/MRI-scans? Unclear risk Not stated
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Li 2014
Methods Single-centre
Participants n = 16 vs 16
Average age = 45.7 (range 30-65) in the FOLFOX4 group, and 42.1 (range 26-70) in
the SOX group
Interventions “Total of 32 patients with advanced gastric cancer proved pathologically were randomly
divided into 2 groups: 16 patients received SOX regimen [oxaliplatin 1.30 mg/m2 as a
2-hour infusion on day 1, S-1 capsules 80 mg/m2·d) twice a day per oral from day 1 to
day 14 every 3 weeks], the other 16 patients received FOLFOX4 regimen [oxaliplatin 85
mg/m2 as a 2 hour infusion on day 1 and a 2 hour infusion of LV 200/(m2·d) followed
by a 5-Fu bolus 400/(m2·d) and 22 hour infusion 600/(m 2·d) for 2 consecutive days
every 2 weeks]. Efficacy was evaluated at least 2 cycles”
Outcomes Response rates
Disease control rates
PFS
OS
Safety
Notes PFS and OS were not analysed using Kaplan-Meier methods. HR for PFS could be
estimated from summary data but HR for OS could not
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple random assignment
Allocation concealment (selection bias) Unclear risk Not described
Incomplete outcome data (attrition bias)
efficacy
High risk Time-to-event analysed not analysed using Kaplan-Meier meth-
ods
Incomplete outcome data (attrition bias)
safety
High risk Quantitative comparison only made for grade 3 or higher
haematological toxicity
Selective reporting (reporting bias) Unclear risk N/A
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Unclear risk Not stated
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Li 2015
Methods “prospectively recruited AGC patients all over China” (did not state number of centres
involved)
2 arms: “randomly assigned in a 1:1 ratio to receive S1 plus cisplatin (CS group) or
fluorouracil plus cisplatin (CF group)”
Participants 255 patients screened, 120 received at least one cycle of CS, 116 received at least one
cycle of CF
Mean age: CS group - 53.3 years, CF group - 55 years
“About 50% of the patients had low differentiated cancer. Approximately 85% of the
patients had more than one site of metastasis and over half of the patients received
previous gastrectomy”
Interventions “S-1 was given as 40mg/m2 twice daily on day 1-21 and cisplatin was 20mg/m2 iv drip
on day 1-4, repeated every 5 weeks in the CS group. In the CF group, 5-Fu was given
as 800 mg/m2/d CI 120h, and the dosage of cisplatin was 20mg/m2 iv on day 1-4,
repeated every 4 weeks”
Outcomes PFS (although TTP was stated as the primary endpoint, the definition they used is more
consistent with PFS)
OS
Safety
Notes “As a pilot study, there is no need for sample size calculation. We planned to enroll 270
patients”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized grouping information for
each patient was generated by central ran-
domization system. At randomization, pa-
tients were stratified by ECOG PS (0-1 vs.
2), numbers of metastasis sites (1 vs. > 1)
and gastrectomy (yes vs no)”
Allocation concealment (selection bias) High risk “Neither patients nor investigators were
masked to treatment assignment in this
open-label study”
Incomplete outcome data (attrition bias)
efficacy
Unclear risk Low rate of attrition but reasons not spec-
ified
Incomplete outcome data (attrition bias)
safety
Unclear risk Low rate of attrition but reasons not spec-
ified
Selective reporting (reporting bias) Unclear risk N/A
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Li 2015 (Continued)
Other bias High risk “As a pilot study, there is noneed for sample
size calculation. We planned to enroll 270
patients”
Blinded review of CT/MRI-scans? High risk “Investigators assessed tumor response and
progression”
Li 2016
Methods SIngle-centre
Non-inferiority comparison of mEOX vs FOLFIRI
RCT
2 arms: modified EOX vs FOLFIRI
Participants 105 patients (55 received EOX, 50 received FOLFIRI)
Interventions “The EOX group was given epirubicin 50 mg/m2 iv on day one, oxaliplatin 85 mg/m2
iv on day 1 and capecitabine at a twice-daily dose of 625 mg/m2 po for 2 wk, which was
repeated every 3 wk”
Outcomes OS
PFS (separately for both first- and second-line)
Objective response rate
Disease control rate
Adverse events
Notes Second-line chemo allowed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified
Allocation concealment (selection bias) Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
efficacy
Unclear risk Patient disposition/CONSORT flow dia-
gramnot provided; unclear howmanywere
screened and excluded, and for what rea-
sons
Incomplete outcome data (attrition bias)
safety
Unclear risk Patient disposition/CONSORT flow dia-
gramnot provided; unclear howmanywere
screened and excluded, and for what rea-
sons
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Li 2016 (Continued)
Selective reporting (reporting bias) Unclear risk Adverse effects (NCI-CTC) categorised
and analysed as grades 1-4 and 3-4
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Unclear risk Not mentioned
Loehrer 1994
Methods Multicentre RCT
3 arms
Quality score: B
Participants n = 165
Median age: 60 years
Metastatic disease: 63%
ECOG 2-3: 27%
Interventions 5-FU: 5-FU 500 mg/m² d 1-5 repeated at d 29
versus
E: epirubicin 90 mg/m² d 1, repeated at d 29 versus
5-FU+E: 5-FU 400 mg/m² d 1-5; epirubicin 90 mg/m² d 1, repeated at d 29
Outcomes Median survival
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables
Allocation concealment (selection bias) Low risk Central allocation
Incomplete outcome data (attrition bias)
efficacy
High risk Analysis for all randomised and screened
patients
Incomplete outcome data (attrition bias)
safety
Unclear risk Analysis for all randomised, screened and
treated patients
Selective reporting (reporting bias) High risk No response rates are given
Other bias Low risk N/A
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Loehrer 1994 (Continued)
Blinded review of CT/MRI-scans? High risk High risk
Lu 2014
Methods “randomized phase II clinical trial conducted at Guizhou Cancer Hospital, China”
Participants “a total of 94 consecutive patients were enrolled to Guizhou Cancer Hospital and ran-
domly divided into two arms: OXS group (47 cases) and S-1 group (47 cases)”
In both arms, about 3/4 of participants were males
Median age was 63 and 65 years in the OXS and S-1 groups
Interventions “Advanced gastric cancer patients were treated with S-1 daily for first 2 weeks of a 3-
week cycle, or S-1 daily for first 2 weeks plus 130 mg/m2 of oxaliplatin administered as
a 2-hour intravenous infusion on day 1 of a 3-week cycle. S-1 was orally administered
in a fixed quantity according to body surface area (BSA) as follows: BSA less than 1.25
m2, 40 mg two times daily; 1.25,BSA,1.5 m2, 50 mg two times daily; and BSA more
than 1.5 m2, 60 mg two times daily”
Outcomes “The primary endpoint was OS, defined as time from date of randomization to date of
death from any cause. The secondary endpoints included PFS, RR, and safety profile.”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was generated using
a computer-generated random sequence
concealed in consecutively numbered
opaque sealed envelopes”
Allocation concealment (selection bias) Low risk “Randomization was generated using
a computer-generated random sequence
concealed in consecutively numbered
opaque sealed envelopes”
Incomplete outcome data (attrition bias)
efficacy
Low risk No patient was lost to follow-up
Incomplete outcome data (attrition bias)
safety
Low risk No patient was lost to follow-up
Selective reporting (reporting bias) Unclear risk OS, PFS, RR and safety included; possible
loss of information because of the way the
adverse events were categorised and anal-
ysed
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Lu 2014 (Continued)
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Unclear risk Not stated
Lutz 2007
Methods Multicentre RCT
3 arms
Quality score: A
Participants n = 90
Median age: 62 years
Metastatic disease: 78 % (HD-FU), 89% (HD-FU/FA); 88% (HD-FU/FA/Cis)
ECOG 2-3: 8% (HD-FU), 8% (HD-FU/FA), 4% (HD-FU/FA/Cis)
Interventions HD-FU: weekly FU 3.000 mg/m² as 24-hour infusion
versus
HD-FU/FA: weeks dl-FA 500 mg/m²/2 hours or l-FA 250 mg/m²/2 hours + FU 2.600
mg/m² as 24-hour infusion
versus
HD-FU/FA/Cis: cisplatin 50 mg/m²/hour on days 1, 15, 29; dl-FA 500 mg/m²/2 hours
or l-FA 250 mg/m²/2 hours; FU 2.000 mg/m²/24-hour continuous infusion on d 1, 8,
15, 22, 29, 36. In all 3 arms, chemotherapy was administered weekly in 6 subsequent
weeks, followed by 1 week rest
Outcomes Tumour response
Median and 1-year overall survival rates
Toxicity
Notes After stage 1 (21 patients in each arm) of the trial, the HD-FU (single agent-arm) arm
was closed because only 2 responses had been observed. Total number of patients in this
arm was 37 because inclusion was not interrupted before interim analysis. The results of
the 2 combination arms were combined in the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimisation technique
Allocation concealment (selection bias) Low risk Central randomisation at the EORTC data
centre
Incomplete outcome data (attrition bias)
efficacy
Low risk 127/145 eligible, reasons for exclusions
provided and valid
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Lutz 2007 (Continued)
Incomplete outcome data (attrition bias)
safety
Low risk 127/145 eligible, reasons for exclusions
provided and valid
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias High risk Single-therapy arm was closed earlier (Si-
mon 2-stage minimax design). The results
of the 2 combination arms were combined
in the analysis
Blinded review of CT/MRI-scans? High risk Computed tomography scans were re-
viewed centrally by the study co-ordinators
Moehler 2005
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 120
Median age: 62 years
Metastatic disease: 100%
Interventions ILF: irinotecan 80 mg/m² + LV 500 mg/m² + 5-FU 2000 mg/m² days 1, 8, 15, 22, 29,
36, repeated at 8 weeks
ELF: etoposide 120 mg/m² + LV 300 mg/m² + 5-FU 500 mg/m² d 1-3, repeated at d
22
Outcomes Tumour response
Median overall survival
Hazard ratio
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Central allocation by the Co-ordination
Centre for Clinical trials Mainz
Incomplete outcome data (attrition bias)
efficacy
Low risk Analysis of the full-analysis set of all treated
patients
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Moehler 2005 (Continued)
Incomplete outcome data (attrition bias)
safety
Low risk Analysis of the full-analysis set of all treated
patients
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Low risk N/A
Blinded review of CT/MRI-scans? Unclear risk Not stated
Moehler 2010
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 118
Median age: 62.5 years
Metastatic disease: 100%
Interventions XI: capecitabine 1000 mg/m² twice daily d 1-14 + irinotecan 250 mg/m² d 1, repeated
at d 22
versus
XP: capecitabine 1000 mg/m² twice daily d 1-14 + cisplatin 80 mg/m² d 1, repeated at
d 22
Outcomes Median overall survival
1- and 2-year rate of OS
Tumour response
Toxicity
Notes The reported results are from the first stage of the study (design with adaptive interim
analysis)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Central allocation
Incomplete outcome data (attrition bias)
efficacy
Low risk Analysis of the full-analysis set of all treated
patients with at least one efficacy assess-
ment
Incomplete outcome data (attrition bias)
safety
Low risk Analysis of the full-analysis set of all treated
patients
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Moehler 2010 (Continued)
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias High risk Results are from the first stage of the study
(design with adaptive interim analysis)
Blinded review of CT/MRI-scans? Unclear risk Not stated
Murad 1993
Methods Single-centre RCT
2 arms
Quality score: not applicable
Participants n = 41
Metastatic disease: 68%
ECOG 2-3: 30%
Interventions FAMTX: Mtx 1000 mg/m² d1; 5-FU 1500 mg/m² d 1; Lv 15 mg p.o. every 6 hours d
1 + 2 ,repeated at d 29
Adriamycin 30 mg/m² d 15, repeated at d 44 versus
BSC
Outcomes Median survival
Response rates
Maximum toxicity for each patient
Hospital admittance for toxicity
Notes After 21 patients were randomised, further participants were directly assigned to the
chemotherapy arm because of “strong evidence for benefit in the treated participants”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
High risk No ITT
Incomplete outcome data (attrition bias)
safety
Unclear risk No ITT
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
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Murad 1993 (Continued)
Other bias Unclear risk After 21 participants were randomised, fur-
ther participants were directly assigned to
the chemotherapy arm because of “strong
evidence for benefit in the treated partici-
pants”
Blinded review of CT/MRI-scans? Unclear risk Not stated
Narahara 2011
Methods Multicentre RCT
2 arms
Quality score: D
The study was conducted in Japan.
Participants n = 326
Median age: 63 years
Metastatic disease: 20%
ECOG 2-3: 3%
Interventions S-1: oral S-1 80 mg/m²/day d 1-28, repeated at 6 weeks
S-1 + irinotecan: oral S-1 80mg/m²/d d 1-21 + irinotecan iv 80mg/m² d 1 + 15, repeated
at 6 weeks
Outcomes Overall survival
Time to treatment failure
Response rates
Toxicity
Notes This studywas conducted in Japan. Pre-planned follow-up of≥ 1.5 years after registration
of all patients was continued to 2.5 years because of a unexpectedly high survival rate
of 22% at the cut-off date after a follow-up of 1.5 years. Second-line chemotherapy was
administered to 76% of patients
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised dynamic allocation
Allocation concealment (selection bias) Low risk Centralised dynamic allocation
Incomplete outcome data (attrition bias)
efficacy
Low risk Full analysis set
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Narahara 2011 (Continued)
Incomplete outcome data (attrition bias)
safety
Unclear risk 4 patients found to be ineligible after start-
ing treatment were excluded from safety
analysis - ?per-protocol analysis
Selective reporting (reporting bias) Low risk Expected endpoints reported
Other bias High risk Second-line chemotherapy was adminis-
tered to a total of 76% of patients. This is
likely to dilute the effect of both treatments
on overall survival, but not on progression-
free-survival
Blinded review of CT/MRI-scans? Unclear risk Extramural review is described (does not
neccessarily mean blinded)
Nishikawa 2012
Methods Multicentre RCT
4 arms
Quality score: D
The study was conducted in Japan.
Participants n = 161
Median age: 67 years
ECOG 2-3: 0 %
Interventions GroupA (sequential 5-FU+paclitaxel): 5-FU800mg/m² c.i.v. d 1-5, repeated at 4weeks,
followed by paclitaxel 80 mg/m² d.i.v. d 1, 8, 15, repeated at 4 weeks after progression
Group B (sequential S-1 + paclitaxel): S-1 80 mg/m² p.o. d 1-28 , repeated at 6 weeks
+ paclitaxel 80 mg/m² d.i.v. d 1, 8, 15, repeated at 4 weeks after progression
Group C (concomitant 5-FU +paclitaxel): 5-FU 600 mg/m² c.i.v. d 1-5 + paclitaxel 80
mg/m² d.i.v. d 8, 15, 22, repeated at 4 weeks
Group D (concomitant S-1 + paclitaxel): S-1 80 mg/m² p.o. d1-14 + paclitaxel 50 mg/
m² d.i.v. d1,15, repeated at 3 weeks
Outcomes Overall survival (10 months overall survival rate)
Progression-free survival
Time to treatment failure
Response rates
Toxicity
Notes This study was conducted in Japan. After publication of the results of the SPIRITS trial
(Koizumi 2008) candidates for accrual were informed about the new treatment standard
in Japan and they were offered the alternative to receive the combination therapy instead
of participating in the trial
Risk of bias
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Nishikawa 2012 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised dynamic randomisation
Allocation concealment (selection bias) Low risk Centralised dynamic randomisation
Incomplete outcome data (attrition bias)
efficacy
Low risk Only two patients in arm A and two in arm
C declined therapies before the start of the
assigned treatment
Incomplete outcome data (attrition bias)
safety
Low risk Only two patients in arm A and two in arm
C declined therapies before the start of the
assigned treatment
Selective reporting (reporting bias) Low risk Expected endpoints are reported
Other bias Unclear risk An irinotecan-containing regimen was rec-
ommended for use in case if further lines
of treatment were given. No information
about the percentage of patients receiving
second line treatment is provided
Blinded review of CT/MRI-scans? Unclear risk not stated
Ochenduszko 2015
Methods Randomised, single-centre phase 3 study
Participants “Most patients had metastatic disease and more than 50 % of patients in each arm
have undergone gastrectomy (primary tumor resection) as part of curative or palliative
treatment. Significantly more patients in the mDCF arm presented with metastases in
the liver (48.1 vs. 17.2 %; p = 0.029)”
Interventions “The EOX regimen was given every 3 weeks, initially for a maximum of eight cycles (24
weeks of treatment). It consisted of epirubicin 50mg/m2 (intravenous bolus), followedby
oxaliplatin 130 mg/m2 (2-h intravenous infusion); capecitabine was administered orally,
twice daily at the dose of 625 mg/m2 for 21 days. The mDCF regimen was administered
every 2 weeks, initially for a maximum of 12 cycles (24 weeks of treatment), docetaxel
40 mg/m2 (intravenous infusion over 60 min) on day 1, followed by leucovorin 400 mg/
m2 (intravenous infusion over 120 min) on day 1, followed by 5-fluorouracil 400 mg/
m2 (intravenous bolus) on day 1, and then 5-fluorouracil 1000 mg/m2/day continuous
intravenous infusion on day 1 and day 2, followed by cisplatin 40 mg/m2 (intravenous
infusion over 60 min) on day 3.”
Outcomes OS
PFS - the definition of PFS was not clearly stated
120Chemotherapy for advanced gastric cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ochenduszko 2015 (Continued)
Safety
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk No loss to follow-up
Incomplete outcome data (attrition bias)
safety
Low risk Only one patient frommDCF arm excluded
due to rapid disease progression
Selective reporting (reporting bias) Unclear risk RR not provided
Other bias High risk “Significantly more patients in the mDCF
arm presented with metastases in the liver
(48.1 vs. 17.2 %; p = 0.029)” - no statistical
adjustmentwasmade for baseline imbalance
CT scans every 8-12 weeks; and disease pro-
gression could also be evaluated based on
clinical symptoms and urgent CT was re-
quested whenever needed
Blinded review of CT/MRI-scans? Unclear risk Not stated
Ocvirk 2012
Methods Single-centre RCT
2 arms
Quality score: D
Participants n = 85
Median age: 55 years
Metastatic disease: 85%
ECOG 2-3: 6%
Interventions ECF: epirubicin 50 mg/m² i.v. d 1 + cisplatin 60 mg/m² i.v. d 1 i.v.+ 5- FU 200 mg/
m²/day continuous infusion d 1-14, repeated at d 22
ECX: epirubicin 50 mg/m² i.v. d1+ cisplatin 60 mg/m² i.v. d 1 + capecitabine 825 mg/
m² orally twice daily d 1-14, repeated at d 22
Treatment was discontinued in case of disease progression, unacceptable toxicity, or if
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Ocvirk 2012 (Continued)
the patient refused further treatment
Outcomes Overall survival
Response rates
Time to progression
Toxicity
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of sequence generation is not
described
Allocation concealment (selection bias) Low risk “Randomisation and allocation were done
by a registration center”
Incomplete outcome data (attrition bias)
efficacy
Low risk All randomised patients were included in
the ITT analysis
Incomplete outcome data (attrition bias)
safety
Low risk All randomised patients were included in
the ITT analysis
Selective reporting (reporting bias) Low risk N/A - except that TTP rather than PFS
reported
Other bias High risk Response assessment was done by abdomi-
nal ultrasound and/or abdominal CT (not
CT of the thorax and abdomen). Both
methods are insufficient
Blinded review of CT/MRI-scans? High risk Response assessment was done by abdomi-
nal ultrasound and/or abdominal CT (not
CT of the thorax and abdomen). Both
methods are insufficient
Ohtsu 2003
Methods Multicentre RCT
3 arms
Quality score: A
Participants n = 280
Median age: 62 years
Metastatic disease: 86%
ECOG 2-3: 17%
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Ohtsu 2003 (Continued)
Interventions FU: 5-FU 800 mg/m² CI d 1-5, repeated at d 29
versus
FP: 5-FU 800 mg/m² CI d 1-5; cisplatin 20 mg/m² d 1-5, repeated at d 29
versus
UFTM: UFT (uracil/tegafur) 375 mg/m² twice daily p.o., mitomycin 5 mg/m² d 1,
repeated at d 8
Outcomes Median survival
Response rates
Toxicity
Notes Full information about second-line therapy given: 51% of participants in the combi-
nation therapy arms and 57% of participants in the single-agent 5-FU arm received a
second-line therapy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimisation
Allocation concealment (selection bias) Low risk JCOG data centre
Incomplete outcome data (attrition bias)
efficacy
Low risk ITT
Incomplete outcome data (attrition bias)
safety
Low risk ITT
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Low risk Both combination chemotherapy arms (FP
andUFTM)were combined in the analysis.
High rates of second-line therapy
Blinded review of CT/MRI-scans? Unclear risk “objective responses confirmed by central
review at regular group meetings”
Popov 2002
Methods Single-centre RCT
2 arms
Quality score: D
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Popov 2002 (Continued)
Participants n = 60
Median age: 56 years
Metastatic disease: 82%
ECOG 2-3: 17%
Interventions 5-FU 2600 mg/m² over 24 hours d 1, repeated at d 15
versus
EAP: etoposide 120 mg/m² d 4-6; adriamycin 20 mg/m² d 1,7; cisplatin 40 mg/m² d
2, 8, repeated at d 29
Outcomes Median survival
Time to progression
Response rates
Toxicity
Notes Study published as abstract, information on final results provided by first author (Popov
2002). Final publication in Medical Oncology 2008.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Method of random numbers
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk No excluded patients
Incomplete outcome data (attrition bias)
safety
Low risk No excluded patients
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Low risk Independent response review was per-
formedby a joint interdisciplinary commit-
tee not involved in the study
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Popov 2008
Methods RCT
2 arms
Quality score: D
Participants n = 72
Median age: 56 years
ECOG 2-3: 29%
Interventions LV5-FU2 oxaliplatin: oxaliplatin 85 mg/m² d 1+ folinic acid 200 mglm², as 2-hour
infusion, d 1-2 + 5-FU 400 mg/m², Lv. bolus d 1-2, repeated at d 15
versus
LV5-FU2-CDDP: cisplatin 50 mg/m², d1+ folinic acid 200 mg/m², as 2-hour infusion,
d 1-2 + 5-FU 400 mg/m², Lv. bolus d1-2 + 5-FU 600 mg/m² , 22-hour continuous
infusion d 1-2, repeated at d 15
The maximum number of cycles foreseen was 12
Outcomes Median overall survival
Median time to progression
Tumour response rates
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
High risk Patients receiving 4 or more cycles were evaluable for
efficacy
Incomplete outcome data (attrition bias)
safety
Low risk Patients receiving 1 cycle were evaluable for toxicity
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Low risk “Independent response reviewwas performedbymem-
bers (surgeon, medical oncologist, radiologist and
pathologist) of the joint interdisciplinary committee
for gastrointestinal tumors of the Institute and theUni-
versity Clinic for gastrointestinal diseases. The com-
mittee members were not involved in the study”
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Pyrhönen 1995
Methods RCT
2 arms
Quality score: B
Participants n = 41
Metastatic disease: 71 %
Interventions FEMTX: methotrexate 1500 mg/m² d 1, 5-FU 1500 mg/m² d 1, Lv 30 mg p.o. every
6 hours d 1, 2, epirubicin 60 mg/m² d 15, repeated at d 29
versus
BSC
Outcomes Median survival
1-and 2-year survival rates
Response rates
Toxicity
Palliative measures
Notes Study terminated after 6 years when 41 participants were randomised because of slow
patient accrual and “conspicuous difference in survival”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randompermutated blocks (length 10) were used. The
block was not known by clinicians
Allocation concealment (selection bias) Low risk Sealed envelopes, Random permutated blocks (length
10) were used. The block was not known by clinicians
Incomplete outcome data (attrition bias)
efficacy
Low risk Only 1 patient in treatment group did not receive at
least one course of chemo
Incomplete outcome data (attrition bias)
safety
Low risk Only 1 patient in treatment group did not receive at
least one course of chemo
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias High risk Early termination of the study
Blinded review of CT/MRI-scans? High risk High risk
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Ridwelski 2008
Methods Multicentre RCT
2 arms
Quality score: B
Participants n = 273
Median age: 62 years
Metastatic disease: 90%
Interventions DC: docetaxel 75 mg/m² + cisplatin 75 mg/m² d 1, repeated at 3 w
FLC: 5-FU 2000 mg/m² + leucovorin 500 mg/m² d 1, 8, 15, 22, 29, 36, repeated at 7
w + cisplatin 50 mg/m² d 1, 15, 29, repeated at 7 w (cisplatin omitted in FLC in cycle
4)
Outcomes Median overall and hazard ratios for survival and time to progression
1-year survival
Tumour response
Toxicity
Notes Study currently published as abstract only. Information on final results provided by first
author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables
Allocation concealment (selection bias) Low risk Central
Incomplete outcome data (attrition bias)
efficacy
Low risk Analysis for all randomised and screened
patients
Incomplete outcome data (attrition bias)
safety
Low risk Analysis for all randomised, screened and
treated patients
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? High risk Per first author
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Ross 2002
Methods Multicentre RCT
2 arms
Quality score: B
Participants n = 334 participants with adenocarcinoma of the stomach or gastro-oesophageal junction
Median age: 55 years
Metastatic disease: 68%
ECOG 2-3: 18%
Interventions ECF: epirubicin 50 mg/m² d 1, repeated at d 22; cisplatin 60 mg/m² d 1, repeated at d
22, 5-FU CI 300 mg/m² continuously
versus
MCF: mitomycin 7 mg/m² d 1, repeated at d 43; cisplatin 60 mg/m² d 1, repeated at d
22, 5-FU CI 300 mg/m² continuously
Outcomes Median survival
Response rates
Quality of life
Toxicity
Notes The original study included 580 participants with inoperable adenocarcinoma, squa-
mous cell carcinoma, or undifferentiated carcinoma of the oesophagus, oesophagogastric
junction or stomach. Information on participants with gastric and gastro-oesophageal
junction adenocarcinoma only was provided by the first author and is included in the
meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Query (correspondence) to first author was
not answered
Allocation concealment (selection bias) Unclear risk Query (correspondence) to first author was
not answered
Incomplete outcome data (attrition bias)
efficacy
Low risk ITT
Incomplete outcome data (attrition bias)
safety
Low risk ITT
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? High risk Not done per first author correspondence
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Roth 1999
Methods Single-centre RCT
2 arms
Quality score: D
Participants n = 122
Median age: 55 years
Metastatic disease: 67%
ECOG 2-3: 48%
Interventions FE: 5-FU 1000 mg/m² CI d 1-5, repeated at d 29; epirubicin 120 mg/m² d 1, repeated
at d 29
versus
FEP: 5-FU 1000 mg/m² CI d 1-5, repeated at d 29, epirubicin 120 mg/m² d 1, repeated
at d 29, P 30 mg/m² d 2, 4, repeated at d 29
Outcomes Median survival
Response rates
Toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk 110/122 received treatment and were as-
sessable
Incomplete outcome data (attrition bias)
safety
Low risk 110/122 received treatment and were as-
sessable
Selective reporting (reporting bias) Low risk All expected outcomes available
Other bias Unclear risk No information about type and schedule
of follow-up
Blinded review of CT/MRI-scans? High risk High risk
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Roth 2007
Methods Multicentre RCT
3 arms
Quality score: A
Participants n = 121
Median age: 59 years
Metastatic disease: 86%
Interventions ECF: epirubicin 50 mg/m² d 1 + cisplatin 60 mg/m² d 1 + FU 200 mg/m²/d as 24-hour
continuous infusion on days 1-21, repeated at d 22
TC: docetaxel 85 mg/m² d 1 + cisplatin 75 mg/m² d 1, repeated at d 22
TCF: TC + FU 300 mg/m²/d as a 24-hour continuous infusion d 1-14, repeated at d
22 for up to 8 cycles
Outcomes Tumour response
Median overall survival and time to progression
Toxicity
Quality of life
Notes Because of the toxicity of this regimen, the dose of docetaxel was reduced to 75 mg/
m² later in the trial. The results of two docetaxel arms were combined in the analysis.
Second-line therapy after disease progression in 56% of patients with docetaxel and 48%
of patients without docetaxel
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Central randomisation at the SAKK Co-
ordinating Center
Incomplete outcome data (attrition bias)
efficacy
Low risk “Of 121 patients randomly assigned be-
tween September 1999 and July 2003, two
were not treated (renal failure, n = 1; and
ineligibility, n = 1) and were excluded. An-
other patient received two cycles of TCF
before being considered ineligible but was
included in the analyses.”
Incomplete outcome data (attrition bias)
safety
Low risk “Of 121 patients randomly assigned be-
tween September 1999 and July 2003, two
were not treated (renal failure, n = 1; and
ineligibility, n = 1) and were excluded. An-
other patient received two cycles of TCF
before being considered ineligible but was
included in the analyses.”
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Roth 2007 (Continued)
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Low risk All responses were confirmed by an inde-
pendent panel of radiologists and an oncol-
ogist
Roy 2012
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 86
Median age: 61 years
Metastatic disease: 94%
ECOG 2-3: 0% (Karnofsky performance status KPS was ≥70% for all patients)
Interventions DI: docetaxel 60 mg/m2 + irinotecan 250 mg/m2 d1, repeated at d 22
DF: docetaxel 85 mg/m2 d 1 + 5-FU 750 mg/m2 d 1-5, repeated at d 22
Outcomes Response rates
Time to progression
Time to treatment failure
Duration of response
Overall survival
Toxicities
Clinical benefit (time to definitive worsening of KPS, time to definitive weight loss, time
to definitive worsening of appetite and pain-free survival)
Notes 43% patients in the DI group and 49% patients in the DF group received second-line
chemotherapy (mostly a platinum containing regimen)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk ITT analysis with only 1 excluded because
of jaundice in the DI group
131Chemotherapy for advanced gastric cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Roy 2012 (Continued)
Incomplete outcome data (attrition bias)
safety
Low risk ITT analysis with only 1 excluded because
of jaundice in the DI group
Selective reporting (reporting bias) Low risk All expected endpoints included
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Unclear risk Assessed by external response review com-
mittee
Sadighi 2006
Methods Single-centre RCT
2 arms
Quality score: D
Participants n=86
Mean age: 56 years
Metastatic disease: 100%
Interventions ECF: epirubicin 60 mg/m² + cisplatin 60 mg/m² + 5-FU 750 mg/m²/day as 5 days
continuous infusion; repeated at d 22 for 6 cycles
TCF: docetaxel 60mg/m² + cisplatin 60mg/m² + 5-FU 750mg/m² as 5 days continuous
infusion; repeated at d 22 for 6 cycles
Outcomes Response rate
Quality of life
Overall survival
Progression-free survival
Notes Extensive analysis of QoL data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Unclear risk No information regarding numbers of pa-
tients beside response rates (primary end-
point)
Incomplete outcome data (attrition bias)
safety
High risk For QoL evaluation, only 71 patients were
included in the comparative analysis be-
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cause 15patients did not complete theQoL
measurements at the beginning of the study
Selective reporting (reporting bias) High risk Missing information regarding PFS as sec-
ondary endpoint
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Unclear risk Not stated
Scheithauer 1996
Methods Multicentre RCT
2 arms
Quality score: B
Participants n = 103
Metastatic disease: 63%
ECOG 2-3: 29%
Interventions FE: 5-FU 400 mg/m² d 1-5; Lv 200 mg/m² d 1-5; epirubicin 50 mg/m² d 1, repeated
at d 29
versus
BSC
Outcomes Median survival
Response rates
1- and 2-year survival rates
Quality of life
Toxicity
Notes Study published as abstract only; additional information provided by first author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk Adequate
Incomplete outcome data (attrition bias)
efficacy
Low risk
Incomplete outcome data (attrition bias)
safety
Low risk
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Selective reporting (reporting bias) Low risk
Other bias Low risk
Blinded review of CT/MRI-scans? High risk High risk
Shirao 2013
Methods Multicentre RCT
2 arms
Quality score: B
The study was conducted in Japan .
Participants n = 237
Median age: 60 years
Metastatic disease: 100% (all patients had peritoneal metastasis), confirmed by imaging
and/or ascites
ECOG 2-3: 3.4%
Interventions 5-FU: 5-FU 800 mg/m² d 1-5, repeated at d 29
versus
MF:methotrexate 100mg/m² d 1 + 5-FU600mg/m² d 1 + leucovorin rescue (leucovorin
10 mg/m² x 6) d 1, repeated at d 8
Outcomes Overall survival, ingestion-possible survival (=surviving days free from nutrition support
in patients with sufficient ingestion aat baseline, ingestive improvement in patients with-
out sufficient ingestion at baseline), safety
Notes The study was registered as NCT00149201 and UMIN-CTR number C000000123
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimization
Allocation concealment (selection bias) Low risk Algorithm concealed to investigators
Incomplete outcome data (attrition bias)
efficacy
Low risk 2 non-treated patients were excluded in
each group.
Incomplete outcome data (attrition bias)
safety
Low risk 2 non-treated patients were excluded in
each group.
Selective reporting (reporting bias) High risk No response and PFS reported
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Other bias High risk Second-line treatment was given to 80.7%
of patients in the 5-FU group and 72.9 in
the MF group, planned interim analysis
Blinded review of CT/MRI-scans? Unclear risk N/A (no response and PFS reported)
Sugimoto 2014
Methods Multicentre, randomised phase 2
“Before randomization, patients were stratified according to unresectable advanced can-
cer/recurrent cancer with adjuvant chemotherapy /recurrent cancer without adjuvant
chemotherapy and ECOG PS 0/1/2”
Participants 102 patients with 51 patients each in SIri and SPac arms
Median age: 64 (SIri) and 62 (SPac)
Advanced/recurrent ratio: 40/11 in both arms
“no prior chemotherapy, except adjuvant chemotherapy completed four weeks or more
before entry”
Interventions Schedule of S-1 was not similar in both arms
Arm A: SIri: Irinotecan (i.v.) over 1.5 h at 80 mg/m² on day 1 and 15, while 40 mg/m²
S-1 (Taiho Pharmaceutical, Tokyo, Japan) was orally administered twice daily for three
weeks from days 1-21 followed by a two-week pause.
Arm B: SPac: Paclitaxel was administered i.v. over 1 h at a dose of 50 mg/m² on day 1
and 8, while 40 mg/m² S-1 was orally administered at twice-daily for two weeks from
day1-14 followed by a one-week pause
Outcomes Primary endpoint: Overall response rate
Secondary endpoints: Progression-free survival, overall survival and safety
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
efficacy
Low risk (All outcomes analysed for all patients)
Incomplete outcome data (attrition bias)
safety
Low risk (All outcomes analysed for all patients)
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Selective reporting (reporting bias) Low risk Expected endpoints included in reporting
Other bias High risk High risk
Schedule of S-1 not similar in two arms
Blinded review of CT/MRI-scans? Low risk (“All radiological assessments were con-
firmed by extratumoral review”)
Thuss-Patience 2005
Methods Multicentre RCT
2 arms
Quality score: A
Participants n = 90
Median age: 62.5 years
Metastatic disease: 98%
ECOG 2-3: 3%
Interventions DF: docetaxel 75 mg/m² d 1 + FU 200 mg/m²/day as a 24-hour continuous infusion d
1-21, repeated at d 22
versus
ECF: epirubicin 50 mg/m² d 1 + cisplatin 60 mg/m² d 1 + FU 200 mg/m²/as a 24-hour
continuous infusion d 1-21, repeated at d 22
Outcomes Tumour response
Median survival
Median time to progression
Toxicity
Notes Phase II study
The trial was not intended and not statistically powered to perform a head-to-head
comparison of response rate and toxicity of the 2 treatment arms. ECF serves as an
internal control arm to avoid selection bias
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers
Allocation concealment (selection bias) Low risk Central allocation
Incomplete outcome data (attrition bias)
efficacy
Low risk Analysis of the full analysis set
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Incomplete outcome data (attrition bias)
safety
Low risk Analysis of the full analysis set
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias High risk The trial was not intended and not statis-
tically powered to perform a head-to-head
comparison of response rate and toxicity of
the 2 treatment arms, ECF serves as an in-
ternal control arm to avoid selection bias
Blinded review of CT/MRI-scans? Low risk Tumour response was assessed together
with an independent radiologist
Van Cutsem 2006
Methods Multicentre RCT
2 arms
Quality score: D
Participants n = 445
Median age: 55 years
Metastatic disease: 96.5%
Interventions DCF: docetaxel 75 mg/m² + cisplatin 75 mg/m² d 1 + 5-FU 750 mg/m²/d as a 24-hour
continuous infusion d 1-5, repeated at d 22
versus
CF: cisplatin 100 mg/m² d 1 + 5-FU 1.000 mg/m²/d as a 24-hour continuous infusion
on d 1-5, repeated at d 29
Outcomes Median overall survival and time to progression
Tumour response
Toxicity
Quality of life
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Central allocation
Incomplete outcome data (attrition bias)
efficacy
Low risk Analysis of the full-analysis set
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Incomplete outcome data (attrition bias)
safety
Low risk Analysis of the full-analysis set
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Low risk All radiologic assessments were reviewed by
an external response review committee and
were assessed by WHO criteria
Van Cutsem 2015
Methods Prospective, multinational, randomised, phase II study
Fifty-two sites in the USA and 11 countries in Europe screened and randomised patients
Participants The majority (69%) of patients were male; mean age was 59 years
Interventions 3-arm study: docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/5-FU (TEF), and doc-
etaxel/oxaliplatin/capecitabine (TEX)
Outcomes PFS
OS
ORR
Safety
Notes “Tumour response was evaluated every 8 weeks and classified according to best overall
response (World Health Organization criteria). Responses were confirmed by two eval-
uations conducted ≥4 weeks apart”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not clear what method
Allocation concealment (selection bias) Low risk RandomiSed centrally using an interactive
voice response system
Incomplete outcome data (attrition bias)
efficacy
Low risk “primary efficacy population was the full
analysis population (FAP: all randomized
and treated patients analysed in the arm to
which they were randomized), with sup-
portive analyses conducted using the in-
tent-to-treat (ITT: all randomized patients)
and per protocol (PP: assessable patients
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[received study treatment and had≥1 post-
baseline tumour assessment] without any
major protocol violation) populations”
Incomplete outcome data (attrition bias)
safety
Low risk “primary efficacy population was the full
analysis population (FAP: all randomized
and treated patients analysed in the arm to
which they were randomized), with sup-
portive analyses conducted using the in-
tent-to-treat (ITT: all randomized patients)
and per protocol (PP: assessable patients
[received study treatment and had≥1 post-
baseline tumour assessment] without any
major protocol violation) populations”
Selective reporting (reporting bias) Low risk PFS, OS, ORR, safety
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? Unclear risk Not stated
Wang 2013
Methods Single-centre RCT
2 arms
Quality score: B
Participants n = 82 participants with metastatic or locally recurrent gastric cancer
ECOG 2: 8.5%
Interventions S-1 +paclitaxel: S-1 depending on body surface area (BSA < 1.25 m2: 80 mg/d; BSA
1.25 to < 1.5 m2: 100 mg/d; BSA > 1.5 m2, 120 mg/d twice daily) d 1-14, paclitaxel
60mg/m2 d 1,8,15, repeated at d 29
versus S-1: S-1 depending on body surface area (BSA < 1.25 m2: 80 mg/d; BSA 1.25 to
<1.5 m2: 100 mg/d; BSA > 1.5 m2, 120 mg/d twice daily) d 1-14, repeated at d 29
Outcomes Overall survival
Progression-free survival
Response rate
Toxicity
Notes Second-line therapy with cisplatin or irinotecan in more than half of the patients
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer-generated, random sequence
Allocation concealment (selection bias) Low risk Consecutively numbered opaque sealed en-
velopes
Incomplete outcome data (attrition bias)
efficacy
Low risk No patients lost to follow-up and all out-
comes could be confirmed
Incomplete outcome data (attrition bias)
safety
Low risk No patients lost to follow up and all out-
comes could be confirmed
Selective reporting (reporting bias) Low risk OS, PFS, ORR, safety
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? High risk Tumor assessment was undertaken with
CT orMRI consistently every 2months by
principal investigators
Wang 2016
Methods Multicentre, prospective, randomised, open-label, phase III trial
Participants Histo: 15% Signet ring, 3% Others
Interventions “Untreated advanced gastric cancer patients randomly received docetaxel and cisplatin
at 60 mg/m2 (day 1) followed by fluorouracil at 600 mg/m2/day (days 1-5; mDCF
regimen) or cisplatin at 75 mg/m2 (day 1) followed by fluorouracil at 600 mg/m2/day
(days 1-5; CF) every 3 weeks”
Outcomes “The primary end point was progression-free survival (PFS). The secondary end points
were OS, overall response rate (ORR), time-to-treatment failure (TTF), and safety”
Notes NCT00811447
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated what method was used. “Ran-
dom assignment was centralized and strat-
ified for center, liver metastases, prior gas-
trectomy, Karnofsky performance status
(KPS) (80 or above vs below 80), and
weight loss during the previous 3 months
(5 % or less vs more than 5 %)”
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Allocation concealment (selection bias) Low risk Random assignment was centralised
Incomplete outcome data (attrition bias)
efficacy
Low risk All patients who received treatment were
included in full analysis set
Incomplete outcome data (attrition bias)
safety
Low risk All patients who received treatment were
included in full analysis set
Selective reporting (reporting bias) Low risk Endpoints were all reported
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? High risk “Tumor response and PFS were evaluated
by investigators, and although much effort
has been done to limit the bias in the eval-
uation of these parameters...”
Webb 1997
Methods Multicentre RCT
2 arms
Quality score: B
Participants n = 199 participants with adenocarcinoma of the stomach or gastro-oesophageal junction
Metastatic disease: 85%
ECOG 2-3: 26%
Interventions ECF: epirubicin 50 mg/m² d 1, repeated at d 22; cisplatin 60 mg/m² d 1, repeated at d
22, 5-FU CI 200 mg/m² d 1-21, repeated at d 22
versus
FAMTX: methotrexate 1500 mg/m² d 1; 5-FU 1500 mg/m² d 1; Lv 30 mg p.o. every
6 hours d 2, 3; adriamycin 30 mg/m² d 15, repeated at d 28
Outcomes Median survival
Response rates
Toxicity
Quality of life
Notes The entire study included 274 participants with inoperable adenocarcinoma or undiffer-
entiated carcinoma of the oesophagus, oesophagogastric junction or stomach. Results for
participants with adenocarcinoma of the stomach or gastro-oesophageal junction only
were provided by the corresponding author and included in the meta-analysis
Risk of bias
Bias Authors’ judgement Support for judgement
141Chemotherapy for advanced gastric cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Webb 1997 (Continued)
Random sequence generation (selection
bias)
Unclear risk Query to first author was not answered
Allocation concealment (selection bias) Unclear risk Query to first author was not answered
Incomplete outcome data (attrition bias)
efficacy
Low risk ITT per correspondence
Incomplete outcome data (attrition bias)
safety
Low risk ITT per correspondence
Selective reporting (reporting bias) Low risk Report includes all expected outcomes
Other bias Unclear risk N/A
Blinded review of CT/MRI-scans? High risk Not done according to correspondence
Wu 2015
Methods Pilot randomiSed-controlled study
Participants “158participantswere initially screened, ofwhom86were excluded.Of these 86patients,
73 did not fulfill the study criteria and 13 declined to participate. The remaining 72
patients (36 treated with SC and 36 treated with C) were entered into the study”
“The mean age of the patients was 64.1 years in the SC group and 62.7 years in the C
group. The performance status was 0 for 41.7% of patients treated with SC and 44.4%
of patients treated with C and it was 1 for 58.3% of patients treated with SC and 44.
4% of patients treated with C. The primary lesion was 55.6% in the SC group and 50.
0% in the C group. Histological types were intestinal (58.3% in the SC group and 61.
1% in the C group), diffuse (36.1% in the SC group and 30.6% in the C group), and
others (5.6% in the SC group and 8.3% in the C group). The diagnosis was AGC (86.
1% in the SC group and 83.3% in the C group) and relapse gastric cancer (13.9% in
the SC group and 16.7% in the C group).”
Interventions “Patients in the C group received cisplatin 75 mg/m2 intravenously over 1-3 h on day
1 and then at 4-week intervals. In addition to receiving the same intervention as the C
group, patients in the SC group were also administered S-1 on days 1-14 of a 21-day
cycle. The daily dose of S-1 was assigned according to the body surface area as follows:
less than 1.25 m2, 40 mg two times daily; more than or equal to 1.25 m2 and less than
1.5 m2, 50 mg two times daily; and more than or equal to 1.5 m2, 60 mg two times
daily.”
Outcomes OS
PFS
Adverse events
Notes
142Chemotherapy for advanced gastric cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wu 2015 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were stratified using the block random-
ization method of the SAS package (version 8.2;
SAS Institute Inc., Cary, NorthCarolina, USA) by
a statistician with no clinical involvement in this
study”
Allocation concealment (selection bias) Low risk “The allocation was concealed in sequentially
numbered, opaque, sealed envelopes containing
the randomization assignments”
Incomplete outcome data (attrition bias)
efficacy
Low risk All participants could undergo evaluations for ef-
ficacy and safety
Incomplete outcome data (attrition bias)
safety
Low risk All participants could undergo evaluations for ef-
ficacy and safety
Selective reporting (reporting bias) High risk Overall response rates were compared although it
did not appear to be prespecified. Furthermore,
details of how response was assessed were not pro-
vided
Other bias High risk Study did not clearly specify minimum required
sample size - “Sample size was calculated on the
basis of an expected 15% difference between the
two groups, with 80% power and a two-sided [al-
pha] value of 0.05”
Comments from statistician BCT:The paper is
not clear about how the sample size is being esti-
mated. In particular, we do not have information
on the HR or the survival probability of the con-
trol group. I assume the 15% difference refers to
absolute difference. I try to work out this differ-
ence from the KM curve of Fig 2. If we assume
a 1 year estimate, then the survival probability is
approx. 25% vs 40% (HR approx. 0.66). If we as-
sume a 0.5 year estimate, then the survival proba-
bility is 75% vs 90% (HR approx. 0.37). This cor-
responds to a total sample size of about 300 and
200 respectively, assuming a two-sided test at 5%
level and a power of 80%. If we estimate the HR
from the median OS that is reported, the HR is
approx. 0.8, and so we would expect an even larger
sample size
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Blinded review of CT/MRI-scans? Unclear risk Not stated
Yamada 2015
Methods Randomised, open-label, multicentre phase III study
Participants 685 patients were enrolled; 343 and 342 patients were randomly assigned to SOX or CS
Interventions “In CS, S-1 was given orally twice daily for the first 3 weeks of a 5-week cycle. The dose
was 80 mg/day for body surface area (BSA) <1.25 m2, 100 mg/day for BSA ≥1.25 to
<1.5 m2, and 120 mg/day for BSA ≥1.5 m2. Cisplatin was administered at 60 mg/m2
as an i.v. infusion with adequate hydration on day 8 of each cycle [9]. In SOX, S-1 was
given as the same way for the first 2 weeks of a 3-week cycle. Oxaliplatin at 100 mg/m2
was infused for 2 h i.v. on day 1 of each cycle”
Outcomes The primary endpointswere noninferiority in progression-free survival (PFS) and relative
efficacy in overall survival (OS) for SOX using adjusted hazard ratios (HRs)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Minimisation method.
Allocation concealment (selection bias) Low risk The randomisation sequence was gener-
ated by an independent team from the trial
sponsor and investigators
Incomplete outcome data (attrition bias)
efficacy
Low risk ITT
Incomplete outcome data (attrition bias)
safety
Low risk ITT
Selective reporting (reporting bias) Low risk PFS, OS, tumor responses, Adverse events
Other bias Unclear risk “During the study period, we did not test
HER2 expression in tumors and could not
know its exact influence on our results.
The proportion of patients who received
trastuzumab after the study treatment was
small (<10%) and similar in both groups.
Therefore, trastuzumab treatment would
not seem to impact on comparing OS be-
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tween both groups.”
“Patients who were alive and free of pro-
gression (i.e. second-line treatment was
started due to any cause) were regarded as
censored cases at the date of the last assess-
ment”
“In February 2011, it appeared to be dif-
ficult to achieve the required number of
events within the preplanned timetable,
and the target number of patients was re-
vised to 680 according to the predefined
procedure in the protocol”
Blinded review of CT/MRI-scans? Low risk “All images for PFS and tumor responses
were reviewed by an independent review
committee, according to the Response
Evaluation Criteria In Solid Tumors (RE-
CIST) version 1.0”
Yamamura 1998
Methods Multicentre RCT
2 arms
Quality score: C
Participants n = 71
Interventions MTX/5-FU/THP: methotrexate 50 mg/m², 5-FU 650 mg/m², pirarubicin 20 mg/m²
d 1, repeated at d 15
versus
5-FU: 5-FU 650 mg/m² d 1, repeated at d 15
Outcomes Median survival
Toxicity
Notes Study translated from Japanese
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Low risk Centralised. Phone call
Incomplete outcome data (attrition bias)
efficacy
Low risk 71/74 evaluable
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Incomplete outcome data (attrition bias)
safety
Low risk 71/74 evaluable
Selective reporting (reporting bias) High risk No response rates available
JCOG criteria for toxicity
Other bias Unclear risk Study translated from Japanese
Blinded review of CT/MRI-scans? Unclear risk N/A
Abbreviations:
BSA: body surface area
BSC: best supportive care
CI: continuous infusion
CT: computed tomography
d: day
dFUR: 5-Deoxyfluouridine
ECOG: Eastern Cooperative Oncology Group
5-FU: 5-Fluorouracil
FA: folinic acid
h: hour
IQR: interquartile range
ITT: intention-to-treat
i.v.: intravenous
KI: Karnofsky-Index
KPS: Karnofsky performance status
Lv: leucovorin
NCI-CTC: National Cancer Institute Common Toxicity Criteria
OS: overall survival
p.o.: per os (orally)
PFS: progression-free survival
QoL: quality of life
RCT: randomised controlled trial
RR: response rate
TTP: time to progression
UFT: uracil/ftorafur
w: week
WHO: World Health Organization
If not stated differently, all drugs were given as intravenous bolus or short infusion (duration max. 2 hours)
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ahn 2002 According to information provided by the first author about 2/3 of included participants had undergone
gastric resection and were treated in adjuvant/additive intention
Ajani 2002 Article about study published elsewhere (Van Cutsem 2006).
Ajani 2006 Non-randomised phase II study.
Akagi 2010 Other indication (patients underwent macroscopically curative resection)
Akazawa 1985 Study not randomised.
Andri 2012 Interventions not relevant for any of the comparisons specified
Anonymous 1979 Not all participants were randomised (some were directly assigned to 1 treatment arm according to their prior
chemotherapy). Systematic cross-over between treatment arms
Anonymous 1982 Study began as three-arm comparison of FAMe, FAMi and FIMe regimens. FMe was added to randomization
later. ICRF-159 =dexrazoxaneL None of the possible permutations between these regimens fit our study
comparisons
Anonymous 1983 18 of 82 included participants were crossed over (< 10 %)
Anonymous 1984 Compared FA, FAMe, and FAMi. None of the possible permutations between these regimens fit our study
comparisons
Aoyama 1981 Study not randomised
Bajetta 1998 Participants not randomised to different chemotherapy regimens, but to one regimen (FEP) with or without
GM-CSF
Baker 1976 Participants with different advanced gastrointestinal cancers were included in the study. No separate results
given for gastric cancer participants
Balana 1990 Preliminary publication.
Berenberg 1989 Final publication: Berenberg 1995 (excluded).
Berenberg 1995 Compares different single-agent chemotherapy regimens.
Beretta 1983 Published as abstract only. No further information obtained by contacting the first author
Beretta 1989 Published as abstract only. No further information obtained by contacting the first author
Berglund 2006 Other indications.
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Bi 2011 Cross-over study.
Bjerkeset 1986 Study included participants with different advanced gastrointestinal cancers. No separate results given for
gastric cancer participants
Bruckner 1986 Preliminary publication.
Brugarolas 1975 Study published as abstract only with insufficient data available. According to information provided by the
first author no further analysis was performed as the study was terminated early due to slow accrual
Bugat 2003 Secondary publication.
Buroker 1979 Does not compare different intravenous combination chemotherapy regimens but 1 intravenous regimen
with or without an additional oral chemotherapy (methyl-CCNU)
Cai 2011 Not an RCT, retrospective analysis of an RCT.
Cascinu 1994 Final publication: Cascinu 1995 (excluded).
Cascinu 1995 Participants not randomised to different chemotherapy regimens but to reduced glutathione or placebo to
prevent cisplatin-induced neurotoxicity
Cascinu 1996 Participants not randomised to different chemotherapy regimens but to different doses ofG-CSF as supportive
therapy
Chau 2013 Testing VEGF inhibitor (ramucirumab) as second-line therapy.
Chen 2011 Gimeracil + oteracil, neither contains a 5-FU prodrug nor is equivalent to S-1. So this combination does not
fit any comparison
Chlebowski 1979 One study arm was treated with oral 5-FU.
Chlebowski 1985 Insufficient information for calculation of HRs given in the publication or provided by the author
Chu 2006 Missing information to calculate HRs for OS
Chung 2011 Not an RCT.
Coates 1984 Included 108 participants with advanced cancer (only 5 gastric cancer patients)
Cocconi 1982 Systematic cross-over between study groups (< 10 % of included participants)
Cocconi 1992 Final publication: Cocconi 1994 (included).
Colucci 1991 Final publication: Colucci 1995 (included).
Constenla 2002 Study not randomised.
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Coombes 1994 Compares different single agents.
Cullinan 1993 Final publication: Cullinan 1994 (included).
Cunningham 2008 Wider indication (inclusion of patients with squamous cell carcinoma of the oesophagus as well)
De Lisi 1985 Final publication: De Lisi 1986 (included).
De Lisi 1988 Second publication to De Lisi 1986 (included).
Diaz-Rubio 1991 Preliminary publication.
Douglass 1983 Final publication: Douglass 1984 (excluded).
Douglass 1984 Not all participants were randomised. Some were directly assigned to 1 study arm according to their prior
treatment
Duffour 2006 Interventions not relevant for any of the comparisons specified
Figoli 1991 Study not randomised. Two consecutive regimens were compared
Ford 2014 Second-line CTX.
Fuchs 2014 Testing VEGF inhibitor (ramucirumab) as second-line therapy.
Fujii 1983 Study not randomised.
Furue 1985 Schizophyllan: mushroom polysaccharide with immunomodulatory properties (biologic therapy), no che-
motherapy
Furukawa 1995 Although described as advanced gastric cancer in the title, according to the text of the article the study
compared different adjuvant chemotherapy regimens
Gao 2010 inclusion pf patients with squamous epithelium carcinoma.
Gioffre 1984 Study not randomised.
Glimelius 1994 Final publication: Glimelius 1997 (excluded).
Glimelius 1995 Study includes participants with different inoperable cancers. Cross-over from BSC to chemotherapy arm
permitted. Primary aim: cost-effectiveness
Glimelius 1997 Study compares chemotherapy versus best supportive care. Provision of chemotherapy upon request in the
best supportive care group was requested by the research ethics committee, and 12 of 30 participants (19.
6%) randomised to best supportive care finally received chemotherapy (cross-over)
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Goseki 1995 Participants were not randomised between different chemotherapy regimens but tomethionine-depleted total
parenteral nutrition versus a conventional amino acid solution
Grau 1988 All participants were treated with chemotherapy after resection (no advanced/metastatic disease)
Grieco 1984 Study not randomised.
Gubanski 2010 Prescheduled cross-over between study arms after four courses
Guimbaud 2014 Considerable use of second-line therapy.
Gupta 1982 Insufficient data on survival available.
Haas 1983 Cross-over after failure was encouraged.
Hawkins 2003 Preliminary data.
Hoffman 1998 Retrospective analysis of clinical benefit and quality of life in participants with different inoperable gastroin-
testinal cancers
Icli 1993 Study not randomised.
Imada 1999 Includes participants treated in adjuvant intention after curative resection of gastric cancer
Inoue 1989 Participants with ascites were treated with intraperitoneal chemotherapy
Jeung 2011 Interventions not relevant for any of the comparisons specified
Kang 2007 Interventions not relevant for any of the comparisons specified
Kelsen 1990 Preliminary publication.
Kilickap 2011 Not an RCT.
Kim 1991 Final publication: Kim 1993 (excluded).
Kim 1993 According to information provided by author (YSP) allocation was done by alternation (not truly randomised)
Kim 2012 Interventions not relevant for any of the comparisons specified
Kim 2013 Meta-analysis is examining second-line therapy vs BSC.
Kitamura 1995 Study compares the effect of different amino-acid solutions (methionine-free amino-acid solution versus
commercial amino-acid solution) in addition to 5-FU chemotherapy
Koizumi 1996 Compares different dosages of cisplatin (60 mg and 80 mg) within the same chemotherapy regimen
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Koizumi 2004 Interventions not relevant for any of the comparisons specified
Koizumi 2012 Not an RCT.
Koizumi 2013 Testing irinotecan plus cisplatin versus irinotecan as second-line therapy
Kolaric 1986 Participants with stomach and rectosigmoid cancer included. No separate information about gastric cancer
provided
Kondo 2000 Study uses oral 5-FU (no intravenous chemotherapy, varying bioavailability)
Kono 2002 Study treatment: adoptive immunotherapy.
Kornek 2002 Does not compare different chemotherapy regimens but the same chemotherapy with or without G-CSF
and/or erythropoietin
Kosaka 1995 One group was treated with intra-arterial chemotherapy.
Kovach 1974 Insufficient data for calculation of HRs given (P value missing)
Kuitunen 1991 Final publication: Pyrhönen 1995 (included).
Kurihara 1991 Compared: tegafur + mitomycin C (FTM), uracil-tegafur + mitomycin C (UFTM), 5’deoxy-flurorouridine
+ cisplatin (5’P), etoposide + doxorubicin + cisplatin (EAP), and 5-fluorouracil + cisplatin (FP). Firstly,
none of the possible permutations between these regimens fit our study comparisons. Secondly, the Ohkuwa
2000 paper resembles a “pooled ” analysis (of other RCTs such as Kurihara 1991) rather than an original RCT.
Kurihara 1995 Participants randomised to either methionine-free or commercial amino-acid solution, with the same (mito-
mycin C/fluorouracil) chemotherapy in both groups
Kurihara 1995a Final publication: Koizumi 1996 (excluded).
Lacave 1985 Final publication: Lacave 1987 (excluded).
Lacave 1987 Does not compare different intravenous chemotherapy regimens but 1 intravenous chemotherapy with or
without an additional oral chemotherapy (methyl-CCNU)
Lee 2008 Interventions not relevant for any of the comparisons specified
Lee 2012 Gastrointestinal endoscopy.
Levard 1998 Participants had oesophageal squamous cell carcinoma.
Li 2002 Drug under investigation was never approved, and the regimen does not fit any of our 10 comparisons. Also
their trial was not solely done in gastric cancer patients, but also included patients with colorectal, oesophageal,
and liver cancer
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Li 2007 Missing information to calculate HRs for OS.
Li 2011 Not relevant for any of the comparisons.
Li 2013 Testing second-line apatinib.
Lim 2011 Not relevant for any of the comparisons.
Livstone 1977 Radiochemotherapy is compared to systemic intravenous chemotherapy
Lordick 2013 Testing whether cetuximab (EGFR targeted mAB) should be included as first-line in combination with
capecitabine and cisplatin
Lorenzen 2007 Not a randomised trial.
Luelmo 2006 Interventions not relevant for any of the comparisons specified
Malik 1990 Study not randomised. Includes participants with gastric and colorectal cancer
Maruta 2007 Second-line chemotherapy.
Massuti 1994 Published as abstract only. No further information obtained by contact with the first author
Massuti 1995 Published as abstract only. No further information obtained by contact with the first author
Mochiki 2012 Interventions not relevant for any of the comparisons specified
Moertel 1976 Insufficient information for calculation of HRs given.
Moertel 1979 The combination therapy arm consisted of only 1ne oral agent (methyl-CCNU, no intravenous chemother-
apy), in addition to 5-FU which was used as single-agent
Moertel 1979a Not all participants were randomised (some were directly assigned to 1 treatment arm according to their prior
treatment). Systematic cross-over between study groups
Moore 2005 Secondary publication.
Mustacchi 1997 Study included participants with different advanced cancers (only 3 patients with gastric cancer)
Nakajima 1984 Study compares different adjuvant chemotherapies.
Nakao 1983 Study treatment included schizophyllan (mushroom polysaccharide with immunomodulatory effects, bio-
logical therapy)
Nakashima 2008 The treatment for each patient was decided by the patient’s choice or randomisation (not a randomised trial)
152Chemotherapy for advanced gastric cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Niitani 1987 Compares different modes of application of the same chemotherapy (continuous and intermittent oral ad-
ministration of 5´ deoxy-5-fluorouridine), not different chemotherapy regimens
Nordin 2001 Study presents different interpretations of quality of life data from a previously performed study (Glimelius
1997). The study included advanced gastric cancer participants, but was excluded because of cross-over
Novik 1999 Compares different single agents.
Ohtsu 2011 Testing whether bevacizumab (VEGF targeted mAB) should be included in first-line chemotherapy combi-
nations
Okines 2010 Not an RCT.
Osawa 1996 Study treatment: adjuvant chemo-immunotherapy.
Pannettiere 1984 Compares 2 modes of application (sequential versus simultaneous) of 1 chemotherapy regimen (FAM)
Park 2004 Interim analysis of Park 2006.
Park 2006 Interventions not relevant for any of the comparisons specified
Park 2008 Interventions not eligible for any of the comparisons specified
Popliela 1982 Study treatment: chemo-immunotherapy.
Popov 1999 Final publication: Popov 2000 (excluded).
Popov 2000 Compares different applications of doxorubicin (bolus versus 8-hour infusion) in the same chemotherapy
regimen (EAP), not different chemotherapy regimens
Pozzo 2004 Interventions not relevant for any of the comparisons specified
Pyrhonen 1992 Final publication: Pyrhönen 1995 (included).
Queisser 1984 Compared 5-fluorouracil and carmustine with or without adriamycin. This does not fit our study comparisons
Rake 1979 39 of 77 included participants receiving chemotherapy as additive therapy after non-curative resection with
histological evidence of residual disease
Roth 1994 Final publication: Roth 1999 (included).
Roth 1995 Final publication: Roth 1999 (included).
Roth 1997 Final publication: Roth 1999 (included).
Sakata 1982 Participants were treated with OK-432 (streptococcal preparation, biological response modifier)
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Sakata 1988 Study included participants with various gastrointestinal tumors, which were treated with a biological therapy
Sakata 1992 Study included participants with different adenocarcinomas.
Sasagawa 1994 Insufficient information for calculation of HRs given.
Sasaki 1989 Publication presents only preliminary results of this study. No information about final results provided by
the first author
Sasaki 1990 Study not randomised.
Sasaki 1992 Study includes participants with colorectal and gastric cancer. Insufficient information given about results in
gastric cancer
Sasaki 1995 Study includes participants with colorectal and gastric cancer. Insufficient information given about results in
gastric cancer
Sato 1991 Study summarises the experience of angiotensin II-induced hypertension to enhance drug delivery for che-
motherapy. Participants were not randomised to different chemotherapy regimens
Sato 1995 Participants were not randomised to different chemotherapy regimens but to angiotensin II-induced hyper-
tension to enhance chemotherapy effects or control
Satoh 2013 Text needed.
Satoh 2014 Testing whether lapatinib (HER2 inhibitor) should be used in second-line therapy in HER2-amplified Asian
population
Schmid 2003 Study not randomised.
Shen 2009 No information on overall survival.
Shin 2007 Interventions not relevant for any of the comparisons specified
Shinoda 1995 Reporting standards to be insufficient and/or the dose schedule to be different from other studies
Shu 1999 Study compared the effect of intraperitoneal combined with intravenous to only intravenous chemotherapy
Shudong 1996 Insufficient information for calculation of HRs given.
Smith 1983 Study included various advanced adenocarcinomas of the gastrointestinal tract (only 5 participants with
gastric cancer)
Sun 2004 Interventions not relevant for any of the comparisons specified (radiochemotherapy)
Sym 2013 A study in participants refractory to first-line chemotherapy - thus no first-line treatment
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Taal 1990 Study not randomised.
Taguchi 1985 Study treatment includes lentinan (mushroompolysaccharide with immunomodulatory properties, biological
therapy)
Takahashi 1991 Study participants had resectable tumours. One group received intraarterial chemotherapy
Tebbutt 2002 Not eligible for any of the comparisons specified.
Tebbutt 2007 Not relevant for any of the comparisons (docetaxel in both treatment arms)
Tebbutt 2010 Included esophageal cancer patients.
Thuss-Patience 2011 Second-line therapy.
Tsushima 1991 Study treatment includes OK (streptococcal preparation, biologic response modifier)
Van Cutsem 2009 Targeted therapy.
Vanhoefer 2000 Compared methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus
infusional fluorouracil and cisplatin. None of the possible permutations between these regimens fit our study
comparisons
Vaughn 1980 Study included participants with advanced gastrointestinal malignancies (only 11 participants with gastric
cancer)
Vestlev 1990 Inconclusive data (time to progression and survival identical)
Villar 1987 Study included participants (13 of 46) with only microscopic disease in the resection margins
Voznyi 1978 One study arm consisted only of oral chemotherapy (CCNU). Two other of 5 study arms differed from others
only in the addition of oral CCNU (does not compare different intravenous chemotherapy regimens)
Wadler 2002 Study treatment includes interferon and filgrastim (biological therapy)
Wakui 1983 Participants had various gastrointestinal malignancies. Therapy includes levamisole (antihelmintic drug with
immunomodulatory properties)
Wakui 1983a Participants had various gastrointestinal malignancies. Therapy included levamisole (antihelmintic drug with
immunomodulatory properties)
Wakui 1986 Study treatment includes lentinan (mushroompolysaccharide with immunomodulatory properties, biological
therapy)
Wang 2007 Not relevant for any of the comparisons.
Waters 1999 Paper reports long-term follow-up of the study published by Webb 1997 (included)
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Wilke 2014 Testing VEGF inhibitor (ramucirumab) as second-line therapy.
Wils 1991 Compared 5-fluorouracil, adriamycin andmethotrexate vs 5-fluorouracil, adriamycin andmitomycin-C. This
does not fit our study comparisons
Wils 1994 Published as abstract only, no further information about final results obtained by contacting the first author
Xu 2013 Tested recombinant human endostatin, and regimen does not fit our comparisons
Yamada 1994 According to information provided by the first author the study was not randomised
Yin 1996 Study treatment includes Elemene (product isolated from the Chinese medical herb Rhizoma zedoariae,
biological therapy)
Yoshida 2003 Compares the feasibility of personalised chemotherapy (according to the expression of molecular markers)
with standard therapy
Yoshikawa 2011 Tested a chemoimmunotherapy combination.
Yoshino 2007 Intervention not eligible for any of the comparisons specified
Yun 2010 Intervention not eligible for any of the comparisons specified
Zhao 2009 missing information to calculate HRs for OS.
Zironi 1992 Final publication: Cocconi 1994 (included)
5-FU: 5-Fluorouracil
A: adriamycin (also known as doxorubicin)
BSC: best supportive care
CTX: chemotherapy
FA: folinic acid
FAMe: 5-FU 325mg/m² d 1-5, A 40mg/m² d 1 until d 36, Me 110mg/m² orally at d 1 repeated at d 71
FAMi: 5-FU 275mg/m² d 1-5, A 30mg/m² d 1 until d 36, M 10mg/m² d1 repeated at d 71
FIMe: 5-FU 325mg/m² d 1-5 repeated at d 36, ICRF-159 500mg/m² orally at d 2-4 and d 36-38, Me 110mg/m² orally at d 1 repeated
at d 71
FMe: 5-FU 300 mg/m² d 1-5 repeated at d 36, Me 175 mg/m² orally at d 1 repeated at d 50
G-CSF: granulocyte-macrophage colony-stimulating factor
HR: hazard ratio
ICRF: razoxane
M: mitomycin C
Me: semustine (also known as methyl-CCNU)
OS: overall survival
RCT: randomised controlled trial
VEGF: vascular endothelial growth factor
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Characteristics of ongoing studies [ordered by study ID]
Elsaid 2005
Trial name or title Randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally
advanced gastric cancer (final publication not found)
Methods RCT
2 arms
Participants N = 64
Interventions Arm A: docetaxel (75 mg/m² d 1) + carboplatin (AUC6 d2) + continuous infusion 5FU (1200 mg/m²/day
d1-3), repeated at d 21
versus
Arm B: Epirubicin (50 mg/m² d 1) + cisplatin (60 mg/m² d1)+ continuous infusion 5FU (200 mg/m²/day
d 1-21)
Prophylactically G-CSF day 4-9 to all participants
Outcomes Toxicity, tumour response, progression-free and overall survival
Starting date 1999
Contact information Amr Abdelaziz Elsaid
amrelsaid@yahoo.com
Alexandria University, Alexandria, Egypt
Notes This study is currently published as abstract only. Participants were enrolled between 1999 and 2004
Higuchi 2012
Trial name or title Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced
gastric cancer
Methods RCT
2 arms
Participants N = 685 with unresectable advanced or recurrent gastric cancer, PS 0-2, age ≥ 20 years
Interventions Arm A (SOX): (oral S-1 40 mg/m² twice a day d 1-14 + oxaliplatin 100 mg/m² iv day 1, repeated at 3 weeks)
versus
Arm B (SP): (oral S-1 40 mg/m² twice a day d 1- 21 + cisplatin 60 mg/m² iv day 8, repeated at 5 weeks)
Outcomes Progression-free survival, response rate (RR), safety, and length of hospital stay per cycle
Starting date
Contact information Yakult Honsha Co., Ltd., Clinical Development, Medical Development Department, Pharmaceutical Divi-
sion, Tel 813-5550-8966 Fax 813-3248-5502
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Notes The study is registered (JapicCTI-101021) and has recruited 685 participants from January 2010 andOctober
2011
Kurihara
Trial name or title Isovorin: Phase III study
Methods RCT
2 arms
Participants Participants with histologically confirmed, advanced gastric adenocarcinoma without prior chemotherapy, PS
0-2, age 20 to 70 years
Interventions 5-FU+ isovorin (active form of leucovorin) versus
S-1 alone
Outcomes Overall survival, response rates, time to progression, safety, quality of life
Starting date -
Contact information Minoru Kurihara, M.D., Showa University, Japan
Notes Sponsor: Wyeth Pharmaceuticals. Final publication not found.
Maiello 2011
Trial name or title Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined
with 5-fluorouracil (5-FU) by continuous infusion as front-line therapy in participants with advanced gastric
cancer (AGC)
Methods RCT
2 arms
Participants N = 77 with advanced gastric cancer and measurable disease
Interventions Arm A (ECX): epirubicin (50 mg/m² d 1) + cisplatin (60 mg/m² d 1) + capecitabine (625 mg/m² twice a
day, d 1-21) repeated at d 21
versus
Arm B (DF): docetaxel (85 mg/m² d1)+ 5-FU (750 mg/m² /day, d1-5) qd 21
Outcomes Response rate, toxicity
Starting date
Contact information G.Colucci, Instituto Oncologici Bari, Bari, Italy
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Maiello 2011 (Continued)
Notes Preliminary results of this study are currently published as abstract only. Final publication not found
NCT01498289
Trial name or title A randomized phase II pilot study prospectively evaluating treatment for participants based on ERCC1
(excision repair cross-complementing 1) for advanced/metastatic oesophageal, gastric or gastroesophageal
junction (GEJ) cancer
Methods Multicentre RCT
2 arms
stratification according to ERCC1
Participants N = 225 with unresectable, advanced or recurrent gastric cancer, age ≥18 years, HER-2 negative
Interventions Arm A (FOLFOX): 4-FU (bolus 400 mg/m², ci 2400 mg/m² )+ LV (400 mg/m²) + oxaliplatin (85 mg/m²)
d 1, repeated at d 14
Arm B docetaxel (30 mg/m² on day 1 + 8 qd 21) + irinotecan (65 mg/m² on day 1 + 8 qd 21)
Outcomes Progression-free survival (PFS) between high-ERCC1 and low-ERCC1 participants treated with FOLFOX
versus irinotecan hydrochloride plus docetaxel, overall survival, response rate, toxicity
Starting date February 2012
Contact information Contact: Kimberly Kaberle: kkaberle@swog.org; Dana Sparks: dsparks@swog.org
Principal Investigator: Syma Iqbal
Notes Sponsors: Southwest Oncology Group and National Cancer Institute (NCI)
NCT01558947
Trial name or title Peri-operative chemotherapy with ECX (Epirubicin + Cisplatin + Capecitabine) or XP (Capecitabine +
Cisplatin) in the treatment of advanced gastric cancer: a randomized, multicentre, parallel vontrol
Methods Allocation: Randomised
Intervention Model: Parallel assignment
Masking: Single-blind (participant)
Primary Purpose: Treatment
Participants Gastric cancer participants, ≥ T2 or N +; or staging II, IIIA, IIIB
Interventions Experimental: chemotherapy with ECX
Preoperative chemotherapy of ECX for 3 cycles (Epirubicin 50 mg/m² on day 1; capecitabine 1000 mg/m²,
2 times /day, 1 to 14 days; cisplatin 60 mg/m² on day 1, need hydration, 21 day/cycle), operation after 2~4
weeks, and postoperative chemotherapy of ECX for 3 cycles 4~6 weeks after surgery
Experimental: chemotherapy with XP
Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000 mg/m², 2 times / day, 1 to 14 days; cisplatin
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60mg/m² onday 1, needhydration, 21day/cycle), operation after 2~4weeks, and postoperative chemotherapy
of XP for 3 cycles 4~6 weeks after surgery
Other Name: XP chemotherapy
Outcomes Relapse-free survival time/rate [ Time Frame: 3 years ]
Starting date January 2011
Contact information Xiangdong Cheng, MD, Zhejiang Cancer Hospital
Notes
NCT01967875
Trial name or title A prospective, multi-center, randomized controlled phase 2 trial of optimising platinum-based chemotherapy
based on ERCC1 expression as first-line treatment in participants with locally advanced or metastatic gastric
cancer
Methods Multicentre RCT
3 arms
Participants N = 180, advanced gastric cancer, 18-65 years, KPS 70, measurable disease
Interventions Active comparator: ERCC1 high expression-group A: Cisplatin 75 mg/m², d 1; Capecitabine 1700 mg/m²/
day to 2000 mg/m²/day d 1-14 repeated at d 21 for 6 cycles.Capecitabine is to be continued until disease
progression or intolerable toxicity
Experimental: ERCC1 high expression-group B: Docetaxel 75 mg/m², d 1; Capecitabine 1700 mg/m²/day to
2000mg/m²/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression
or intolerable toxicity
Active comparator: ERCC1 low expression group: Cisplatin 75 mg/m², d 1; Capecitabine 1700 mg/m²/day
to 2000 mg/m²/day d 1-14 repeated at d 21 for 6 cycles. Capecitabine is continued until disease progression
or intolerable toxicity
Outcomes Progression-free survival, overall survival, objective response rate, disease control rate, duration of response,
safety, quality of life
Starting date July 2013
Contact information Yunpeng Liu: cmuliuyunpeng@hotmail.com, Jing Liu:liujing˙cmu@hotmail.com
Notes Sponsor: China Medical University, China
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NCT02076594
Trial name or title A randomized phase III study of low-docetaxel oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin
and capecitabine (Eox) In patients with locally advanced unresectable or metastatic gastric cancer
Methods Phase 3
Allocation: Randomised
Intervention Model: Parallel assignment
Masking: Open-label
Primary Purpose: Treatment
Participants N = 462
Age 18 to 69 years
· Histologically proven diagnosis of adenocarcinoma of the stomach
· HER2 negative tumour or HER2+ tumours not qualifying for herceptin therapy
· Locally advanced (non resectable) or metastatic gastric cancer
Interventions Experimental arm A: docetaxel & oxaliplatin & capecitabine
Participants will receive cycles every 3 weeks of docetaxel (35 mg/m², intravenous at days 1 and 8 by 1-hour
infusion)and oxaliplatin (80 mg/m², intravenous at day 1 by 2-hour infusion) and capecitabine (750 mg/ m²,
oral tablets of 500 mg and 150 mg, x2 daily for 2 weeks)
Experimental arm B: epirubicin & oxaliplatin & capecitabine
Participants will receive cycles every 3 weeks of epirubicin (50 mg/m², intravenous on day 1 by 2-hour
infusion)and oxaliplatin (130 mg/m², intravenous on day 1 by 2-hour infusion) and capecitabine (625 mg/
m²,oral tablets of 500 mg and 150 mg, x2 daily for 3 weeks)
Outcomes Overall survival (OS) [Time frame: Measured as the time from randomisation to the date of death from any
cause, assessed up to 18 months of follow-up]
Progression-free survival (PFS) [Time frame: Measured as the time from randomisation to the date of local
or regional progression, distant metastasis, second primary malignancy or death from any cause, whichever
comes first, assessed up to 18 months of follow-up]
Objective Response Rate (CR + PR) according to RECIST 1.1 guideline [Time frame: Measured as the time
from randomisation, assessed up to 18 months of follow-up]
Disease control rate: CR+PR+SD lasting > 12weeks [Time frame:Measured as the time from randomisation,
assessed up to 18 months of follow-up]
To assess tolerability of the treatments of participants with locally advanced unresectable or metastatic gastric
cancer treated with docetaxel plus oxaliplatin plus capecitabine (Arm A) or with epirubicin plus oxaliplatin
plus capecitabine (Arm B)
Starting date January 2013
Contact information Contact: Roberto Labianca, MD +39 035 2673691 rlabianca@hpg23.it
Notes
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NCT02114359
Trial name or title Comparison of efficacy and tolerance between combination therapy and monotherapy as first line chemo-
therapy in elderly participants with advanced gastric cancer: a multicenter randomized phase 3 study
Methods Multicentre RCT
Phase 3
Allocation: Randomised
Intervention Model: Parallel assignment
Masking: Open-label
Primary Purpose: Treatment
Participants N = 332, >70 years, Eastern Cooperative Oncology Group 0-2, Measurable or evaluable disease, HER-2
negative
Interventions Experimental: Platinum/fluoropyrimidine combination chemotherapy
· Drug: Capecitabine/cisplatin
Capecitabine/cisplatin (XP) : cisplatin 50 mg/m² (80% dose of 60 mg/²m) iv over 15 min D1, capecitabine
1000 mg/m² (80% dose of 1250 mg/m²) orally twice a day D1-14, repeated at 3 weeks
· Drug: S-1/cisplatin
S-1/cisplatin (SP) : cisplatin 50 mg/m² (80% dose of 60 mg/²m) iv ov 15min D1, S-1 30 mg/m² (80% dose
of 40 mg/m²) orally twice a day D1-14, repeated at 3 weeks
· Drug: Capecitabine/oxaliplatin
Capecitabine+oxaliplatin (XELOX): oxaliplatin 100 mg/m² (80% dose of 130 mg/m²)iv ov 120 min D1,
capecitabine 800 mg/m² (80% dose of 1000 mg/m²) orally twice a day D1-14, repeated at 3 weeks
· Drug: 5-fluorouracil/oxaliplatin
5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80 mg/m² (80% dose of 100 mg/m²) iv ov 120 min,
leucovorin 80 mg/m² (80% dose of 100 mg/m²) iv ov 120min, 5-fluorouracil 1900 mg/m² (80% dose of
2400 mg/m²) iv ov 46h D1, repeated at 2 weeks
Active Comparator: Fluoropyrimidine mono chemotherapy
· Drug: Capecitabine
Capecitabine : 1250 mg/m² orally twice a day D1-14 repeated at 3 weeks (if Ccr < 60 mL/min, 1000 mg/m²
orally twice a day)
· Drug: S-1
S-1 : 40 mg/m² orally twice a day D1-14 repeated at 3 weeks (if Ccr < 60 mL/min, 30 mg/m² orally twice a
day)
· Drug: 5-fluorouracil
5-fluorouracil (FL) : leucovorin 100 mg/m² iv ov 2h, 5-fluorouracil 2400 mg/m² iv ov 46 h D1, repeated at
2 weeks
Arm A (XP): cisplatin 50 mg/m² d1, capecitabine 1000 mg/m2 orally twice a day d 1-14, repeated at day 21
Arm B (SP): cisplatin 50mg/m2 d1, S-1 30mg/m2 orally twice a day d 1-14, repeated at d 21
Arm C (XELOX): oxaliplatin 100 mg/m2d1, capecitabine 800 mg/² orally twice a day d1 -14, repeated at
day 21
Arm D (FOLFOX): oxaliplatin 80 mg/m², leucovorin 80 mg/m², 5-fluorouracil 1900 mg/m² ci 46 h d 1,
repeated at day 14
Outcomes Comparison of overall survival [Time frame: up to 3 years]
Comparison of progression-free survival [Time frame: up to 2 years]
Comparison of response rate [Time frame: up to 2 years]
Comparison of adverse events [Time frame: up to 2 years]
Comparison of quality of life [Time frame: up to 2 years]
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Starting date February 2014
Contact information In Sil Choi, M.D., Ph.D.; 82-10-9137-3883; hmoischoi@hanmail.net
Notes Sponsor and Collaborators: Seoul National University Hospital, Ministry of Health&Welfare, Korea, Korean
Cancer Study Group
NCT02289378
Trial name or title Dose-dense biweekly docetaxel, oxaliplatin and 5-fluorouracil as first-line treatment in advanced gastric cancer
(DaeMon-Plus)
Methods Phase 2
Intervention Model: Single-group assignment
Masking: Open-label
Primary Purpose: Treatment
Participants N = 30
Age 18-75 years
·Participantswith histologically or cytologically confirmedunresectable gastric adenocarcinomawhose ECOG
performance status are 0-2
Interventions Experimental: docetaxel, oxaliplatin and 5-Fu
Docetaxel 50 mg/m² Oxaliplatin 85 mg/m² 5-Fu 2800 mg/m² Repeated every two weeks
Outcomes Progression-free survival [Time frame: 2 years]
Starting date November 2014
Contact information Ping Lan, MD The Sixth Affilated Hospital of Sun Yat-sen University
Notes
NCT02289547
Trial name or title Randomized phase 3 study of XELOX (capecitabine plus oxaliplatin) followed by maintenance capecitabine
or observation in participants with advanced gastric adenocarcinoma
Methods Multicentre RCT
2 arms
Phase 3
Allocation: Randomised
Intervention Model: Parallel assignment
Masking: Open-label
Primary Purpose: Treatment
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Participants N = 184 advanced or recurrent gastric cancer, age ≥18 years, HER-2 negative, with more than stable disease
after 6 cycles 1st line of XELOX chemotherapy (objective response, non-complete response/non-progressive
disease in cases of non-measurable disease before XELOX chemotherapy)
Interventions Arm A : Capecitabine: capecitabine 1000 mg/m² twice a day D1-14, repeated at 3 weeks
Arm B : Observation
Outcomes Progression-free survival, overall survival, quality of life (as measured by QLQ-c30 and STO-22), Toxicity
profile
Starting date January 2015
Contact information Byoungyong Shim: shimby@catholic.ac.kr; Ho Jung An:
Notes Sponsor: The Catholic University of Korea
NCT02549911
Trial name or title Hyperthermic intraperitoneal chemotherapy, intravenous chemotherapy combined with surgery for the treat-
ment of advanced gastric cancer with peritoneal metastasis
Methods Phase 2
Intervention Model: Single-group assignment
Masking: Open-label
Primary Purpose: Treatment
Participants N = 40
18-75 years
Gastric cancer confirmed by endoscopic biopsy , and enhanced CT suspected to have peritoneal metastasis,
including ascites, ovarian metastasis, omentum or peritoneal metastasis
Interventions Experimental: HIPEC,Chemotherapy AND surgery
1. Surgical exploration,if PCI < 20,then we perform this study
2. HIPEC
RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m² ,
twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil
Potassium Capsules): 80 mg/m², twice daily (after the breakfast and supper) for two weeks, and then
suspend for one week.
3. Chemotherapy (3 cycles) : Taxol 150 mg/m² ,d 1, S-1: 80 mg/m², twice daily (after breakfast and
supper) for two weeks, and then suspend for one week.
4. Surgery: Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery
(resection of primary tumours and metastases )
5. after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles
Intervention: Other: HIPEC, chemotherapy AND surgery
Outcomes R0 resection [Time frame: 3 months]
Adverse events [Time frame: 6 months]
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Overall survival time [Time Frame: 3 years]
Starting date September 2015
Contact information Yian Du, MD; ypfzmu@163.com; 86-571-88128031
Notes
NCT02583659
Trial name or title The first-line combined chemotherapy for advanced gastric cancer: A prospective observational clinical study
Methods Observational Model: Cohort
Time Perspective: Prospective
Participants N = 250
Histopathology or cytopathology confirmed unresectable locally advanced, or recurrent, or metastatic che-
motherapy-naive gastric cancer and gastroesophageal adenocarcinoma participants
Interventions Observational Model: Cohort
Time Perspective: Prospective
Outcomes Overall survival (OS) [Time frame: From date of enrolment until the date of death from any cause, assessed
up to 60 months]
Progression-free survival (PFS) [Time frame: From date of enrolment until the date of first documented
progression or date of death from any cause, whichever came first, assessed up to 60 months]
Objective response rate (ORR) [Time frame: The sum of complete remission (CR) rate and partial remission
(PR) rate. Response will be measured through first-line treatment completion, up to 1 year]
Disease control rate (DCR) [Time frame: The sum of CR rate, PR rate and stable disease (SD) rate. Response
will be measured through first-line treatment completion, up to 1 year]
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [Time frame:
Through first-line treatment completion, up to 24 weeks.]
Starting date January 2013
Contact information Xianglin Yuan, MD,PHD
Tongji hospital of Tongji Medical College, Huazhong University of Science and Technology
Notes
NCT02855788
Trial name or title Phase II study of weekly metronomic chemotherapy using weekly aclitaxel, Oxaliplatin, Leucovorin and 5-
FU (POLF) in participants with advanced gastric cancer
Methods Phase 2
Intervention Model: Single-group assignment
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NCT02855788 (Continued)
Masking: Open-label
Primary Purpose: Treatment
Participants N = 40
18-70 years
AJCC stage 3 or 4 gastric cancer
Interventions Experimental: POLF regimen
Paclitaxel 60 mg/m² , oxaliplatin 50 mg/m² , leucovorin 20 mg/m² , and 5-FU 425 mg/m² IV weekly
Intervention: Drug: paclitaxel 60 mg/m² , oxaliplatin 50 mg/m² , leucovorin 20 mg/m² , and 5-FU 425 mg/
m² IV weekly
Outcomes Response rate [Time frame: 3 months]
-based on Recist 1.1
Adverse events [Time frame: 2 years]
-based on NCI-CTC v.2
Progression-free survival [Time frame: 2 years]
Overall survival [Time frame: 2 years]
Starting date May 2015
Contact information Contact: Nick N Chen, M.D., Ph.D. 206-588-1722 nicknchenmd@gmail.com
Contact: Jie Liu, M.D. 021-5288236 jieliu@fudan.edu.cn
Notes
NCT03006432
Trial name or title ASE III randomised trial to evaluate folfox with or without docetaxel (TFOX) as 1st line chemotherapy for
locally advanced or metastatic oesophago-gastric carcinoma (GASTFOX)
Methods Phase 3
Allocation: Randomised
Intervention Model: Parallel assignment
Masking: No masking
Primary Purpose: Treatment
Participants N = 506
Gastric or gastro-oesophageal junction adenocarcinoma (all Siewert), histologically proven (on primary tu-
mour or metastatic lesion),
HER2 negative (positive HER2 status is defined by a positive IHC test of 3+ or IHC of 2+ with positive
FISH)
Metastatic or non-resectable (locally advanced) disease
Interventions Active Comparator: FOLFOX
Cycles every 15 days until progression disease
Experimental: TFOX
Cycles every 15 days until progression disease
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NCT03006432 (Continued)
Interventions: Drug: oxaliplatin
1. Drug: 5Fluorouracil bolus
2. Drug: 5Fluorouracil continuous
3. Drug: docetaxel
4. Drug: folinic Acid
Outcomes Progression-free survival [Time frame: 12 months after last randomisation]
Overall survival toxicity events (adverse events) according to NCI-CTC v4.0 [Time frame: 12 months after
last randomisation]
Objective response rate [Time frame: 12 months after last randomisation]
Toxicity events according to NCI-CTC v4.0 [Time frame: 12 months after last randomisation]
Starting date December 2016
Contact information Contact: Marie MOREAU +33 (0)380393404 marie.moreau@u-bourgogne.fr
Notes PRODIGE 51
Tsuburaya 2012
Trial name or title A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin
(SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS
II)
Methods Multicentre RCT
2 arms
Participants N = 100 (planned)
Interventions Arm A: S-1 (40 mg/m² twice a day d1-21) + cisplatin (60 mg/m² d 8) repeated at d 35
versus
Arm B: capecitabine (1000 mg/² d1-14) + cisplatin (80 mg/m² d 1) repeated at d 21
Outcomes Progression-free survival, overall survival, time to treatment failure, tumour response, safety
Starting date August 2011
Contact information Akira Tsuburaya, Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2, Nakao, 241-
0815, Yokohama, Asahi-ku, Japan, tuburayaa@kcch.jp
Notes The study is registered (NCT01406249), the study protocol is published. Estimated study completion date
is June 2015. The study is not yet published
5-FU: 5-fluorouracil
ci: continuous infusion
d: day
E: epirubicin
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G-CSF: granulocyte colony stimulating factor
PFS: progression-free survival
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Chemotherapy versus best supportive care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 3 184 Hazard ratio (Random, 95% CI) 0.37 [0.24, 0.55]
2 Time to progression 2 144 Hazard ratio (Fixed, 95% CI) 0.31 [0.22, 0.43]
Comparison 2. Combination versus single-agent chemotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 23 4447 Hazard ratio (Fixed, 95% CI) 0.84 [0.79, 0.89]
2 Tumour response 18 2833 Odds Ratio (M-H, Fixed, 95% CI) 2.30 [1.94, 2.72]
3 Time to progression 4 720 Hazard ratio (Random, 95% CI) 0.69 [0.55, 0.87]
4 Treatment-related death 18 3876 Odds Ratio (M-H, Fixed, 95% CI) 1.64 [0.83, 3.24]
Comparison 3. 5-FU/cisplatin/anthracycline combinations versus 5-FU/cisplatin combinations (without anthra-
cyclines)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 4 579 Hazard ratio (Fixed, 95% CI) 0.74 [0.61, 0.89]
2 Tumour response 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Time to progression 1 Hazard Ratio (Fixed, 95% CI) Subtotals only
Comparison 4. 5-FU/cisplatin/anthracycline combinations versus 5-FU/anthracycline combinations (without
cisplatin)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 7 1147 Hazard ratio (Random, 95% CI) 0.82 [0.73, 0.92]
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Comparison 5. Chemotherapy with irinotecan versus non-irinotecan-containing regimes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 10 2135 Hazard Ratio (Fixed, 95% CI) 0.87 [0.80, 0.95]
1.1 Substitutive comparisons 6 826 Hazard Ratio (Fixed, 95% CI) 0.87 [0.75, 1.00]
1.2 Additive comparisons 3 500 Hazard Ratio (Fixed, 95% CI) 0.88 [0.76, 1.03]
1.3 Other comparisons 2 809 Hazard Ratio (Fixed, 95% CI) 0.87 [0.76, 1.00]
2 Tumour response 10 1266 Odds Ratio (M-H, Random, 95% CI) 1.72 [1.24, 2.40]
2.1 Substitutive comparisons 6 756 Odds Ratio (M-H, Random, 95% CI) 1.53 [0.93, 2.50]
2.2 Additive comparisons 3 345 Odds Ratio (M-H, Random, 95% CI) 2.18 [1.25, 3.80]
2.3 Other Comparisons 2 165 Odds Ratio (M-H, Random, 95% CI) 1.87 [0.89, 3.91]
3 Progression-free survival 7 1640 Hazard Ratio (Fixed, 95% CI) 0.76 [0.69, 0.84]
3.1 Substitutive comparison 5 741 Hazard Ratio (Fixed, 95% CI) 0.85 [0.72, 1.00]
3.2 Additive comparisons 1 90 Hazard Ratio (Fixed, 95% CI) 0.51 [0.33, 0.77]
3.3 Other comparisons 2 809 Hazard Ratio (Fixed, 95% CI) 0.74 [0.66, 0.84]
4 Treatment-related death 9 1979 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.23, 3.32]
5 Treatment discontinuation due
to toxicity
9 1979 Odds Ratio (M-H, Random, 95% CI) 1.00 [0.46, 2.20]
Comparison 6. Chemotherapy with docetaxel versus non-docetaxel-containing regimes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 8 2001 Hazard Ratio (Fixed, 95% CI) 0.86 [0.78, 0.95]
1.1 Substitutive comparisons 3 479 Hazard Ratio (Fixed, 95% CI) 1.05 [0.87, 1.27]
1.2 Additive comparisons 4 1466 Hazard Ratio (Fixed, 95% CI) 0.80 [0.71, 0.91]
1.3 Other comparisons 1 56 Hazard Ratio (Fixed, 95% CI) 0.80 [0.46, 1.39]
2 Tumour response 9 1820 Odds Ratio (M-H, Random, 95% CI) 1.37 [1.03, 1.83]
2.1 Substitutive comparison 4 525 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.71, 1.50]
2.2 Additive comparison 4 1235 Odds Ratio (M-H, Random, 95% CI) 1.83 [1.45, 2.32]
2.3 Other comparisons 1 60 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.12, 0.96]
3 Time to progression 2 360 Hazard Ratio (Random, 95% CI) 1.06 [0.85, 1.32]
4 Progression-free survival 5 1498 Hazard Ratio (Random, 95% CI) 0.76 [0.63, 0.91]
4.1 Substitutive comparisons 1 119 Hazard Ratio (Random, 95% CI) 1.15 [0.77, 1.72]
4.2 Additive comparison
(PFS)
3 1323 Hazard Ratio (Random, 95% CI) 0.70 [0.61, 0.81]
4.3 Other comparisons 1 56 Hazard Ratio (Random, 95% CI) 0.94 [0.55, 1.60]
5 Treatment-related death 7 2113 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.55, 2.20]
6 Treatment discontinuation due
to toxicity
5 1066 Odds Ratio (M-H, Random, 95% CI) 0.81 [0.53, 1.25]
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Comparison 7. Chemotherapy with capecitabine versus 5-FU-containing regimes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall Survival 5 732 Hazard Ratio (Fixed, 95% CI) 0.94 [0.79, 1.11]
2 Tumour response 4 636 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.40, 1.79]
3 Time to progression 1 Hazard Ratio (Fixed, 95% CI) Subtotals only
4 Progression-free survival 4 647 Hazard Ratio (Random, 95% CI) 0.98 [0.77, 1.23]
5 Treatment-related death 2 481 Odds Ratio (M-H, Random, 95% CI) 1.88 [0.23, 15.15]
6 Treatment discontinuation due
to toxicity
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 8. Chemotherapy with oxaliplatin versus the same regime including cisplatin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall Survival 5 1105 Hazard Ratio (Random, 95% CI) 0.81 [0.67, 0.98]
2 Tumour response 5 1081 Odds Ratio (M-H, Fixed, 95% CI) 1.38 [1.08, 1.76]
3 Progression-free survival 4 1034 Hazard Ratio (Random, 95% CI) 0.88 [0.66, 1.19]
4 Treatment-related death 5 1132 Odds Ratio (M-H, Fixed, 95% CI) 0.47 [0.17, 1.30]
5 Treatment discontinuation due
to toxicity
3 970 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.44, 2.13]
Comparison 9. Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum (without fluoropyrim-
idine)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 3 482 Hazard Ratio (Fixed, 95% CI) 0.86 [0.71, 1.06]
2 Tumour response 3 482 Odds Ratio (M-H, Fixed, 95% CI) 2.08 [1.37, 3.15]
3 Progression-free survival 3 482 Hazard Ratio (Fixed, 95% CI) 0.74 [0.59, 0.93]
4 Treatment-related death 3 482 Odds Ratio (M-H, Fixed, 95% CI) 1.95 [0.73, 5.17]
5 Treatment discontinuation due
to toxicity
2 234 Odds Ratio (M-H, Fixed, 95% CI) 1.71 [0.79, 3.69]
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Comparison 10. S-1 versus 5-FU-containing regimes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall Survival 4 1793 Hazard Ratio (Fixed, 95% CI) 0.91 [0.83, 1.00]
2 Tumour response 7 1753 Odds Ratio (M-H, Random, 95% CI) 1.73 [1.01, 2.94]
3 Progression-free survival 4 1942 Hazard Ratio (Random, 95% CI) 0.85 [0.70, 1.04]
4 Time-to treatment failure 5 1818 Hazard Ratio (Random, 95% CI) 0.88 [0.76, 1.01]
5 Treatment-related deaths 4 1962 Odds Ratio (M-H, Fixed, 95% CI) 0.56 [0.30, 1.06]
6 Treatment discontinuation due
to toxicity
3 1726 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.63, 1.13]
Analysis 1.1. Comparison 1 Chemotherapy versus best supportive care, Outcome 1 Overall survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 1 Chemotherapy versus best supportive care
Outcome: 1 Overall survival
Study or subgroup Chemotherapy
Best
Supportive
Care log [Hazard ratio] Hazard ratio Weight Hazard ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Murad 1993 30 10 -1.1 (0.33) 27.0 % 0.33 [ 0.17, 0.64 ]
Pyrho¨nen 1995 21 20 -1.38 (0.32) 28.1 % 0.25 [ 0.13, 0.47 ]
Scheithauer 1996 52 51 -0.71 (0.21) 45.0 % 0.49 [ 0.33, 0.74 ]
Total (95% CI) 103 81 100.0 % 0.37 [ 0.24, 0.55 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 3.32, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 4.81 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Chemotherapy versus best supportive care, Outcome 2 Time to progression.
Review: Chemotherapy for advanced gastric cancer
Comparison: 1 Chemotherapy versus best supportive care
Outcome: 2 Time to progression
Study or subgroup Chemotherapy
Best
Supportive
Care log [Hazard ratio] Hazard ratio Weight Hazard ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Scheithauer 1996 52 51 -1.18 (0.2) 76.4 % 0.31 [ 0.21, 0.45 ]
Pyrho¨nen 1995 21 20 -1.16 (0.36) 23.6 % 0.31 [ 0.15, 0.63 ]
Total (95% CI) 73 71 100.0 % 0.31 [ 0.22, 0.43 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 6.72 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Combination versus single-agent chemotherapy, Outcome 1 Overall survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 2 Combination versus single-agent chemotherapy
Outcome: 1 Overall survival
Study or subgroup Combination Chemo Single-agent therapy log [Hazard ratio] Hazard ratio Weight Hazard ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Barone 1998 36 36 -0.12 (0.24) 1.6 % 0.89 [ 0.55, 1.42 ]
Boku 2009 236 468 -0.174 (0.071) 18.6 % 0.84 [ 0.73, 0.97 ]
Bouche 2004 89 45 -0.43 (0.19) 2.6 % 0.65 [ 0.45, 0.94 ]
Colucci 1995 35 36 -0.36 (0.26) 1.4 % 0.70 [ 0.42, 1.16 ]
Cullinan 1985 51 51 -0.11 (0.2) 2.3 % 0.90 [ 0.61, 1.33 ]
Cullinan 1994 183 69 -0.11 (0.13) 5.5 % 0.90 [ 0.69, 1.16 ]
De Lisi 1986 42 42 0.15 (0.76) 0.2 % 1.16 [ 0.26, 5.15 ]
Hironaka 2016 95 47 0.0084 (0.208) 2.2 % 1.01 [ 0.67, 1.52 ]
Koizumi 2008 148 150 -0.26 (0.12) 6.5 % 0.77 [ 0.61, 0.98 ]
Koizumi 2014 314 321 -0.178 (0.083) 13.6 % 0.84 [ 0.71, 0.98 ]
Komatsu 2011 48 47 -0.052 (0.203) 2.3 % 0.95 [ 0.64, 1.41 ]
Levi 1986 94 93 -0.55 (0.15) 4.2 % 0.58 [ 0.43, 0.77 ]
Loehrer 1994 64 94 -0.16 (0.17) 3.2 % 0.85 [ 0.61, 1.19 ]
Lu 2014 47 47 -0.511 (0.224) 1.9 % 0.60 [ 0.39, 0.93 ]
Lutz 2007 108 37 -0.27 (0.173) 3.1 % 0.76 [ 0.54, 1.07 ]
Narahara 2011 155 160 -0.113 (0.089) 11.8 % 0.89 [ 0.75, 1.06 ]
Nishikawa 2012 78 79 0.02 (0.187) 2.7 % 1.02 [ 0.71, 1.47 ]
Ohtsu 2003 175 105 0.04 (0.12) 6.5 % 1.04 [ 0.82, 1.32 ]
Popov 2002 30 30 -0.15 (0.5) 0.4 % 0.86 [ 0.32, 2.29 ]
Shirao 2013 119 118 -0.062 (0.135) 5.1 % 0.94 [ 0.72, 1.22 ]
Wang 2013 41 41 -0.598 (0.25) 1.5 % 0.55 [ 0.34, 0.90 ]
Wu 2015 36 36 -0.213 (0.292) 1.1 % 0.81 [ 0.46, 1.43 ]
Yamamura 1998 37 34 -0.13 (0.24) 1.6 % 0.88 [ 0.55, 1.41 ]
Total (95% CI) 2261 2186 100.0 % 0.84 [ 0.79, 0.89 ]
Heterogeneity: Chi2 = 21.76, df = 22 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 5.70 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Combination versus single-agent chemotherapy, Outcome 2 Tumour response.
Review: Chemotherapy for advanced gastric cancer
Comparison: 2 Combination versus single-agent chemotherapy
Outcome: 2 Tumour response
Study or subgroup Combination Chemo Single-agent therapy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Levi 1986 30/75 9/70 3.2 % 4.52 [ 1.95, 10.45 ]
De Lisi 1986 9/41 6/41 2.7 % 1.64 [ 0.53, 5.12 ]
Colucci 1995 13/31 9/31 3.0 % 1.77 [ 0.62, 5.06 ]
Barone 1998 7/32 6/33 2.6 % 1.26 [ 0.37, 4.26 ]
Popov 2002 10/30 3/30 1.1 % 4.50 [ 1.09, 18.50 ]
Ohtsu 2003 42/159 12/99 6.2 % 2.60 [ 1.29, 5.24 ]
Bouche 2004 30/78 6/43 2.7 % 3.85 [ 1.45, 10.23 ]
Lutz 2007 33/94 2/33 1.1 % 8.39 [ 1.89, 37.26 ]
Koizumi 2008 47/87 33/106 7.7 % 2.60 [ 1.44, 4.68 ]
Boku 2009 68/181 64/349 15.5 % 2.68 [ 1.79, 4.02 ]
Komatsu 2011 10/36 7/32 3.0 % 1.37 [ 0.45, 4.17 ]
Narahara 2011 39/94 25/93 8.3 % 1.93 [ 1.04, 3.57 ]
Nishikawa 2012 17/32 14/37 3.4 % 1.86 [ 0.71, 4.87 ]
Koizumi 2014 92/237 65/243 22.2 % 1.74 [ 1.18, 2.56 ]
Wang 2013 19/41 10/41 3.0 % 2.68 [ 1.05, 6.86 ]
Hironaka 2016 53/95 20/47 6.7 % 1.70 [ 0.84, 3.45 ]
Lu 2014 24/47 13/47 3.6 % 2.73 [ 1.16, 6.43 ]
Wu 2015 18/35 14/33 4.0 % 1.44 [ 0.55, 3.74 ]
Total (95% CI) 1425 1408 100.0 % 2.30 [ 1.94, 2.72 ]
Total events: 561 (Combination Chemo), 318 (Single-agent therapy)
Heterogeneity: Chi2 = 14.90, df = 17 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 9.55 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Combination versus single-agent chemotherapy, Outcome 3 Time to
progression.
Review: Chemotherapy for advanced gastric cancer
Comparison: 2 Combination versus single-agent chemotherapy
Outcome: 3 Time to progression
Study or subgroup Combination Chemo Single-agent therapy log [Hazard ratio] Hazard ratio Weight Hazard ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Levi 1986 94 93 -0.48 (0.37) 9.2 % 0.62 [ 0.30, 1.28 ]
Loehrer 1994 64 94 -0.04 (0.26) 17.1 % 0.96 [ 0.58, 1.60 ]
Ohtsu 2003 175 105 -0.55 (0.13) 45.7 % 0.58 [ 0.45, 0.74 ]
Komatsu 2011 48 47 -0.252 (0.19) 28.0 % 0.78 [ 0.54, 1.13 ]
Total (95% CI) 381 339 100.0 % 0.69 [ 0.55, 0.87 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.90, df = 3 (P = 0.27); I2 =23%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Combination versus single-agent chemotherapy, Outcome 4 Treatment-related
death.
Review: Chemotherapy for advanced gastric cancer
Comparison: 2 Combination versus single-agent chemotherapy
Outcome: 4 Treatment-related death
Study or subgroup Combination Chemo Single-agent therapy Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cullinan 1985 1/51 1/51 7.3 % 1.00 [ 0.06, 16.43 ]
Levi 1986 2/94 3/93 22.0 % 0.65 [ 0.11, 4.00 ]
Cullinan 1994 3/183 0/69 5.3 % 2.70 [ 0.14, 52.86 ]
Colucci 1995 0/35 1/36 10.9 % 0.33 [ 0.01, 8.46 ]
Popov 2002 1/30 0/30 3.5 % 3.10 [ 0.12, 79.23 ]
Ohtsu 2003 5/169 1/104 8.9 % 3.14 [ 0.36, 27.26 ]
Bouche 2004 1/89 1/45 9.8 % 0.50 [ 0.03, 8.18 ]
Lutz 2007 1/108 0/37 5.4 % 1.05 [ 0.04, 26.25 ]
Koizumi 2008 0/148 0/150 Not estimable
Boku 2009 3/234 1/466 4.9 % 6.04 [ 0.62, 58.38 ]
Komatsu 2011 0/46 0/47 Not estimable
Narahara 2011 2/155 0/160 3.6 % 5.23 [ 0.25, 109.78 ]
Koizumi 2014 2/310 0/313 3.7 % 5.08 [ 0.24, 106.27 ]
Shirao 2013 1/116 2/117 14.7 % 0.50 [ 0.04, 5.59 ]
Wang 2013 0/41 0/41 Not estimable
Hironaka 2016 0/95 0/47 Not estimable
Lu 2014 0/47 0/47 Not estimable
Wu 2015 0/36 0/36 Not estimable
Total (95% CI) 1987 1889 100.0 % 1.64 [ 0.83, 3.24 ]
Total events: 22 (Combination Chemo), 10 (Single-agent therapy)
Heterogeneity: Chi2 = 6.70, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 5-FU/cisplatin/anthracycline combinations versus 5-FU/cisplatin combinations
(without anthracyclines), Outcome 1 Overall survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 3 5-FU/cisplatin/anthracycline combinations versus 5-FU/cisplatin combinations (without anthracyclines)
Outcome: 1 Overall survival
Study or subgroup 5-FU/P/anthracycline 5-FU/P log [Hazard ratio] Hazard ratio Weight Hazard ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
KRGGC 1992 25 22 -0.56 (0.38) 6.8 % 0.57 [ 0.27, 1.20 ]
Kim 2001 60 60 -0.19 (0.34) 8.5 % 0.83 [ 0.42, 1.61 ]
Ross 2002 169 165 -0.24 (0.12) 68.3 % 0.79 [ 0.62, 1.00 ]
Cascinu 2011 39 39 -0.536 (0.245) 16.4 % 0.59 [ 0.36, 0.95 ]
Total (95% CI) 293 286 100.0 % 0.74 [ 0.61, 0.89 ]
Heterogeneity: Chi2 = 1.75, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 5-FU/cisplatin/anthracycline combinations versus 5-FU/cisplatin combinations
(without anthracyclines), Outcome 2 Tumour response.
Review: Chemotherapy for advanced gastric cancer
Comparison: 3 5-FU/cisplatin/anthracycline combinations versus 5-FU/cisplatin combinations (without anthracyclines)
Outcome: 2 Tumour response
Study or subgroup 5-FU/P/anthracycline 5-FU/P Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cascinu 2011 25/39 15/39 2.86 [ 1.14, 7.16 ]
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 5-FU/cisplatin/anthracycline combinations versus 5-FU/cisplatin combinations
(without anthracyclines), Outcome 3 Time to progression.
Review: Chemotherapy for advanced gastric cancer
Comparison: 3 5-FU/cisplatin/anthracycline combinations versus 5-FU/cisplatin combinations (without anthracyclines)
Outcome: 3 Time to progression
Study or subgroup 5-FU/P/anthracycline 5-FU/P log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Cascinu 2011 39 39 -0.486 (0.24) 0.62 [ 0.38, 0.98 ]
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 5-FU/cisplatin/anthracycline combinations versus 5-FU/anthracycline
combinations (without cisplatin), Outcome 1 Overall survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 4 5-FU/cisplatin/anthracycline combinations versus 5-FU/anthracycline combinations (without cisplatin)
Outcome: 1 Overall survival
Study or subgroup 5-FU/anthracycline/P 5-FU/anthracycline log [Hazard ratio] Hazard ratio Weight Hazard ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
GITSG 1988 85 162 -0.15 (0.13) 14.3 % 0.86 [ 0.67, 1.11 ]
Kikuchi 1990 32 33 -0.54 (0.25) 4.8 % 0.58 [ 0.36, 0.95 ]
Cocconi 1994 88 55 -0.37 (0.15) 11.5 % 0.69 [ 0.51, 0.93 ]
Cullinan 1994 51 132 0.07 (0.15) 11.5 % 1.07 [ 0.80, 1.44 ]
Webb 1997 98 101 -0.25 (0.1) 20.3 % 0.78 [ 0.64, 0.95 ]
Roth 1999 54 56 -0.3 (0.15) 11.5 % 0.74 [ 0.55, 0.99 ]
Cocconi 2003 100 100 -0.11 (0.08) 26.0 % 0.90 [ 0.77, 1.05 ]
Total (95% CI) 508 639 100.0 % 0.82 [ 0.73, 0.92 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.39, df = 6 (P = 0.21); I2 =28%
Test for overall effect: Z = 3.39 (P = 0.00069)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Chemotherapy with irinotecan versus non-irinotecan-containing regimes,
Outcome 1 Overall survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 5 Chemotherapy with irinotecan versus non-irinotecan-containing regimes
Outcome: 1 Overall survival
Study or subgroup Irinotecan Non-Irinotecan log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Substitutive comparisons
Bouche 2004 45 44 -0.202 (0.222) 3.6 % 0.82 [ 0.53, 1.26 ]
Moehler 2005 56 58 -0.22 (0.205) 4.2 % 0.80 [ 0.54, 1.20 ]
Dank 2008 170 163 -0.08 (0.12) 12.2 % 0.92 [ 0.73, 1.17 ]
Moehler 2010 53 50 -0.256 (0.21) 4.0 % 0.77 [ 0.51, 1.17 ]
Roy 2012 42 43 -0.231 (0.22) 3.6 % 0.79 [ 0.52, 1.22 ]
Sugimoto 2014 51 51 -0.0121 (0.22) 3.6 % 0.99 [ 0.64, 1.52 ]
Subtotal (95% CI) 417 409 31.2 % 0.87 [ 0.75, 1.00 ]
Heterogeneity: Chi2 = 1.29, df = 5 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
2 Additive comparisons
Bouche 2004 45 45 -0.374 (0.214) 3.8 % 0.69 [ 0.45, 1.05 ]
Komatsu 2011 48 47 0.052 (0.203) 4.3 % 1.05 [ 0.71, 1.57 ]
Narahara 2011 155 160 -0.113 (0.089) 22.2 % 0.89 [ 0.75, 1.06 ]
Subtotal (95% CI) 248 252 30.2 % 0.88 [ 0.76, 1.03 ]
Heterogeneity: Chi2 = 2.13, df = 2 (P = 0.34); I2 =6%
Test for overall effect: Z = 1.61 (P = 0.11)
3 Other comparisons
Boku 2009 236 468 -0.174 (0.071) 34.8 % 0.84 [ 0.73, 0.97 ]
Li 2016 50 55 0.21 (0.215) 3.8 % 1.23 [ 0.81, 1.88 ]
Subtotal (95% CI) 286 523 38.6 % 0.87 [ 0.76, 1.00 ]
Heterogeneity: Chi2 = 2.88, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 2.02 (P = 0.043)
Total (95% CI) 951 1184 100.0 % 0.87 [ 0.80, 0.95 ]
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(. . . Continued)
Study or subgroup Irinotecan Non-Irinotecan log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 6.34, df = 10 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 3.22 (P = 0.0013)
Test for subgroup differences: Chi2 = 0.04, df = 2 (P = 0.98), I2 =0.0%
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Analysis 5.2. Comparison 5 Chemotherapy with irinotecan versus non-irinotecan-containing regimes,
Outcome 2 Tumour response.
Review: Chemotherapy for advanced gastric cancer
Comparison: 5 Chemotherapy with irinotecan versus non-irinotecan-containing regimes
Outcome: 2 Tumour response
Study or subgroup Irinotecan Non-Irinotecan Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Substitutive comparisons
Bouche 2004 18/38 6/43 6.6 % 5.55 [ 1.90, 16.22 ]
Dank 2008 54/154 42/134 14.9 % 1.18 [ 0.72, 1.94 ]
Moehler 2005 24/48 14/51 9.2 % 2.64 [ 1.15, 6.10 ]
Moehler 2010 20/53 21/48 9.7 % 0.78 [ 0.35, 1.73 ]
Roy 2012 13/42 11/43 7.9 % 1.30 [ 0.51, 3.36 ]
Sugimoto 2014 17/51 16/51 9.2 % 1.09 [ 0.48, 2.51 ]
Subtotal (95% CI) 386 370 57.5 % 1.53 [ 0.93, 2.50 ]
Total events: 146 (Irinotecan), 110 (Non-Irinotecan)
Heterogeneity: Tau2 = 0.21; Chi2 = 11.46, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 1.68 (P = 0.093)
2 Additive comparisons
Bouche 2004 18/45 6/45 6.9 % 4.33 [ 1.52, 12.34 ]
Komatsu 2011 10/36 7/32 6.3 % 1.37 [ 0.45, 4.17 ]
0.05 0.2 1 5 20
Favours non-irinotecan Favours irinotecan
(Continued . . . )
181Chemotherapy for advanced gastric cancer (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Irinotecan Non-Irinotecan Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Narahara 2011 39/94 25/93 12.5 % 1.93 [ 1.04, 3.57 ]
Subtotal (95% CI) 175 170 25.7 % 2.18 [ 1.25, 3.80 ]
Total events: 67 (Irinotecan), 38 (Non-Irinotecan)
Heterogeneity: Tau2 = 0.05; Chi2 = 2.47, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.74 (P = 0.0062)
3 Other Comparisons
Dong 2014 18/30 10/30 6.8 % 3.00 [ 1.05, 8.60 ]
Li 2016 24/50 22/55 10.0 % 1.38 [ 0.64, 3.00 ]
Subtotal (95% CI) 80 85 16.8 % 1.87 [ 0.89, 3.91 ]
Total events: 42 (Irinotecan), 32 (Non-Irinotecan)
Heterogeneity: Tau2 = 0.08; Chi2 = 1.34, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 1.66 (P = 0.097)
Total (95% CI) 641 625 100.0 % 1.72 [ 1.24, 2.40 ]
Total events: 255 (Irinotecan), 180 (Non-Irinotecan)
Heterogeneity: Tau2 = 0.13; Chi2 = 17.53, df = 10 (P = 0.06); I2 =43%
Test for overall effect: Z = 3.23 (P = 0.0013)
Test for subgroup differences: Chi2 = 0.89, df = 2 (P = 0.64), I2 =0.0%
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Analysis 5.3. Comparison 5 Chemotherapy with irinotecan versus non-irinotecan-containing regimes,
Outcome 3 Progression-free survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 5 Chemotherapy with irinotecan versus non-irinotecan-containing regimes
Outcome: 3 Progression-free survival
Study or subgroup Irinotecan Non-Irinotecan log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Substitutive comparison
Bouche 2004 45 44 -0.205 (0.222) 4.8 % 0.81 [ 0.53, 1.26 ]
Moehler 2005 56 58 -0.0943 (0.195) 6.2 % 0.91 [ 0.62, 1.33 ]
Dank 2008 170 163 -0.21 (0.12) 16.3 % 0.81 [ 0.64, 1.03 ]
Moehler 2010 53 50 0.131 (0.338) 2.1 % 1.14 [ 0.59, 2.21 ]
Sugimoto 2014 51 51 -0.165 (0.209) 5.4 % 0.85 [ 0.56, 1.28 ]
Subtotal (95% CI) 375 366 34.7 % 0.85 [ 0.72, 1.00 ]
Heterogeneity: Chi2 = 1.07, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
2 Additive comparisons
Bouche 2004 45 45 -0.676 (0.214) 5.1 % 0.51 [ 0.33, 0.77 ]
Subtotal (95% CI) 45 45 5.1 % 0.51 [ 0.33, 0.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.16 (P = 0.0016)
3 Other comparisons
Boku 2009 236 468 -0.318 (0.066) 54.0 % 0.73 [ 0.64, 0.83 ]
Li 2016 50 55 -0.141 (0.195) 6.2 % 0.87 [ 0.59, 1.27 ]
Subtotal (95% CI) 286 523 60.1 % 0.74 [ 0.66, 0.84 ]
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 4.80 (P < 0.00001)
Total (95% CI) 706 934 100.0 % 0.76 [ 0.69, 0.84 ]
Heterogeneity: Chi2 = 7.37, df = 7 (P = 0.39); I2 =5%
Test for overall effect: Z = 5.59 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.56, df = 2 (P = 0.06), I2 =64%
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Analysis 5.4. Comparison 5 Chemotherapy with irinotecan versus non-irinotecan-containing regimes,
Outcome 4 Treatment-related death.
Review: Chemotherapy for advanced gastric cancer
Comparison: 5 Chemotherapy with irinotecan versus non-irinotecan-containing regimes
Outcome: 4 Treatment-related death
Study or subgroup Irinotecan Non-Irinotecan Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sugimoto 2014 0/51 0/51 Not estimable
Roy 2012 0/42 0/43 Not estimable
Komatsu 2011 0/46 0/47 Not estimable
Moehler 2010 0/53 2/50 13.8 % 0.18 [ 0.01, 3.87 ]
Dank 2008 1/170 5/163 21.9 % 0.19 [ 0.02, 1.62 ]
Bouche 2004 0/45 2/89 13.9 % 0.38 [ 0.02, 8.18 ]
Moehler 2005 1/56 1/58 15.7 % 1.04 [ 0.06, 16.98 ]
Narahara 2011 2/155 0/160 13.9 % 5.23 [ 0.25, 109.78 ]
Boku 2009 3/234 1/466 20.7 % 6.04 [ 0.62, 58.38 ]
Total (95% CI) 852 1127 100.0 % 0.88 [ 0.23, 3.32 ]
Total events: 7 (Irinotecan), 11 (Non-Irinotecan)
Heterogeneity: Tau2 = 0.89; Chi2 = 7.39, df = 5 (P = 0.19); I2 =32%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Chemotherapy with irinotecan versus non-irinotecan-containing regimes,
Outcome 5 Treatment discontinuation due to toxicity.
Review: Chemotherapy for advanced gastric cancer
Comparison: 5 Chemotherapy with irinotecan versus non-irinotecan-containing regimes
Outcome: 5 Treatment discontinuation due to toxicity
Study or subgroup Irinotecan Non-Irinotecan Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bouche 2004 11/45 20/89 12.0 % 1.12 [ 0.48, 2.59 ]
Moehler 2005 1/56 1/58 5.1 % 1.04 [ 0.06, 16.98 ]
Dank 2008 17/170 35/163 12.8 % 0.41 [ 0.22, 0.76 ]
Boku 2009 75/234 40/466 13.4 % 5.02 [ 3.29, 7.68 ]
Moehler 2010 10/53 16/50 11.7 % 0.49 [ 0.20, 1.23 ]
Komatsu 2011 13/46 11/47 11.6 % 1.29 [ 0.51, 3.27 ]
Narahara 2011 23/155 12/160 12.4 % 2.15 [ 1.03, 4.49 ]
Roy 2012 6/42 12/43 11.0 % 0.43 [ 0.14, 1.28 ]
Sugimoto 2014 4/51 7/51 10.1 % 0.53 [ 0.15, 1.95 ]
Total (95% CI) 852 1127 100.0 % 1.00 [ 0.46, 2.20 ]
Total events: 160 (Irinotecan), 154 (Non-Irinotecan)
Heterogeneity: Tau2 = 1.16; Chi2 = 62.63, df = 8 (P<0.00001); I2 =87%
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes,
Outcome 1 Overall survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes
Outcome: 1 Overall survival
Study or subgroup Docetaxel Non-Docetaxel log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Substitutive comparisons
Thuss-Patience 2005 45 45 0.021 (0.21) 5.8 % 1.02 [ 0.68, 1.54 ]
Roth 2007 79 40 0.049 (0.213) 5.7 % 1.05 [ 0.69, 1.59 ]
Ridwelski 2008 133 137 0.062 (0.13) 15.3 % 1.06 [ 0.82, 1.37 ]
Subtotal (95% CI) 257 222 26.8 % 1.05 [ 0.87, 1.27 ]
Heterogeneity: Chi2 = 0.03, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Additive comparisons
Van Cutsem 2006 221 224 -0.244 (0.123) 17.0 % 0.78 [ 0.62, 1.00 ]
Al-Batran 2013 72 71 -0.186 (0.22) 5.3 % 0.83 [ 0.54, 1.28 ]
Koizumi 2014 314 321 -0.178 (0.083) 37.4 % 0.84 [ 0.71, 0.98 ]
Wang 2016 121 122 -0.343 (0.159) 10.2 % 0.71 [ 0.52, 0.97 ]
Subtotal (95% CI) 728 738 70.0 % 0.80 [ 0.71, 0.91 ]
Heterogeneity: Chi2 = 0.92, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.60 (P = 0.00031)
3 Other comparisons
Ochenduszko 2015 27 29 -0.226 (0.282) 3.2 % 0.80 [ 0.46, 1.39 ]
Subtotal (95% CI) 27 29 3.2 % 0.80 [ 0.46, 1.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 1012 989 100.0 % 0.86 [ 0.78, 0.95 ]
Heterogeneity: Chi2 = 6.46, df = 7 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0038)
Test for subgroup differences: Chi2 = 5.52, df = 2 (P = 0.06), I2 =64%
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Analysis 6.2. Comparison 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes,
Outcome 2 Tumour response.
Review: Chemotherapy for advanced gastric cancer
Comparison: 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes
Outcome: 2 Tumour response
Study or subgroup Docetaxel Non-Docetaxel Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Substitutive comparison
Thuss-Patience 2005 17/43 16/43 7.7 % 1.10 [ 0.46, 2.63 ]
Sadighi 2006 18/44 17/42 7.8 % 1.02 [ 0.43, 2.41 ]
Roth 2007 22/79 10/40 7.7 % 1.16 [ 0.49, 2.76 ]
Ridwelski 2008 32/117 33/117 12.7 % 0.96 [ 0.54, 1.70 ]
Subtotal (95% CI) 283 242 36.1 % 1.03 [ 0.71, 1.50 ]
Total events: 89 (Docetaxel), 76 (Non-Docetaxel)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
2 Additive comparison
Van Cutsem 2006 81/185 57/184 16.3 % 1.74 [ 1.13, 2.66 ]
Al-Batran 2013 35/72 20/71 10.3 % 2.41 [ 1.21, 4.83 ]
Koizumi 2014 92/237 65/243 17.4 % 1.74 [ 1.18, 2.56 ]
Wang 2016 59/121 41/122 14.0 % 1.88 [ 1.12, 3.16 ]
Subtotal (95% CI) 615 620 58.1 % 1.83 [ 1.45, 2.32 ]
Total events: 267 (Docetaxel), 183 (Non-Docetaxel)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 5.04 (P < 0.00001)
3 Other comparisons
Dong 2014 10/30 18/30 5.8 % 0.33 [ 0.12, 0.96 ]
Subtotal (95% CI) 30 30 5.8 % 0.33 [ 0.12, 0.96 ]
Total events: 10 (Docetaxel), 18 (Non-Docetaxel)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
Total (95% CI) 928 892 100.0 % 1.37 [ 1.03, 1.83 ]
Total events: 366 (Docetaxel), 277 (Non-Docetaxel)
Heterogeneity: Tau2 = 0.09; Chi2 = 15.31, df = 8 (P = 0.05); I2 =48%
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Chi2 = 14.40, df = 2 (P = 0.00), I2 =86%
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Analysis 6.3. Comparison 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes,
Outcome 3 Time to progression.
Review: Chemotherapy for advanced gastric cancer
Comparison: 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes
Outcome: 3 Time to progression
Study or subgroup Docetaxel Non-Docetaxel log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Thuss-Patience 2005 45 45 -0.037 (0.22) 25.6 % 0.96 [ 0.63, 1.48 ]
Ridwelski 2008 133 137 0.095 (0.129) 74.4 % 1.10 [ 0.85, 1.42 ]
Total (95% CI) 178 182 100.0 % 1.06 [ 0.85, 1.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes,
Outcome 4 Progression-free survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes
Outcome: 4 Progression-free survival
Study or subgroup Docetaxel Non-Docetaxel log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Substitutive comparisons
Roth 2007 79 40 0.14 (0.205) 14.0 % 1.15 [ 0.77, 1.72 ]
Subtotal (95% CI) 79 40 14.0 % 1.15 [ 0.77, 1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
2 Additive comparison (PFS)
Koizumi 2014 314 321 -0.268 (0.081) 31.8 % 0.76 [ 0.65, 0.90 ]
Van Cutsem 2006 221 224 -0.385 (0.11) 26.5 % 0.68 [ 0.55, 0.84 ]
Wang 2016 121 122 -0.545 (0.164) 18.4 % 0.58 [ 0.42, 0.80 ]
Subtotal (95% CI) 656 667 76.7 % 0.70 [ 0.61, 0.81 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.52, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 4.97 (P < 0.00001)
3 Other comparisons
Ochenduszko 2015 27 29 -0.0606 (0.27) 9.4 % 0.94 [ 0.55, 1.60 ]
Subtotal (95% CI) 27 29 9.4 % 0.94 [ 0.55, 1.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
Total (95% CI) 762 736 100.0 % 0.76 [ 0.63, 0.91 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 8.36, df = 4 (P = 0.08); I2 =52%
Test for overall effect: Z = 2.91 (P = 0.0036)
Test for subgroup differences: Chi2 = 5.89, df = 2 (P = 0.05), I2 =66%
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Analysis 6.5. Comparison 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes,
Outcome 5 Treatment-related death.
Review: Chemotherapy for advanced gastric cancer
Comparison: 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes
Outcome: 5 Treatment-related death
Study or subgroup Docetaxel Non-Docetaxel Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Thuss-Patience 2005 0/45 1/45 9.7 % 0.33 [ 0.01, 8.22 ]
Van Cutsem 2006 6/221 10/224 63.4 % 0.60 [ 0.21, 1.67 ]
Roth 2007 1/79 0/40 4.3 % 1.55 [ 0.06, 38.85 ]
Ridwelski 2008 2/133 0/137 3.2 % 5.23 [ 0.25, 109.93 ]
Al-Batran 2013 0/72 1/71 9.8 % 0.32 [ 0.01, 8.09 ]
Koizumi 2014 2/310 0/313 3.2 % 5.08 [ 0.24, 106.27 ]
Wang 2016 4/211 1/212 6.4 % 4.08 [ 0.45, 36.79 ]
Total (95% CI) 1071 1042 100.0 % 1.10 [ 0.55, 2.20 ]
Total events: 15 (Docetaxel), 13 (Non-Docetaxel)
Heterogeneity: Chi2 = 5.84, df = 6 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 6.6. Comparison 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes,
Outcome 6 Treatment discontinuation due to toxicity.
Review: Chemotherapy for advanced gastric cancer
Comparison: 6 Chemotherapy with docetaxel versus non-docetaxel-containing regimes
Outcome: 6 Treatment discontinuation due to toxicity
Study or subgroup Docetaxel Non-Docetaxel Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Thuss-Patience 2005 4/45 5/45 8.3 % 0.78 [ 0.20, 3.12 ]
Van Cutsem 2006 59/221 56/224 37.4 % 1.09 [ 0.71, 1.67 ]
Roth 2007 8/79 7/40 12.3 % 0.53 [ 0.18, 1.59 ]
Ridwelski 2008 13/133 27/137 22.6 % 0.44 [ 0.22, 0.90 ]
Al-Batran 2013 17/72 14/70 19.4 % 1.24 [ 0.56, 2.75 ]
Total (95% CI) 550 516 100.0 % 0.81 [ 0.53, 1.25 ]
Total events: 101 (Docetaxel), 109 (Non-Docetaxel)
Heterogeneity: Tau2 = 0.08; Chi2 = 6.16, df = 4 (P = 0.19); I2 =35%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Chemotherapy with capecitabine versus 5-FU-containing regimes, Outcome 1
Overall Survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 7 Chemotherapy with capecitabine versus 5-FU-containing regimes
Outcome: 1 Overall Survival
Study or subgroup Capecitabine 5-FU log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Kang 2009 160 156 -0.162 (0.136) 41.0 % 0.85 [ 0.65, 1.11 ]
Li 2016 55 50 -0.211 (0.215) 16.4 % 0.81 [ 0.53, 1.23 ]
Ochenduszko 2015 29 27 0.225 (0.283) 9.5 % 1.25 [ 0.72, 2.18 ]
Ocvirk 2012 40 45 -0.17 (0.216) 16.3 % 0.84 [ 0.55, 1.29 ]
Van Cutsem 2015 82 88 0.256 (0.212) 16.9 % 1.29 [ 0.85, 1.96 ]
Total (95% CI) 366 366 100.0 % 0.94 [ 0.79, 1.11 ]
Heterogeneity: Chi2 = 4.55, df = 4 (P = 0.34); I2 =12%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Chemotherapy with capecitabine versus 5-FU-containing regimes, Outcome 2
Tumour response.
Review: Chemotherapy for advanced gastric cancer
Comparison: 7 Chemotherapy with capecitabine versus 5-FU-containing regimes
Outcome: 2 Tumour response
Study or subgroup Capecitabine 5-FU Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kang 2009 64/139 44/137 28.4 % 1.80 [ 1.11, 2.94 ]
Li 2016 22/55 24/50 24.0 % 0.72 [ 0.33, 1.57 ]
Ocvirk 2012 12/40 14/45 21.6 % 0.95 [ 0.38, 2.39 ]
Van Cutsem 2015 21/82 41/88 26.0 % 0.39 [ 0.21, 0.76 ]
Total (95% CI) 316 320 100.0 % 0.85 [ 0.40, 1.79 ]
Total events: 119 (Capecitabine), 123 (5-FU)
Heterogeneity: Tau2 = 0.45; Chi2 = 14.10, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Chemotherapy with capecitabine versus 5-FU-containing regimes, Outcome 3
Time to progression.
Review: Chemotherapy for advanced gastric cancer
Comparison: 7 Chemotherapy with capecitabine versus 5-FU-containing regimes
Outcome: 3 Time to progression
Study or subgroup Capecitabine 5-FU log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Ocvirk 2012 40 45 -0.324 (0.222) 0.72 [ 0.47, 1.12 ]
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Chemotherapy with capecitabine versus 5-FU-containing regimes, Outcome 4
Progression-free survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 7 Chemotherapy with capecitabine versus 5-FU-containing regimes
Outcome: 4 Progression-free survival
Study or subgroup Capecitabine 5-FU log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Kang 2009 160 156 -0.223 (0.13) 46.6 % 0.80 [ 0.62, 1.03 ]
Li 2016 55 50 0.14 (0.195) 27.5 % 1.15 [ 0.78, 1.69 ]
Ochenduszko 2015 29 27 0.0606 (0.27) 16.4 % 1.06 [ 0.63, 1.80 ]
Van Cutsem 2015 82 88 0.322 (0.371) 9.4 % 1.38 [ 0.67, 2.86 ]
Total (95% CI) 326 321 100.0 % 0.98 [ 0.77, 1.23 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.88, df = 3 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Chemotherapy with capecitabine versus 5-FU-containing regimes, Outcome 5
Treatment-related death.
Review: Chemotherapy for advanced gastric cancer
Comparison: 7 Chemotherapy with capecitabine versus 5-FU-containing regimes
Outcome: 5 Treatment-related death
Study or subgroup Capecitabine 5-FU Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kang 2009 1/156 2/155 38.9 % 0.49 [ 0.04, 5.50 ]
Van Cutsem 2015 11/82 3/88 61.1 % 4.39 [ 1.18, 16.35 ]
Total (95% CI) 238 243 100.0 % 1.88 [ 0.23, 15.15 ]
Total events: 12 (Capecitabine), 5 (5-FU)
Heterogeneity: Tau2 = 1.41; Chi2 = 2.43, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Chemotherapy with capecitabine versus 5-FU-containing regimes, Outcome 6
Treatment discontinuation due to toxicity.
Review: Chemotherapy for advanced gastric cancer
Comparison: 7 Chemotherapy with capecitabine versus 5-FU-containing regimes
Outcome: 6 Treatment discontinuation due to toxicity
Study or subgroup Capecitabine 5-FU Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kang 2009 28/156 28/155 0.99 [ 0.56, 1.77 ]
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Chemotherapy with oxaliplatin versus the same regime including cisplatin,
Outcome 1 Overall Survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 8 Chemotherapy with oxaliplatin versus the same regime including cisplatin
Outcome: 1 Overall Survival
Study or subgroup Oxaliplatin Cisplatin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Al Batran 2008 112 108 -0.195 (0.29) 9.2 % 0.82 [ 0.47, 1.45 ]
Hironaka 2016 47 48 -0.528 (0.235) 12.8 % 0.59 [ 0.37, 0.93 ]
Kim 2014 39 38 -0.102 (0.226) 13.6 % 0.90 [ 0.58, 1.41 ]
Popov 2008 36 36 -0.357 (0.129) 27.4 % 0.70 [ 0.54, 0.90 ]
Yamada 2015 317 324 -0.043 (0.089) 37.0 % 0.96 [ 0.80, 1.14 ]
Total (95% CI) 551 554 100.0 % 0.81 [ 0.67, 0.98 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 6.55, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 2.22 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Chemotherapy with oxaliplatin versus the same regime including cisplatin,
Outcome 2 Tumour response.
Review: Chemotherapy for advanced gastric cancer
Comparison: 8 Chemotherapy with oxaliplatin versus the same regime including cisplatin
Outcome: 2 Tumour response
Study or subgroup Oxaliplatin Cisplatin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al Batran 2008 39/102 26/93 15.4 % 1.60 [ 0.87, 2.92 ]
Hironaka 2016 31/47 22/48 6.8 % 2.29 [ 1.00, 5.24 ]
Kim 2014 31/39 26/38 5.0 % 1.79 [ 0.64, 5.04 ]
Popov 2008 15/36 9/36 4.8 % 2.14 [ 0.79, 5.85 ]
Yamada 2015 177/318 169/324 68.0 % 1.15 [ 0.84, 1.57 ]
Total (95% CI) 542 539 100.0 % 1.38 [ 1.08, 1.76 ]
Total events: 293 (Oxaliplatin), 252 (Cisplatin)
Heterogeneity: Chi2 = 3.94, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.55 (P = 0.011)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Chemotherapy with oxaliplatin versus the same regime including cisplatin,
Outcome 3 Progression-free survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 8 Chemotherapy with oxaliplatin versus the same regime including cisplatin
Outcome: 3 Progression-free survival
Study or subgroup Oxaliplatin Cisplatin log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Al Batran 2008 112 108 -0.397 (0.225) 22.3 % 0.67 [ 0.43, 1.04 ]
Hironaka 2016 47 48 -0.511 (0.272) 18.1 % 0.60 [ 0.35, 1.02 ]
Kim 2014 39 38 0.251 (0.232) 21.6 % 1.29 [ 0.82, 2.03 ]
Yamada 2015 318 324 0.004 (0.091) 38.0 % 1.00 [ 0.84, 1.20 ]
Total (95% CI) 516 518 100.0 % 0.88 [ 0.66, 1.19 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 7.28, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 Chemotherapy with oxaliplatin versus the same regime including cisplatin,
Outcome 4 Treatment-related death.
Review: Chemotherapy for advanced gastric cancer
Comparison: 8 Chemotherapy with oxaliplatin versus the same regime including cisplatin
Outcome: 4 Treatment-related death
Study or subgroup Oxaliplatin Cisplatin Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al Batran 2008 0/112 0/102 Not estimable
Hironaka 2016 0/47 0/49 Not estimable
Kim 2014 1/39 1/38 8.7 % 0.97 [ 0.06, 16.15 ]
Popov 2008 0/36 2/36 21.6 % 0.19 [ 0.01, 4.08 ]
Yamada 2015 4/338 8/335 69.7 % 0.49 [ 0.15, 1.64 ]
Total (95% CI) 572 560 100.0 % 0.47 [ 0.17, 1.30 ]
Total events: 5 (Oxaliplatin), 11 (Cisplatin)
Heterogeneity: Chi2 = 0.60, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Chemotherapy with oxaliplatin versus the same regime including cisplatin,
Outcome 5 Treatment discontinuation due to toxicity.
Review: Chemotherapy for advanced gastric cancer
Comparison: 8 Chemotherapy with oxaliplatin versus the same regime including cisplatin
Outcome: 5 Treatment discontinuation due to toxicity
Study or subgroup Oxaliplatin Cisplatin Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Al Batran 2008 12/112 11/102 33.3 % 0.99 [ 0.42, 2.36 ]
Hironaka 2016 10/47 5/49 25.2 % 2.38 [ 0.75, 7.58 ]
Yamada 2015 17/328 30/332 41.5 % 0.55 [ 0.30, 1.02 ]
Total (95% CI) 487 483 100.0 % 0.97 [ 0.44, 2.13 ]
Total events: 39 (Oxaliplatin), 46 (Cisplatin)
Heterogeneity: Tau2 = 0.29; Chi2 = 5.04, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 9.1. Comparison 9 Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum
(without fluoropyrimidine), Outcome 1 Overall survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 9 Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum (without fluoropyrimidine)
Outcome: 1 Overall survival
Study or subgroup TPF TP log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Ajani 2005 79 76 0.172 (0.181) 32.4 % 1.19 [ 0.83, 1.69 ]
Roth 2007 41 38 -0.046 (0.245) 17.7 % 0.96 [ 0.59, 1.54 ]
Van Cutsem 2015 170 78 -0.39 (0.146) 49.9 % 0.68 [ 0.51, 0.90 ]
Total (95% CI) 290 192 100.0 % 0.86 [ 0.71, 1.06 ]
Heterogeneity: Chi2 = 6.05, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 1.42 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum
(without fluoropyrimidine), Outcome 2 Tumour response.
Review: Chemotherapy for advanced gastric cancer
Comparison: 9 Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum (without fluoropyrimidine)
Outcome: 2 Tumour response
Study or subgroup TPF TP Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ajani 2005 34/79 20/76 36.4 % 2.12 [ 1.07, 4.17 ]
Roth 2007 15/41 7/38 14.4 % 2.55 [ 0.91, 7.21 ]
Van Cutsem 2015 62/170 18/78 49.1 % 1.91 [ 1.04, 3.53 ]
Total (95% CI) 290 192 100.0 % 2.08 [ 1.37, 3.15 ]
Total events: 111 (TPF), 45 (TP)
Heterogeneity: Chi2 = 0.22, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 3.45 (P = 0.00057)
Test for subgroup differences: Not applicable
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Analysis 9.3. Comparison 9 Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum
(without fluoropyrimidine), Outcome 3 Progression-free survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 9 Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum (without fluoropyrimidine)
Outcome: 3 Progression-free survival
Study or subgroup TPF TP log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Ajani 2005 79 76 -0.223 (0.217) 28.7 % 0.80 [ 0.52, 1.22 ]
Roth 2007 41 38 -0.236 (0.243) 22.9 % 0.79 [ 0.49, 1.27 ]
Van Cutsem 2015 170 78 -0.372 (0.167) 48.4 % 0.69 [ 0.50, 0.96 ]
Total (95% CI) 290 192 100.0 % 0.74 [ 0.59, 0.93 ]
Heterogeneity: Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
Test for subgroup differences: Not applicable
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Analysis 9.4. Comparison 9 Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum
(without fluoropyrimidine), Outcome 4 Treatment-related death.
Review: Chemotherapy for advanced gastric cancer
Comparison: 9 Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum (without fluoropyrimidine)
Outcome: 4 Treatment-related death
Study or subgroup TPF TP Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ajani 2005 3/79 1/76 15.1 % 2.96 [ 0.30, 29.11 ]
Roth 2007 1/41 0/38 7.7 % 2.85 [ 0.11, 72.16 ]
Van Cutsem 2015 14/170 4/78 77.3 % 1.66 [ 0.53, 5.22 ]
Total (95% CI) 290 192 100.0 % 1.95 [ 0.73, 5.17 ]
Total events: 18 (TPF), 5 (TP)
Heterogeneity: Chi2 = 0.26, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 9.5. Comparison 9 Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum
(without fluoropyrimidine), Outcome 5 Treatment discontinuation due to toxicity.
Review: Chemotherapy for advanced gastric cancer
Comparison: 9 Taxane-platinum-fluoropyrimidine combinations versus taxane-platinum (without fluoropyrimidine)
Outcome: 5 Treatment discontinuation due to toxicity
Study or subgroup TPF TP Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ajani 2005 15/79 9/76 73.1 % 1.74 [ 0.71, 4.27 ]
Roth 2007 5/41 3/38 26.9 % 1.62 [ 0.36, 7.30 ]
Total (95% CI) 120 114 100.0 % 1.71 [ 0.79, 3.69 ]
Total events: 20 (TPF), 12 (TP)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 S-1 versus 5-FU-containing regimes, Outcome 1 Overall Survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 10 S-1 versus 5-FU-containing regimes
Outcome: 1 Overall Survival
Study or subgroup S-1 5-FU log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Ajani 2010 521 508 -0.085 (0.068) 50.7 % 0.92 [ 0.80, 1.05 ]
Boku 2009 234 234 -0.187 (0.095) 26.0 % 0.83 [ 0.69, 1.00 ]
Chen 2015 30 30 -0.026 (0.116) 17.4 % 0.97 [ 0.78, 1.22 ]
Li 2015 120 116 0.045 (0.198) 6.0 % 1.05 [ 0.71, 1.54 ]
Total (95% CI) 905 888 100.0 % 0.91 [ 0.83, 1.00 ]
Heterogeneity: Chi2 = 1.81, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 S-1 versus 5-FU-containing regimes, Outcome 2 Tumour response.
Review: Chemotherapy for advanced gastric cancer
Comparison: 10 S-1 versus 5-FU-containing regimes
Outcome: 2 Tumour response
Study or subgroup S-1 5-FU Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ajani 2010 117/402 123/385 19.3 % 0.87 [ 0.65, 1.18 ]
Boku 2009 49/174 15/175 16.1 % 4.18 [ 2.24, 7.80 ]
Chen 2015 16/30 14/30 11.8 % 1.31 [ 0.47, 3.60 ]
Dong 2014 18/30 10/30 11.4 % 3.00 [ 1.05, 8.60 ]
Huang 2013 50/119 27/110 16.7 % 2.23 [ 1.26, 3.93 ]
Li 2014 9/16 7/16 8.5 % 1.65 [ 0.41, 6.68 ]
Li 2015 27/120 25/116 16.2 % 1.06 [ 0.57, 1.96 ]
Total (95% CI) 891 862 100.0 % 1.73 [ 1.01, 2.94 ]
Total events: 286 (S-1), 221 (5-FU)
Heterogeneity: Tau2 = 0.36; Chi2 = 26.41, df = 6 (P = 0.00019); I2 =77%
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 S-1 versus 5-FU-containing regimes, Outcome 3 Progression-free survival.
Review: Chemotherapy for advanced gastric cancer
Comparison: 10 S-1 versus 5-FU-containing regimes
Outcome: 3 Progression-free survival
Study or subgroup S-1 5-FU log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ajani 2010 521 508 -0.01 (0.071) 31.6 % 0.99 [ 0.86, 1.14 ]
Boku 2009 234 234 -0.262 (0.095) 28.2 % 0.77 [ 0.64, 0.93 ]
Huang 2013 119 110 -0.445 (0.154) 20.1 % 0.64 [ 0.47, 0.87 ]
Li 2015 109 107 0.027 (0.155) 20.0 % 1.03 [ 0.76, 1.39 ]
Total (95% CI) 983 959 100.0 % 0.85 [ 0.70, 1.04 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 9.98, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 10.4. Comparison 10 S-1 versus 5-FU-containing regimes, Outcome 4 Time-to treatment failure.
Review: Chemotherapy for advanced gastric cancer
Comparison: 10 S-1 versus 5-FU-containing regimes
Outcome: 4 Time-to treatment failure
Study or subgroup S-1 5-FU log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ajani 2010 521 508 -0.14 (0.06) 34.0 % 0.87 [ 0.77, 0.98 ]
Boku 2009 234 234 -0.32 (0.09) 26.3 % 0.73 [ 0.61, 0.87 ]
Chen 2015 30 30 -0.03 (0.055) 35.3 % 0.97 [ 0.87, 1.08 ]
Huang 2013 119 110 0.37 (0.37) 3.5 % 1.45 [ 0.70, 2.99 ]
Li 2014 16 16 -0.25 (0.75) 0.9 % 0.78 [ 0.18, 3.39 ]
Total (95% CI) 920 898 100.0 % 0.88 [ 0.76, 1.01 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.50, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Not applicable
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Analysis 10.5. Comparison 10 S-1 versus 5-FU-containing regimes, Outcome 5 Treatment-related deaths.
Review: Chemotherapy for advanced gastric cancer
Comparison: 10 S-1 versus 5-FU-containing regimes
Outcome: 5 Treatment-related deaths
Study or subgroup S-1 5-FU Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ajani 2010 13/521 25/508 94.2 % 0.49 [ 0.25, 0.98 ]
Boku 2009 1/234 0/234 1.9 % 3.01 [ 0.12, 74.34 ]
Huang 2013 1/119 1/110 3.9 % 0.92 [ 0.06, 14.95 ]
Li 2015 0/120 0/116 Not estimable
Total (95% CI) 994 968 100.0 % 0.56 [ 0.30, 1.06 ]
Total events: 15 (S-1), 26 (5-FU)
Heterogeneity: Chi2 = 1.31, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.073)
Test for subgroup differences: Not applicable
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Analysis 10.6. Comparison 10 S-1 versus 5-FU-containing regimes, Outcome 6 Treatment discontinuation
due to toxicity.
Review: Chemotherapy for advanced gastric cancer
Comparison: 10 S-1 versus 5-FU-containing regimes
Outcome: 6 Treatment discontinuation due to toxicity
Study or subgroup S-1 5-FU Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ajani 2010 56/521 73/508 67.3 % 0.72 [ 0.49, 1.04 ]
Boku 2009 22/234 18/234 16.6 % 1.25 [ 0.65, 2.39 ]
Huang 2013 19/119 18/110 16.0 % 0.97 [ 0.48, 1.96 ]
Total (95% CI) 874 852 100.0 % 0.85 [ 0.63, 1.13 ]
Total events: 97 (S-1), 109 (5-FU)
Heterogeneity: Chi2 = 2.25, df = 2 (P = 0.32); I2 =11%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. CENTRAL update January 2013
1. exp stomach neoplasms/
2. (stomach adj5 neoplas$).ti,ab.
3. (stomach adj5 cancer$).ti,ab.
4. (stomach adj5 carcin$).ti,ab.
5. (stomach adj5 tumo$).ti,ab.
6. (stomach adj5 metasta$).ti,ab.
7. (stomach adj5 malig$).ti,ab.
8. (gastric adj5 neoplas$).ti,ab.
9. (gastric adj5 cancer$).ti,ab.
10. (gastric adj5 carcin$).ti,ab.
11. (gastric adj5 tumo$).ti,ab.
12. (gastric adj5 metasta$).ti,ab.
13. (gastric adj5 malig$).ti,ab.
14. or/1-13
15. exp drug therapy/
16. chemothera$.ti,ab.
17. drug therap$.ti,ab.
18. antineoplastic$.ti,ab.
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19. or/15-18
20. exp palliative care/
21. palliat$.ti,ab.
22. unresect$.ti,ab.
23. inopera$.ti,ab.
24. advanc$.ti,ab.
25. (best adj5 support$ adj5 care).ti,ab.
26. unopera$.ti,ab.
27. (non adj5 resect$).ti,ab.
28. nonresect$.ti,ab.
29. or/20-28
30. 14 and 19
31. 29 and 30
32. limit 31 to yr=“2009 - 2013”
Appendix 2. MEDLINE update March 2009-Jan 2013
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp stomach neoplasms/
13. (stomach adj5 neoplas$).tw.
14. (stomach adj5 cancer$).tw.
15. (stomach adj5 carcin$).tw.
16. (stomach adj5 tumo$).tw.
17. (stomach adj5 metasta$).tw.
18. (stomach adj5 malig$).tw.
19. (gastric adj5 neoplas$).tw.
20. (gastric adj5 cancer$).tw.
21. (gastric adj5 carcin$).tw.
22. (gastric adj5 tumo$).tw.
23. (gastric adj5 metasta$).tw.
24. (gastric adj5 malig$).tw.
25. or/12-24
26. exp drug therapy/
27. chemothera$.tw.
28. drug therap$.tw.
29. antineoplastic$.tw.
30. or/26-29
31. exp palliative care/
32. palliat$.tw.
33. unresect$.tw.
34. inopera$.tw.
35. advanc$.tw.
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36. (best adj5 support$ adj5 care).tw.
37. unopera$.tw.
38. (non adj5 resect$).tw.
39. nonresect$.tw.
40. or/31-39
41. 25 and 30
42. 40 and 41
43. 42 and 11
44. limit 43 to ed=20090309-20130131
Appendix 3. Embase update March 2009-Jan 2013
1. exp randomized controlled trial/
2. randomi?ed controlled trial$.tw.
3. exp randomization/
4. exp single blind procedure/
5. exp double blind procedure/
6. or/1-5
7. animal.hw.
8. human.hw.
9. 7 not (7 and 8)
10. 6 not 9
11. exp clinical trial/
12. (clin$ adj3 stud$).ti,ab,tw.
13. (clin$ adj3 trial$).ti,ab,tw.
14. ((singl$ or doubl$ or treb$ or tripl$) adj3 (blind$ or mask$)).ti,ab,tw.
15. exp placebo/
16. placebo$.ti,ab,tw.
17. random.ti,ab,tw.
18. (crossover$ or cross-over$).ti,ab,tw.
19. or/11-18
20. 19 not 9
21. 20 not 10
22. exp comparative study/
23. exp evaluation/
24. exp prospective study/
25. exp controlled study/
26. (control$ or prospective$ or volunteer$).ti,ab,tw.
27. or/22-26
28. 27 not 9
29. 10 or 21 or 28
30. exp stomach tumor/
31. (stomach adj5 neoplas$).tw.
32. (stomach adj5 cancer$).tw.
33. (stomach adj5 carcin$).tw.
34. (stomach adj5 tumo$).tw.
35. (stomach adj5 metasta$).tw.
36. (stomach adj5 malig$).tw.
37. (gastric adj5 neoplas$).tw.
38. (gastric adj5 cancer$).tw.
39. (gastric adj5 carcin$).tw.
40. (gastric adj5 tumo$).tw.
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41. (gastric adj5 metasta$).tw.
42. (gastric adj5 malig$).tw.
43. or/30-42
44. exp drug therapy/
45. chemothera$.tw.
46. drug therap$.tw.
47. antineoplastic$.tw.
48. or/44-47
49. exp palliative therapy/
50. palliat$.tw.
51. unresect$.tw.
52. inopera$.tw.
53. advanc$.tw.
54. (best adj5 support$ adj5 care).tw.
55. unopera$.tw.
56. (non adj5 resect$).tw.
57. nonresect$.tw.
58. or/49-57
59. 43 and 48
60. 58 and 59
61. 29 and 60
62. limit 61 to em=200910-201306
WH A T ’ S N E W
Date Event Description
30 June 2016 New search has been performed Searches rerun and results incorporated
30 June 2016 New citation required and conclusions have changed We added26 included studies, twonewcomparisons (9)Tax-
ane-platinum-fluoropyrimidine combinations versus tax-
ane-platinum (without fluoropyrimidine) and (10) S-1 ver-
sus 5-FU containing regimens and subgroup analyses to
comparisons 5 and 6; Irinotecan versus non-irinotecan-con-
taining regimens and docetaxel versus non-docetaxel-con-
taining regimens
H I S T O R Y
Date Event Description
6 December 2009 New citation required and conclusions have changed Conclusions changed, authors changed.
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(Continued)
3 December 2009 New search has been performed Updated, new studies added and change of statistical
model due to heterogeneity
30 October 2008 Amended Converted to new review format.
28 May 2004 Amended Conclusions changed.
1 February 2004 Amended New studies found and included or excluded.
C O N T R I B U T I O N S O F A U T H O R S
Wagner AD: Protocol development, eligibility and quality assessment, data extraction and analysis, drafting of final review.
Unverzagt S: Eligibility and quality assessment in the update, responsible statistician of the current update. Data extraction and analysis,
and drafting of the final review (2017 update).
Moehler, M: Review of search results, drafting of the final review (2017 update).
Grothe W: Literature searches, eligibility and quality assessment, data extraction and analysis.
Haerting J: Protocol development, statistician in initial version of the review.
Syn, NL: Review of search results, quality assessment, data extraction and analysis, drafting of final review (2017 update).
Ho, J: Review of search results, data extraction and analysis, drafting of final review (2017 update).
Yong, WP: Review of search results, drafting of final review (2017 update).
Tai, BC: Data extraction and analysis (2017 update).
D E C L A R A T I O N S O F I N T E R E S T
ADW: has received consulting fees fromEli Lilly, Celgene,MerckKG/Phizer,MSD,TAIHOandRoche pharmaceuticals for consultancy
work over the past three years, travel and accomodation support from Janssen and support from Merck Serono to conduct a clinical
trial of targeted treatment for gastric cancer, which is beyond the scope of this review. The overall number of consultancy agreements
per year is low (usually less than five advisory boards/year, with fees of between 500 and 1500 Euro per event). All funds were paid
to her institution in accordance with their guidelines. A portion of the money that the institution receives is transferred to ADW and
represents a trivial percentage of her salary.
NLXS: none known.
MM: has received consulting fees from Eli Lilly, Onyx, Roche, Nordic, Amgen, MSD, Merck Serono, Pfizer and BMS. He has received
payment for lectures from Falk, Nordic, Amgen, mci, MSD, Merck Serono, Pfizer and BMS. His institution has received funds for
independent research grants from Merck, Amgen, BMS, Taiho, Roche, AIO, MSD, and the EORTC.
WG: none known.
WPY: has received payment from Eli Lilly for service on speaker bureaus and travelling/accommodation for conferences from BMS
and Taiho, unrelated to this review.
BCT: has received a payment fromBoehringer Ingelheim for providing a lecture, and royalties fromWiley-Blackwell from a publication.
Her institution has received funds from the Health Science Authority (Singapore) for statistical consultancy.
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SU: none known.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Germany.
• Department of Internal Medicine IV, Martin-Luther-University Halle-Wittenberg, Germany.
• Institute of Medical Epidemiology, Biometry and Informatics, Martin-Luther-University, Halle-Wittenberg, Germany.
• Co-ordinating Centre for Clinical Trials, Halle (supported by German Ministry of Education & Research, Grant Number
BMBF/FKZ: 01GH0105 KKS, Halle), Germany.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There were a large number of categories of different combination chemotherapy regimens and the number of relevant studies in each
category was not known when writing the protocol. For this reason we were unable to plan in advance the best way to compare categories
of all relevant categories of combination chemotherapies (Van Cutsem 2009).
We clarified how we dealt with multiple study arms from one study.
In the first update of this review (Wagner 2010, submitted in November 2009), we chose to add the following comparisons based on
their clinical relevance and the availability of a sufficient number of relevant studies. Among these, comparisons 3 and 4 have been
added in the discussion of the previously published version of this review as they were not specified in advance. Comparisons 5 to 8
have been specified in advance in the last update of the review.
In this second update of this review (submitted in March 2017), we added two additional comparisons (9 and 10) and we differentiated
between additive and substitutive comparisons in comparisons 5 and 6.
Comparison number:
3. 5-FU/cisplatin/anthracycline combinations versus 5-FU/cisplatin (without anthracyclines)
4. 5-FU/cisplatin/anthracycline-combinations versus 5-FU/anthracycline combinations (without cisplatin)
5. Irinotecan versus non-irinotecan-containing regimens
6. Docetaxel versus non-docetaxel-containing regimens
7. Regimens including oral 5-FU prodrugs versus intravenous fluoropyrimidines
8. Oxaliplatin versus cisplatin-containing regimens
9. Taxane-platinum-fluoropyrimidin combinations versus taxane-platinum (without fluoropyrimidine)
10. S-1 versus 5-FU-containing regimens
The method for statistical analysis in case of significant heterogeneity (I² > 20%) is a random-effects model. Although the original
version of the protocol does not state this, these changes were requested after methodological review by the Cochrane UGPD group.
This methodological change is responsible for differences in HRs between this and the previously published version of the review
(Wagner 2006).
As recent studies have increasingly reported progression-free survival instead of time to progression, we included the former as secondary
endpoints in this update.
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While there was no evidence for both - the use of second-line therapy and targeted therapies - at the time the protocol for this review was
written, both second-line and these targeted agents (trastuzumab in first-line for HER-2 positive people and ramucirumab in second-
line) have changed the management options for advanced gastric cancer significantly and are therefore included in the discussion of
the treatment options although not analysed in detail by this review.
In this updated review, we no longer use the Jadad scale to assess methodological quality (Jadad 1996). Instead we independently
assessed the risk of bias in the included studies using the ’Risk of bias’ assessment tool described in Chapter 8 of theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anthracyclines [administration & dosage]; Antineoplastic Combined Chemotherapy Protocols [∗therapeutic use]; Camptothecin [ad-
ministration & dosage; analogs & derivatives]; Cisplatin [administration & dosage]; Fluorouracil [administration & dosage]; Random-
ized Controlled Trials as Topic; Stomach Neoplasms [∗drug therapy; mortality]; Taxoids [administration & dosage]
MeSH check words
Humans
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